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ABSTRACT 
Studies up to date in the western literature involving changes in coagulation 
in patients with peripheral vascular disease(PVD) have consistently reported 
activation of coagulation based on measurement of raised levels of markers 
of activation of coagulation(clot formation), decreased fibrinolysis (breakdown 
of fibrin), platelet activation leading to increased aggregation and defective 
endothelial (arterial wall) function in patients with PVD that leads to 
thrombosis in arterial circulation thus designating this group of patients as 
‗hypercoagulable.‘ Interestingly these patients are not deemed as such in 
clinical practice as the routine coagulation tests(RCTs) currently employed do 
not identify these abnormalities. The overall purpose of the research 
described in this thesis was to identify changes in coagulation in patients with 
peripheral vascular disease using Thromboelastography (TEG), a technique 
which exploits the visco-elastic properties of a blood clot as it forms, retracts 
or lyses (breaks down) using a small volume of whole blood.   
Validation of TEG technique employing citrated whole blood (CWB) and 
heparinase modified (hepTEG) methods and standardisation of analysis to 
overcome variability in TEG analysis, blood sample instability due to storage 
times was carried out. TEG analysis after sample storage between 1-2 hours 
showed no significant inter or intra sample assay variability confirming 
excellent reproducibility( (p= NS; reliability coefficients (Alpha) greater than 
0.9 for R time, K time, Angle, Maximal Amplitude (MA) and Coagulation 
Index(CI)). hepTEG method confirmed complete reversal of heparin effect in 
blood samples obtained from participants following heparin administration.(R 
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time: 9.16+/- 1.68 Vs 8.90 +/- 1.48 p=NS; K time: 2.98+/- 0.87 Vs 3.20 +/- 
1.05 p=NS; Angle: 56.86+/- 6.39 Vs 56.90 +/- 5.30 p=NS; MA 56.34+/- 6.39 
Vs 56.79+/-6.23 p=NS; CI: 0.59+/-1.19 Vs 0.88+/-1.00 p=NS). 50 age 
matched controls to obtain reference values for comparison and 
documentation of any significant changes in TEG parameters due to age, 
gender anaesthesia and surgery was completed. Preparation /induction of 
anaesthesia led to a significant trend towards activation of coagulation in all 
age groups and gender (Angle 56.23 +/-0.89, CI  54.42, 58.04  Vs 58.21+/-
0.83, CI 56.54, 59.88;p=0.003 and MA 56.40 +/- 0.79 CI 54.80, 58.01 Vs 
59.36 +/- 0.89, CI 57.56, 61.15; p=0.003 and CI 0.71 +/- 0.14, CI 0.42, 1.00 
Vs 1.35 +/- 0.17, CI 1.00, 1.69;p=0.003) 
Surgical stimulus led to a further activation of coagulation that followed 
induction of anaesthesia (Angle: 58.21+/- 0.83, CI 56.54, 59.88 Vs 60.98 +/- 
0.69, CI 59.59, 62.37; p=0.001). TEG parameter values obtained from 
healthy controls aged over 45 are used as reference values for this study.    
TEG showed no significant differences in TEG parameters when samples 
obtained from an upper limb artery and a vein were analysed. However when 
samples from the main lower limb artery (common femoral artery/CFA) and 
the major vein that drains the same limb (common femoral vein/CFV) in 
patients with symptomatic PVD, TEG identified significant activation of 
coagulation in samples obtained from the vein that drains an ischaemic limb 
(decrease in R time (p0.05), an increase in MA (p0.05) and an increase in 
CI (p0.002)). This interesting finding led to a hypothesis that ischaemic 
tissue has a prominent role in the activation of coagulation observed in 
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patients with PVD. To test this hypothesis, common femoral venous and 
arterial samples from 30 patients with symptomatic PVD were analysed using 
TEG. TEG identified significant activation of coagulation in samples obtained 
from an artery downstream (CFA) when compared to those obtained from an 
artery that is proximal (Aorta). This change towards hypercoagulation was 
also found to be positively related to the degree of narrowing or stenotic 
disease (quantified using angiography) between these two sampling 
points(R, r=0.442, p0.05 / MA, r=0.379, p0.05 / CI r=0.429, p0.05). A 
significant positive relationship in between degree of ischaemia (ABPI) and 
difference in TEG parameter values in between arterial and venous blood 
samples obtained from an ischaemic limb (ABPI) on that side (CI v ABPI r = 
-0.427 p0.05, MA v ABPI r =-0.370 p0.05) was also found in this study. 
These findings suggest activation of coagulation as the blood flows down an 
atherosclerotic vessel and in combination with the observed changes due to 
the presence of peripheral ischemia tissue suggested that the 
hypercoagulability observed in PVD may have its origins in the ishaemic limb 
itself. 
To clarify the role of non-ionic contrast media (NICM) in the context of 
conflicting findings regarding its thrombogenic potential especially in patients 
with PVD undergoing angiography, aortic blood samples(n=30) were 
obtained before and after injection of NICM. Heparinase modified TEG 
analysis showed that there was no activation of coagulation immediately after 
NICM exposure and in fact there was a significant trend towards 
hypocoagulation in contrast to the published reports of increased 
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thrombogenicity after NICM exposure (increase in R time (time to fibrin 
formation) (CI 7.8,10.18 minutes)  (p=0.036), in K time (dynamics of clot 
formation) (CI 2.2,2.8 minutes) (p=0.028), and a reduction in Angle 
(decreased acceleration of fibrin build up) (CI 53.10,62.7 degrees) 
(p=0.013),MA (reduced ultimate clot strength) (CI 54.5,62.7 mm) (p=0.013) 
and (CI) (decreased overall coagulation status) (0.31,1.95) (p=0.032)). This 
study also showed that despite this significant reduction in the activation of 
coagulation after NICM exposure, PVD patients were consistently 
procoagulant when compared to age- matched controls(n=30) who were not 
exposed to NICM (R time: p=0.029/K time: p=0.001/Angle: p=0.003/MA: 
p=0.020 and CI: p=0.014) 
Patients with ischaemic heart disease, a consequence of significant coronary 
artery atherosclerosis have reduced amounts of naturally occurring 
anticoagulant substances like heparan, heparan-sulphate proteoglycan and 
endogenous heparin. Since patients with PVD exhibit similar pathology in 
addition to the presence of peripheral ischaemic tissue, to identify any similar 
defect in PVD, blood samples from patients with symptomatic PVD(n=28) 
and age matched control subjects were analysed using hepTEG. Heparinase 
modified TEG analysis identified for the first time, heparinase sensitive 
heparin-like activity in peripheral venous samples in patients with PVD (R 
time 7.50  0.44 min / CI 6.54, 8.46 Vs 7.17  0.40 min / CI 6.30, 8.05 / 
p=0.041). Endogenous heparin-like activity is found to be reduced in PVD 
and this reduction also correlated with the degree of peripheral ischaemia 
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(ABPI) (correlation coefficient: abpi: 1.000 / change in R time 0.350 / 
p=0.021) 
TEG analysis of samples from 30 patients with aortic aneurysmal disease 
and 14 aortic occlusive disease undergoing revascularisation and 30 controls 
were carried out using hepTEG method. Baseline TEG parameter values in 
the aneurysm group showed significant activation of coagulation when 
compared to the controls (R time (p=0.001); K time (p=0.008) and (CI) 
(p=0.047)). Following release of the aortic cross-clamp a significant trend 
towards activation of coagulation was noted in the aneurysm group and a 
similar but pronounced activation of coagulation was noted in the occlusive 
group, confirming activation of coagulation following reperfusion of ischaemic 
tissues (R time (p=0.042); K time (p=0.043) MA (p= 0.034) and CI (p=0.026)). 
Further TEG analysis during postoperative period showed that both these 
patient groups exhibit sustained periods of hypercoagulability. In addition to 
these findings hepTEG method further revealed underlying 
hypercoagulability, despite exogenous heparin administration, confirming 
presence and activation of non- AT-III dependent pathways of activation of 
coagulation in these patients. 
TEG analysis of blood samples from 86 patients admitted with symptoms 
peripheral ischaemia requiring revascularisation surgery or amputation were 
carried out and TEG parameter values obtained from control group was used 
for comparison. Serial blood sampling (n=13) at various stages of surgery( 
baseline, before and after anaesthesia, before commencement of surgery 
before clamp of lower limb artery, before release of clamp, after release of 
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clamp, 3, 6, 12, 24, 48, 72 hrs, 7 days and 6 weeks after surgery) for CWB 
TEG and hepTEG methods were carried out. Baseline TEG showed 
significant activation of coagulation in PVD when compared to age matched 
controls (R time (p=0.003) Angle (p=0.016) MA (p=0.002) and CI (p=0.002). 
Following revascularisation there was a significant decrease in the time to 
fibrin formation and a significant increase in the maximum strength of clot 
suggesting increased platelet-fibrinogen and the overall coagulation status of 
the blood.( R time (p=0.026), MA (p=0.004) and CI (p=0.002)). These 
findings confirmed that ischaemic limb promoted activation of coagulation 
especially after revascularisation. This study demonstrated significant 
activation of coagulation before, during and after revascularisation 
procedures for critical limb ischaemia. TEG analysis also confirmed a 
prothrombotic state after revascularisation (MA (p=0.013) and CI (p=0.032)) 
that is shown to be associated with development of any post-operative 
thrombotic ischaemic event. 
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PAI-1                                     Plasminogen activator Inhibitor-1 
 
PAOD                                    Peripheral Arterial Occlusive Disease 
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SFMC                                    Soluble fibrin monomer complexes 
 
SMC Smooth Muscle Cells 
 
TAT                                       Thrombin-Antithrombin Complex 
 
TEG                                      Thromboelastography 
 
TF                                          Tissue factor 
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CHAPTER 1 - INTRODUCTION 
 
 
1.1 - COAGULATION AND FIBRINOLYSIS 
1.1.1 Coagulation 
Haemostasis is one of the basic mechanisms of homeostasis. It ensures 
minimisation of blood loss from the circulation in the event of trauma whilst 
maintaining patency of the vascular tree. In combination with platelets, the 
coagulation pathway acts to rapidly seal any breach in the circulation. The 
fibrinolytic pathway acts to lyse clot and therefore functions as a check on 
coagulation, limiting the extension of clot formation and maintaining vessel 
patency.  A number of endogenous ‗natural anti-coagulants‘ also exist 
which further moderate the action of the clotting cascade1. As well as 
trauma, other factors are known to stimulate these mechanisms. 
Inflammation and ischaemia have both been demonstrated to be pro-
thrombotic. The end point of the coagulation pathway (Figure 1.1) is the 
conversion of fibrinogen to fibrin and the formation of a fibrin clot. This is 
mediated by the serial conversion of pro-enzymes or factors(Table 1.1) into 
their active forms which, together with various co-factors, in turn catalyse 
the activation of the next pro-enzyme in the chain2. This cascade, along 
with several positive feedback loops, result in a magnification of the 
response to the original stimulus. Two pathways in coagulation, intrinsic and 
extrinsic have been established in vitro3.  
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Figure 1.1 - The Coagulation Pathway 
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Table 1.1 Coagulation Factors 
 
Factor Number 
or Name  
Synonym  Purpose  
I Fibrinogen A precursor of fibrin 
II Prothrombin A precursor of thrombin, which 
converts fibrinogen to fibrin; activates 
factors V, VIII, XI, and XIII; and binds 
to thrombomodulin to activate protein 
C Is vitamin K–dependent 
V Proaccelerin Is activated to factor Va, which is a 
cofactor for the enzyme factor Xa in 
the factor Xa/Va/phospholipid 
complex that cleaves prothrombin to 
thrombin. 
VII 
 
 
 
 
 
Proconvertin Binds to tissue factor and is then 
activated to form the enzymatic 
component of the factor VIIa/tissue 
factor complex that activates factors 
IX and X. Is vitamin K–dependent 
VIII Antihemophilic 
globulin 
Is activated to factor VIIIa, which is a 
cofactor for the enzyme factor IXa in 
the factor IXa/VIIIa/phospholipid 
complex that activates factor X 
Factor VIIIa is inactivated by activated 
protein C in complex with protein S 
(as is factor Va) 
Is a large cofactor protein (as is factor 
V) Circulates in plasma bound to von 
Willebrand's factor multimers. 
IX Christmas 
factor 
Is activated to factor IXa, which is the 
enzyme of the factor. 
IXa/VIIIa/phospholipid complex that 
activates factor X. Is vitamin K–
dependent 
X Stuart-Prower 
factor 
Is activated to factor Xa, which is the 
enzyme of the factor 
Xa/Va/phospholipid complex that 
cleaves prothrombin to thrombin 
Is vitamin K–dependent. 
XI Plasma 
thromboplastin 
antecedent 
Is activated to factor XIa, which 
activates factor IX in a reaction 
requiring Ca2+ ions 
 
Prekallikrein 
 
Fletcher factor 
 
Participates in a reciprocal reaction in 
which it is activated to kallikrein by 
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factor XIIa 
As kallikrein, catalyzes further 
activation of factor XII to factor XIIa 
Circulates as a biomolecular complex 
with high mol wt kininogen 
High mol wt 
kininogen 
Fitzgerald 
factor 
Circulates as a bimolecular complex 
with prekallikrein 
 
XII 
 
Hageman 
factor 
 
When activated to factor XIIa by 
surface contact, kallikrein, or other 
factors, activates prekallikrein and 
factor XI, triggering the intrinsic 
coagulation pathway in vitro 
XIII Fibrin 
stabilizing 
factor 
When activated by thrombin, 
catalyzes formation of peptide bonds 
between adjacent fibrin monomers, 
thus strengthening and stabilizing the 
fibrin clot 
Protein C — Is activated by thrombin bound to 
thrombomodulin; then proteolyses 
and destroys (in the presence of 
protein S and phospholipid) the 
cofactor activity of factors VIIIa and 
Va 
Is vitamin K–dependent 
Protein S — Circulates in plasma as free protein S 
and as protein S bound to C4b-
binding protein of the complement 
system 
Functions in its free form as a 
cofactor for activated protein C 
Is vitamin K–dependent 
Cell surface factors 
Tissue factor Tissue 
thromboplastin 
Is a lipoprotein that is constitutively 
present on the membrane of certain 
tissue cells, including perivascular 
fibroblasts, boundary epithelial cells 
(eg, epithelial cells of the skin, 
amnion, and GI and GU tracts), and 
glial cells of the nervous system 
May also develop in pathologic states 
on activated monocytes and 
macrophages and on activated 
vascular endothelium 
Is present on some tumour cells 
Binds factor VIIa, which initiates the 
extrinsic coagulation pathway 
Procoagulant — Acidic phospholipid (primarily 
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phospholipid phosphatidyl serine) present on the 
surface of activated platelets and 
other tissue cells 
Is a component of the factor 
IXa/VIIIa/phospholipid activator of 
factor X and of the factor 
Xa/Va/phospholipid activator of 
prothrombin 
Functions as the lipid moiety of tissue 
factor 
Thrombomodulin — Is an endothelial cell surface binding 
site for thrombin, which, when bound 
to thrombomodulin, activates protein 
C. 
 
1.1.2 The Intrinsic Pathway 
The Intrinsic Pathway is initiated by plasma coming into contact with 
negatively charged surfaces in association with kallikrein. This causes the 
activation of clotting Factor XII to its' active form, XIIa. XIIa, together with 
high molecular weight kininogen (HMWK) and thrombin, catalyses the 
conversion of Factor XI to XIa. XIa catalyses its' own production, thereby 
providing positive feedback for this activation. Factor XIa, with calcium ions 
as co-factor, catalyses the conversion of Factor IX to IXa. Thrombin 
catalyses the conversion of Factor VIII to VIIIa and this then combines with 
IXa on membrane surfaces to form the tenase complex which further acts 
via the common pathway. Calcium ions are again a co-factor for this 
reaction. Although this pathway is well recognised in vitro, it has in fact 
been demonstrated that XII, pre-kallikrein and HMWK deficiencies have no 
bleeding phenotypes, suggesting they are not required for haemostasis, 
though they may be involved in fibrin formation during inflammation and 
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wound healing. The von Willebrand factor acts as a carrier for Factor VIII, 
prolonging it‘s' half-life and protecting it from inactivation by activated 
protein C. 
1.1.3 The Extrinsic Pathway 
The Extrinsic Pathway is initiated when plasma comes into contact with 
thromboplastin (also known as tissue factor), a receptor ubiquitous in extra 
vascular tissues. This catalyses the conversion of Factor VII to VIIa which 
then combines with thromboplastin in a calcium ion dependant reaction. 
VIIa, VIIa/thromboplastin and Xa all exert positive feedback on the 
conversion of VII to its' active form. The VIIa/thromboplastin molecule also 
stimulates the activation of IX in the Extrinsic Pathway. Activated Factor 
VIIa is present in low concentrations (10-100 pm) in normal plasma. The 
formation of the IXa/VIIIa (tenase) and VIIa/thromboplastin complexes allow 
the reactions of the Common Pathway to proceed as both these 
compounds, with calcium ions as co-factor, catalyse the conversion of 
Factor X to Xa. The activation of Factor V is catalysed by the presence of 
thrombin. Factors Va and Xa then combine in the presence of calcium ions 
to form the molecule known as prothrombinase. Prothrombinase catalyses 
the conversion of prothrombin to thrombin, with co-factor calcium, and 
thrombin then catalyses the conversion of fibrinogen to fibrin plus by-
products fibrinopeptides A and B. The activation of Factors X and V, and 
the combination of their active forms, take place on the surface membranes 
of platelets or endothelial cells. 
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The terminal event in the coagulation pathways is the conversion of 
fibrinogen to fibrin by the action of thrombin. Thrombin acts to cleave 
fibrinogen and the cleaved portions being referred to as fibrinopeptide A and 
B respectively) thus forming the fibrin monomer which is then able to 
polymerise. The fibrin polymers are initially held together by weak non-
covalent bonds but the action of factor XIII results in the formation of a stable 
fibrin polymer bound by covalent bonds. 
1.1.4 The Fibrinolytic Pathway 
The fibrinolytic system (Figure 1.2) acts to lyse fibrin clot formed by the 
processes stated above. Plasmin catalyses the breakdown of fibrin into its 
degradation products. The inactive molecule plasminogen is converted to its 
active form plasmin by the cleavage of a single peptide bond. This may occur 
via an intrinsic pathway (by the action of factors XIa, XIIa, kallikrein and 
HMWK) or by the action of specific activators.  Two plasminogen activators 
are released from endothelial cells into the plasma, tissue plasminogen 
activator (t-PA) and urokinase plasminogen activator (u-PA). They catalyse 
the cleavage of plasminogen to plasmin.  Plasmin, Xa and kallikrein promote 
the cleavage of single chain u-PA and t-PA into their much more active two-
chain forms (tcu-PA). Single chain u-PA (scu-PA) has relatively little 
proteolytic activity in solution but this is enhanced by the presence of fibrin. 
Two chain u-PA is unaffected by the presence of fibrin. Both forms of t-PA 
show considerably enhanced activity when bound to fibrin. Inhibition of 
fibrinolysis may occur at the level of the plasminogen activators or by action 
on plasmin itself.  
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Figure 1.2 - The Fibrinolytic Pathway 
 
 
 
 
 
 
 
 
 
 
1.1.5 Regulation of Fibrinolysis  
Fibrinolysis is regulated by plasminogen activator inhibitors (PAIs) and 
plasmin inhibitors that slow fibrinolysis (Figure 1.3). PAI-1, the most important 
PAI, inactivates tPA and urokinase and is released from vascular endothelial 
cells and activated platelets. The primary plasmin inhibitor is α2-antiplasmin, 
which quickly inactivates free plasmin escaping from clots. Some α2-
antiplasmin is also cross-linked to fibrin by the action of factor XIIIa during 
clotting. This may prevent excessive plasmin activity within clots. tPA and 
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urokinase are rapidly cleared by the liver, which is another mechanism of 
preventing excessive fibrinolysis. 
Figure 1.3 - Regulation of Fibrinolysis 
 
 
 
 
 
 
1.1.6 Natural Anticoagulant Mechanisms 
There are 3 major anti-coagulant systems occurring naturally in normal 
plasma4. The glycoprotein antithrombin III acts by combining with the 
proteases of the coagulation cascade in the ratio 1:1 to form inactive 
complexes. This process is the major mechanism for the inhibition of 
thrombin and Factors Xa and XIa, but is slow in the absence of heparin, 
which accelerates the reaction by a factor of a thousand. AT-III and heparin 
only inhibit factor VIIa when it is complexed with thromboplastin. The anti-
coagulant tissue factor pathway inhibitor (TFPI) acts by combining with Xa. 
The resultant complex combines with the VIIa/Thromboplastin complex in 
the presence of calcium ions, thereby inactivating it. The action of the third 
anti-coagulant, protein C differs from the other two in that it inhibits two of 
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the non-proteolytic co-factors, Va and VIIIa. Thrombin binds to 
thrombomodulin, a transmembrane receptor present on vascular endothelial 
cells. The resultant complex catalyses the activation of protein C on the 
membrane surfaces of endothelial cells and platelets, activated protein C 
(APC), in the presence of the co-factor protein S, catalyses the conversion 
of Factors Va and VIIIa to their inactive forms. APC is itself inhibited in the 
plasma by protein C inhibitor (PAI-3). In addition, 60% of protein S is 
normally complexed to the acute phase protein C4b-binding protein and is 
not functionally active. The proportion of bound protein S may increase in 
the presence of inflammation, reducing it‘s‘ activity further. The mechanism 
of action of PAI-2 is uncertain. It may only be relevant in pregnancy5. At the 
level of plasmin itself, molecule α2-anti-plasmin combines with plasmin in 
the ratio of 1:1 to form an inactive compound and thereby inhibits its action. 
1.1.7 The Role of the Platelet 
In the event of vascular trauma, circulating platelets adhere to the affected 
area and aggregate to form a platelet clot that helps plugs the breach in the 
vessel wall. This constitutes a vital component of haemostasis6. However, 
they also perform an important role in the processes of coagulation, 
fibrinolysis and anti-coagulation. The platelet surface membrane provides a 
highly catalytic surface on which many of the reactions of the coagulation 
pathway take place. In particular, the platelet membrane strongly binds both 
fibrinogen and insoluble fibrin, promoting the conversion of fibrinogen to 
fibrin and stabilising the fibrin clot. Platelets are also a source of many of 
the factors affecting coagulation and fibrinolysis, including Factors V, XI and 
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XII, fibrinogen, HMWK, protein S and PAI-1. Conversely, the components of 
the clotting cascade have an effect on platelet function. Thrombin is the 
most potent activator of fibrinogen binding, platelet aggregation and clot 
retraction.   
1.1.8 The Role of the Endothelium 
The endothelium is a critical component of the haemostatic system. Under 
disease and injury-free conditions, the endothelium is antithrombotic, 
helping to maintain blood in its fluid form. Conversely, when the 
endothelium is disrupted for any reason, it becomes an integral component 
in the response to this7. 
1.1.8.1 Functions of Uninjured Endothelium 
The uninjured endothelium helps to prevent intravascular blood coagulation 
by effects on the clotting cascade, platelet function and the fibrinolytic 
system8. Vascular endothelial cells produce a number of heparinoid 
substances, such as heparan and dermatan sulphate. These are catalysts 
for the inactivation of factors XIa, Xa, XIa and Thrombin by inhibitors such 
as antithrombin, resulting in an anti-coagulant effect on the luminal surface. 
The endothelial surface is also involved in the action of the natural 
anticoagulants Protein C and Protein S. Protein S is produced by the 
vascular endothelium, as is thrombomodulin (a surface receptor). When 
thrombin is generated, it combines with the thrombomodulin receptor. The 
resultant complex activates Protein C which, when bound to Protein S, 
cleaves factors Va and VIIIa, preventing further thrombin generation. 
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Protein C also promotes fibrinolysis by inhibition of PAI-39. Tissue factor 
pathway inhibitor is also synthesized by the endothelium. This is thought to 
inhibit the activation of factor X by the Tissue Factor-factor VIIa complex at 
the start of the clotting cascade10. 
Adherence of platelets to the vascular endothelium is vital for effective 
haemostasis, but this is inhibited in normal vessels. The endothelium 
produces prostacyclin and nitric oxide (NO), both of which are powerful 
inhibitors of platelet adhesion to the vascular wall, in addition to their effects 
on vascular smooth muscle tone. Prostacyclin production (by the action of 
cyclooxygenases) is stimulated by the presence of thrombin while NO 
production is stimulated by a number of cytokines, including tumour 
necrosis factor11.  
Vascular endothelial cells promote fibrinolysis by producing plasminogen 
activators. The most important is t-PA, secreted in response to thrombin, 
histamine, vasopressin and others, but urokinase can also be produced as 
part of an inflammatory response. The plasminogen activation inhibitors 
(PAIs) are also produced by the vascular endothelium, as well as by 
platelets12. 
1.1.8.2 Haemostatic Function of Injured Endothelium 
When the vascular wall is disrupted, either by injury or disease processes, 
procoagulant properties that are normally suppressed or dormant, over-ride 
its natural antithrombotic state. The presence of tissue factor initiates the 
clotting cascade by interaction with factor VII and is the major mechanism of 
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coagulation initiation. Tissue factor expression is known to be induced by a 
wide range of stimuli, including cytokines (IL-1, TNF), infective organisms 
and their lipopolysaccharide endotoxins, homocysteine and thrombin. Injury 
to the endothelium also produces a reduction in fibrinolysis, further 
heightening the procoagulant state13. It has been demonstrated that 
treatment of cultured vascular endothelial cells with IL-1 results in reduced 
t-PA secretion and a concomitant increase in PAI-1 secretion with the 
balance between the two shifting towards reduced fibrinolytic activity14.    
1.1.9 Inflammation and Coagulation 
The presence of atherosclerotic disease is accompanied by a low grade 
inflammatory response. Many of the acute phase proteins that are produced 
as a part of this response have an effect on blood coagulation, such as 
fibrinogen. In addition, some inflammatory mediators such as IL-1, IL-6 and 
tumour necrosis factor (TNF) appear to have an effect on haemostasis. The 
role of IL-6 in activation of coagulation has been studied in humans and 
apes, using both endotoxin and recombinant IL-6. 
1.1.9.1 Interleukin 6 (IL-6) 
Interleukin 6 (IL-6) is an inflammatory cytokine, forming part of the acute 
phase response to infection or injury. It has effects on a wide range of 
systems, including aspects of coagulation and haemostasis. IL-6 can be 
produced by many different cell types, both immune and immune accessory 
cells and non-immune cells, after appropriate stimulation. These include 
monocytes and macrophages, fibroblasts, endothelial cells, vascular 
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smooth muscle cells as well as several tumour cell lines. The action of IL-6 
is mediated via a transmembrane receptor which is not involved in signal 
transduction itself, but instead acts on another transmembrane receptor, 
gp130. A soluble form of the IL-6 receptor, consisting of the extracellular 
portion of the receptor, also exists. IL-6 is able to activate the gp130 
receptor via this soluble receptor. This enables IL-6 to act on many cells 
that do not carry transmembrane IL-6 receptors, facilitating its action on 
such a wide variety of cell types.  
The association between inflammation and atherosclerotic disease is well 
recognised. Given its central role in the inflammatory response, it is 
therefore not surprising that IL-6 has been implicated in cardiovascular and 
peripheral vascular disease. It has previously been demonstrated that IL-6 
is produced by both normal and aneurysmal endothelial cells and IL-6 gene 
transcripts have been demonstrated in atherosclerotic lesions. Seino et al15 
examined levels of IL-6 mRNA in atherosclerotic lesions from the arteries of 
patients undergoing revascularisation procedures. These were found to be 
10 to 40 times higher than levels in non-atherosclerotic arteries. In addition, 
these transcripts were found to be in the thickened intimal layer of the 
lesion. Rus et al16 similarly found elevated IL-6 levels in fibrous plaques 
when compared to normal intima. This would suggest that the increased 
levels of IL-6 seen in the circulation in arterial disease arises from the 
atherosclerotic plaques themselves, in which there is low grade 
inflammation, rather than being a marker of a systemic inflammatory 
response. A similar picture is seen in aneurysmal disease as well. 
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Szekanecz et al17 demonstrated significantly elevated concentrations of IL-6 
in the culture supernatants of explants of abdominal aortic aneurysm (AAA) 
when compared to normal aortic explants. However, levels were also 
significantly greater than those from aorta affected by occlusive arterial 
disease. Shteinberg et al18 similarly found elevated IL-6 concentrations in 
aortic wall from AAAs in comparison to aortic occlusive disease. Interleukin-
6 may also exert part of its effect in vascular disease by influencing 
fibrinogen levels. As stated above, IL-6 is a powerful component of the 
acute phase response. Fibrinogen is one of the products of this response. 
IL-6 is a direct stimulant for increased hepatic production of fibrinogen, 
which in turn affects changes in blood by increasing the viscosity. 
To summarise, coagulation is an intricate and a dynamic process that 
maintains haemostasis by regulating coagulation and fibrinolysis. The role 
of platelets, natural anticoagulant mechanisms and vascular factors are vital 
to this. 
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1.2 PERIPHERAL VASCULAR DISEASE 
1.2.1 Introduction 
Peripheral vascular disease is a common condition throughout the world. 
Several large population studies have examined the prevalence and 
incidence of both symptomatic and asymptomatic disease. These have 
indicated a prevalence of almost nil below the age of 40 years, increasing to 
between 1% and 2% for those aged 40 to 60 years and rising sharply with 
age beyond this. Prevalence of 20% or more has been reported for subjects 
over 75 years. Annual incidence rates also rise with increasing age, with 
reported incidences of 0.2-0.3% in subjects between 45 and 55 years and 
0.5% for 55-65 year olds. The presence of peripheral vascular disease 
correlates strongly with the presence of coronary vascular disease, cerebro-
vascular disease and diabetes. A significant number of patients with 
intermittent claudication die within 5 years from the time of presentation.  
Several studies have demonstrated increased risk of death, from all causes 
and from cardiovascular disease, in patients with PVD compared to age and 
sex matched controls without the condition. A study of the population of 
Framingham19 in Massachusetts between 1949 and 1963 found a relative 
risk of death from all causes of 1.9 in men with PVD and 2.3 for women. The 
relative risks of death for those with co-existent angina pectoris was 2.8 
(men) and 5.2 (women). The Whitehall Study20 of 18,388 male civil servants 
aged 40-64 years between 1967 and 1969 found that those with probable 
intermittent claudication, on the basis of the London School of Hygiene and 
Tropical Medicine Questionnaire, had relative risks of death from all causes 
 
 
 
18 
 
of 1.72 and 2.69 from cardiovascular death. The Speedwell Study's21 
examination of 2348 men aged 45-59 years between 1979 and 1982 showed 
that those with a diagnosis of PVD on the basis of the same questionnaire 
had a relative risk of death of 3.8 from all causes and 4.4 from all circulatory 
causes, after adjustment for age and smoking. Similar relative risks of death 
to these are found in other studies from the United States, Scandinavia and 
the United Kingdom. Population studies have demonstrated a strong 
association between the presence of peripheral vascular disease and an 
increased risk of death, with a predominance of death from cardiovascular 
disease. 
1.2.2 Presentation 
Atherosclerosis underlies most peripheral arterial disease. Although a 
majority of patients are asymptomatic at the time of diagnosis, a percentage 
of patients with PVD will present with intermittent claudication, characterized 
by cramping pain in the legs with exertion that is relieved with rest22, which 
will worsen in approximately 10-20% and progress to critical limb ischemia. 
Narrowed vessels that cannot supply sufficient blood flow to exercising leg 
muscles may cause intermittent claudication, which is brought on by exercise 
and relieved by rest. As vessel narrowing increases, critical limb ischemia 
can develop when the blood flow does not meet the metabolic demands of 
tissue at rest. Critical limb ischemia23 is defined not only by the clinical 
presentation but also by an objective measurement of impaired blood flow.  
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Critical limb ischemia include either one of the following (1) more than two 
weeks of recurrent foot pain at rest that requires regular use of analgesics 
and is associated with an ankle systolic pressure of 50 mm Hg or less, or a 
toe systolic pressure of 30 mm Hg or less, or (2) a non-healing wound or 
gangrene of the foot or toes, with similar hemodynamic measurements. 
 While critical limb ischemia may be due to an acute condition such as an 
embolus or thrombosis, most cases are the progressive result of a chronic 
condition, most commonly atherosclerosis.  
1.2.3 Pathophysiology of Peripheral Vascular Disease  
Plaques tend to localize at the bifurcations or proximal segments of large and 
medium-size arteries. The femoral and popliteal arteries are affected in 80% 
to 90% of symptomatic PVD patients, the tibial and peroneal arteries in 40% 
to 50%, and the aortoiliac arteries in 30%. Single or multiple arterial stenoses 
produce impaired hemodynamics at the tissue level in patients with PVD24. 
Arterial stenoses, end result of significant peripheral atherosclerosis lead to 
alterations in the distal pressures available to affected muscle groups and to 
blood flow. Atherosclerosis involves several highly interrelated processes, 
including lipid disturbances, platelet activation, thrombosis, endothelial 
dysfunction, inflammation, oxidative stress, vascular smooth cell activation, 
altered matrix metabolism, remodelling, and genetic factors. There are seven 
stages of development of an atherosclerotic plaque25. First LDL moves into 
the subendothelium and is oxidized by macrophage and SMCs (1 and 2). 
Release of growth factors and cytokines attracts additional monocytes (3 and 
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4). Foam cell accumulation and SMC proliferation result in growth of the 
plaque (6, 7, and 8).This sequence is shown schematically in Figure. 1.2.1.  
 
Figure 1.2.1 -The 7 Stages of Development of an Atherosclerotic Plaque 
 
Source: Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874. 
 
1.2.4 Risk Factors  
Risk factors play an important role in initiating and accelerating the complex 
process of atherosclerosis. Major risk factors for vascular disease are 
smoking, diabetes mellitus, dyslipidaemia, and hypertension26. 
Smoking 
Smoking is associated with a marked twofold increased risk for 
cerebrovascular and fourfold increased risk for peripheral vascular disease27. 
The number of pack-years is associated with global atherosclerotic disease 
severity, including increased incidence of myocardial infarction28, higher risk 
of stroke, and an increased risk of amputation, peripheral graft occlusion, and 
death.  
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Diabetes 
Diabetes, predominately type 2, is a clear risk factor for stroke, particularly 
ischaemic stroke, with prospective studies reporting up to a threefold 
increase of the relative risk and a more severe stroke-related disability and 
mortality. Although diabetes has been found to be associated with 
angiographically demonstratable extracranial carotid and basilar artery 
occlusion, few reports have clarified the influence of diabetes on large vessel 
cranial atherosclerosis. Diabetes is one of the strongest predictors for PVD 
(twofold increase of relative risk of intermittent claudication) and its 
associated complications, including higher amputation (up to 10-fold 
increase) and mortality rates29.  
Dyslipidaemia 
Several epidemiologic studies have clearly shown that total 
hypercholesterolaemia is among the most important risk factors for PVD30. 
Independent lipidaemic risk factors include elevated levels of total 
cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and 
lipoprotein (a). Elevated levels of high-density lipoprotein cholesterol (HDL-C) 
and apolipoprotein (a-1), the major protein component of HDL-C, seem to 
confer a protective effect. Low HDL-C, high triglycerides, and more recently, 
high lipoprotein (a) levels have been also associated with an increased risk of 
MI and stroke.  
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Hypertension 
Hypertension is associated with all forms of cardiovascular disease and the 
associated mortality increases progressively and linearly with increasing 
blood pressure levels31.  
 
Predisposing risk factors 
Predisposing risk factors for atherosclerosis are those that confer their risk 
through conventional factors and through potentially independent effects. 
Those that are nonmodifiable include advanced age, gender (male sex; 
postmenopausal women), family history and genetics, and race (eg, African 
Americans) and ethnicity32. Those that are modifiable include overweight and 
obesity, physical inactivity, insulin resistance (even without diabetes), and 
socioeconomic-behavioral factors such as social isolation, depression, type A 
personality, work, and family stress. 
Conditional risk factors 
Conditional risk factors have an association with an increased risk of 
cardiovascular disease, although their independent contribution is not well 
documented. They include homocysteine, C-reactive protein (CRP), 
fibrinogen, lipoprotein (a), and hypertriglyceridemia. 
Homocysteine 
Reports from prospective and retrospective studies suggest that elevated 
homocysteine levels are an independent risk factor for vascular disease33 
associated with a mildly increased risk of CHD, stroke, PD, and venous 
thromboembolism.  
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C-reactive protein 
Observational and prospective studies have consistently reported that 
elevated CRP serum levels definitely have prognostic value for 
cardiovascular events and death34. To date, CRP is the only inflammatory 
marker used in clinical practice, but it needs to be emphasized that the 
predictive value of CRP can be estimated only through high-precision assays 
for high-sensitivity CRP. It is within these lower, previously ―normal‖ ranges 
that the high-sensitivity CRP levels seem to have predictive abilities for 
cardiovascular events. 
 
Fibrinogen 
Several prospective studies have associated fibrinogen levels and 
subsequent cardiovascular disease risk35, particularly for coronary heart 
disease and cerebrovascular disease. Some have advocated that fibrinogen 
may have equal effectiveness as total cholesterol in predicting future risk. 
However, whether elevated fibrinogen levels are a cause or consequence of 
atherosclerosis remains unclear. 
Inflammatory markers 
Apart from CRP and fibrinogen, several other inflammatory markers have 
been associated with atherosclerosis and cardiovascular disease36. Serum 
amyloid A (an apolipoprotein associated with HDL-C), high white blood cell 
count, cytokines (interleukins 6 and 18, tumor necrosis factor-α [TNF-α], 
monocyte chemotactic protein-1 [MCP-1]), endothelial adhesion molecules 
(intercellular adhesion molecule 1, P-selectin, etc), circulating soluble CD40 
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ligand (an immune mediator), protease-activated receptors (PARs), and 
lipoprotein-associated phospholipase A2 have been all associated with PVD. 
 
Infection 
Several infectious agents have been associated with the formation of 
atherosclerotic plaque and its complications. Of bacteria, Chlamydia 
pneumoniae, a human respiratory pathogen, has been most strongly 
associated with cardiovascular disease, particularly with acute myocardial 
infarction (MI), cerebrovascular symptoms, PVD, and abdominal aortic 
aneurysm expansion37. However, the lack of standardized methods of testing 
for C pneumoniae infection led to conflicting findings. Currently, the presence 
of C pneumoniae in atherosclerotic vascular tissues merely suggests an 
association; it does not establish an etiologic relationship.  
Haemostatic factors and hypercoagulable states 
There is now sufficient evidence that correlates, apart from homocysteine 
and fibrinogen, other hemostatic factors and hypercoagulable states with 
atherosclerosis. D-dimers, plasminogen activator inhibitor activity, von 
Willebrand factor, and procoagulant factor VII are independent risk factors for 
CHD, PVD, and stroke38. Antiphospholipid antibodies such as lupus 
anticoagulant and anticardiolipin antibodies are also associated with vascular 
damage and have been advocated as independent risk factors for PVD. No 
therapeutic interventions have yet been proposed.  
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Creatinine, urate, and microalbuminuria 
Renal impairment is associated with an increased risk of death in advanced 
PVD, irrespective of the presence of hypertension and diabetes. 
Hyperuricemia is associated with worse functional status of the peripheral 
circulation in hypertensive patients. Microalbuminuria is gaining recognition 
as a marker of an atherogenic milieu and cardiovascular disease. The 
presence, but not magnitude of albuminuria, is an important risk factor for 
PVD in diabetic but not in non-diabetic subjects39.  
 
1.2.5 Management  
The consensus document produced by the Trans -Atlantic intersociety TASC 
working group40 outlines the guidelines for management of patients with 
symptomatic PVD. 
1. Clinical history and physical examination, including the coronary and 
cerebral circulations. 
2. Hematologic and biochemical tests—complete blood count, platelet 
count, fasting blood glucose, hemoglobin Aκ, and creatinine levels, 
fasting lipid profile, and urinalysis (for glycosuria and proteinuria) 
3. Resting electrocardiogram. 
4. Ankle or toe pressure measurement or other objective measures of 
severity of ischemia. 
5. Imaging of lower limb arteries in patients considered for endovascular 
or surgical intervention. 
6. Duplex scan of carotid arteries—should be considered for select 
patients at high risk.  
7. A more detailed coronary assessment may be performed in select 
patients for whom coronary ischemic symptoms would otherwise merit 
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such an assessment if CLI were not present (such coronary 
assessments should generally not impede associated CLI care). 
 
1.2.5.1 Diagnosis of PVD 
Symptomatic PVD can be diagnosed by the presence typical symptoms of 
claudication or pain at rest and calculating the ankle-brachial Pressure index 
(ABPI). The ABPI is the ratio of systolic blood pressure measured at the 
ankle by a Doppler ultrasound device to the higher systolic blood pressure at 
the brachial arteries.  
The estimation of ABPI is helpful because of the following: 
1. Most PVD patients are asymptomatic or have atypical leg symptoms. 
2. Among symptomatic patients, 11% to 33% report classic intermittent 
claudication, and up to one third fail to communicate their symptoms to 
their health care provider.  
3. Those with asymptomatic PVD have a risk of cardiovascular events 
(e.g., myocardial infarction, stroke, cardiovascular mortality) 
comparable with that of patients with symptomatic coronary artery 
disease. 
4. The severity of PVD (as determined by a lower ABI value or 
presentation with symptomatic disease) predicts limb outcome and 
patient survival.  
5. The ABPI is an accurate measure (ABPI less than 0.9 has a sensitivity 
of 95% and specificity of 100% in detecting PVD) that is noninvasive, 
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inexpensive, office-based, and can be reliably performed by primary 
care providers and other health care personnel.   
Based on these characteristics, the most recent American College of 
Cardiology–American Heart Association (ACC/AHA) guidelines advocate 
ABPI measurement for high-risk individuals. It is hoped that such strategy will 
facilitate early detection and institution of management strategies (e.g., risk 
factor modification, exercise rehabilitation, limb revascularization) that will 
help prevent disability, decrease cardiovascular events, and lower early 
mortality. 
The shortcomings of the ABPI test include the potential to miss mild proximal 
disease of the aorta and iliac arteries (also referred to as inflow disease) in 
those with well-developed collaterals and those with significant medial artery 
calcification. Thus, an exercise ABPI should be determined when the resting 
ABPI value is normal if the pretest probability of PVD is high. Other 
diagnostic tests (e.g., pulse volume recording, duplex ultrasonography, 
magnetic resonance imaging, and computed tomography angiography) are 
recommended for those with calcified vessels (e.g., older individuals, those 
with long-standing diabetes or end-stage renal disease) suspected of having 
PVD but with a resting ABPI value of more than 1.3. Conventional contrast-
mediated arteriography rarely is needed to establish the diagnosis of PVD; it 
is largely limited to patients being considered for revascularisation 
procedures. 
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1.2.5.2 Treatment  
The goals of PVD management are limb salvage, symptom relief, improving 
functional status, and preventing cardiovascular events (acute myocardial 
infarction [MI], stroke, and vascular death). All PVD patients require intensive 
cardiovascular risk reduction and should be referred to a supervised exercise 
program. Limb revascularization procedures are offered to select patients. 
Indications for limb revascularisation include acute limb ischemia, critical limb 
ischemia, or lifestyle-limiting claudication. Options include endovascular / 
percutaneous or surgical bypass graft repairs to treat occluded arterial 
segments. 
To summarise, PVD is a major manifestation of atherosclerosis and is 
associated with significant cardiovascular morbidity, limb loss and death.  
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1.3 COAGULATION CHANGES IN PERIPHERAL 
VASCULAR DISEASE 
 
1.3.1 Coagulation in Peripheral Vascular Disease 
Patients with peripheral arterial occlusive disease (PAOD) also known as 
peripheral vascular disease (PVD) are found to be hypercoagulable. They 
manifest an increased risk of developing thrombotic events for varying 
reasons. Virchow's triad41 of reduced blood flow, increased coagulability and 
tissue wall damage promotes the occurrence of intravascular thrombosis. 
The formation and progression of atherosclerotic plaques and intra-arterial 
thrombosis are both mechanisms that may result in narrowing or occlusion of 
arteries seen in cardiovascular and peripheral vascular disease.  
 
1.3.2 Fibrinogen 
Fibrinogen metabolism has been shown to be abnormal in both 
symptomatic and asymptomatic peripheral vascular disease in a number of 
studies, and correlations have been demonstrated between disease 
severity and fibrinogen levels. Fibrinogen is also an acute phase protein, 
whose concentration is increased in the event of trauma, inflammation or 
infection. Dormandy et al42 measured fibrinogen levels in 126 patients with 
intermittent claudication. Sixty percent of the patients had fibrinogen levels 
above the normal upper limit of 4 g/l. In addition, there was a significant 
correlation between plasma fibrinogen and disease progression. Plasma 
fibrinogen also correlated strongly with plasma viscosity. Lowe et al43 
reported the results of the Edinburgh Artery Study with respect to a number 
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of coagulation factors, including fibrinogen, in 1993. In this study, 1592 men 
and women were drawn at random from general practices in Edinburgh and 
screened for both symptomatic and asymptomatic peripheral vascular 
disease. Patients were assessed for PVD using the WHO questionnaire on 
intermittent claudication and medical examination, including assessment of 
ankle-brachial pressure indices and a reactive hyperaemia test. Plasma 
fibrinogen levels were assessed in a sample of peripheral venous blood by 
a thrombin-clotting turbidometric method. Patients with both intermittent 
claudication and major asymptomatic disease had levels of plasma 
fibrinogen significantly greater than in patients with minor asymptomatic 
disease or controls. There was also found to be a strong inverse correlation 
when plasma fibrinogen was related separately to ABPI and this correlation 
was much more marked in men than in women. Woodburn et al44 reported 
similar results in 219 patients with stable intermittent claudication: venous 
plasma fibrinogen levels were significantly elevated in patients when 
compared to age-matched controls and there was a strong correlation 
between severity of disease, assessed by angiographic scoring, and 
fibrinogen. However, multivariate analysis showed that only fibrin 
degradation products were independently associated with angiographic 
severity of disease. Lassila et al45 also showed a relation between 
fibrinogen levels and severity of PVD, as measured by ABPIs, in 409 stable 
claudicants. Smith et al46 followed 607 patients with intermittent claudication 
in Edinburgh for 6 years and related the incidence of vascular events to 
haemostatic factors. The main outcomes observed were stroke (both fatal 
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and non-fatal), myocardial infarction and cardiac death. They observed a 
significantly higher median level of fibrinogen in those who suffered a 
vascular event than those who did not. There is also some evidence that 
raised fibrinogen levels are related to the patency of bypass grafts. 
Wiseman et al47 investigated 157 patients undergoing saphenous vein 
femoropopliteal bypass grafting. At one year, 113 grafts remained patent 
and 44 had occluded. Plasma fibrinogen concentration was identified as the 
strongest predictor of graft occlusion, followed by smoking. Hamer et al48 
demonstrated a significant difference between fibrinogen levels in patients 
with patent or occluded femoropopliteal or aorto-iliac segments after 
reconstructive surgery when followed up for more than 12 months. Lee et 
al, in an analysis of data from the Edinburgh Artery Study49, found that 
fibrinogen levels in diabetics with peripheral arterial disease were 
significantly raised compared to diabetics without evidence of PVD. When 
adjustment for fibrinogen, VWf, t-PA and D-dimers were made, the odds 
ratio for PVD was reduced from 1.45 to 1.11, suggesting that haemostatic 
factors, including fibrinogen, may be partly responsible for the increased 
risk for PVD observed among diabetics. Fibrinogen is one of the acute 
phase proteins synthesised in the liver in response to stimuli such as 
trauma, inflammation or infection. This response has been demonstrated in 
the presence of peripheral vascular disease. Stuart et al50 showed elevated 
levels of the acute phase proteins fibrinogen, antithrombin III, factor VIII and 
serum globulin, as well as high platelet count and activity and neutrophilia, 
in 40 patients with peripheral arterial disease compared to 29 healthy 
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controls.   
It has also been demonstrated that inflammatory markers such as 
interleukins (IL) 1 and 6 and tumour necrosis factor alpha are elevated both 
locally and systemically in the presence of vascular disease, suggesting 
that an inflammatory reaction is taking place in the atherosclerotic plaque. It 
has been postulated that elevated levels of these cytokines, particularly IL-
6, stimulate the synthesis of fibrinogen in the liver and thus the 
hyperfibrinogenaemia seen in vascular disease. While the relationship 
between fibrinogen and vascular disease has been most completely 
characterised, an association between a number of the other components 
of the haemostatic system and vascular disease has also been 
investigated.  
 
1.3.3 Markers of Activation of Coagulation in PVD 
Aside from increased fibrinogen levels, raised levels of fibrin degradation 
products, in particular D-dimers, have been demonstrated in a number of 
studies. There is also good evidence of abnormal coagulation activation (as 
witnessed by abnormal levels of thrombin-antithrombin complexes (TAT) 
and Prothrombin fragments F1.2), and of impaired fibrinolysis in peripheral 
vascular disease. The high levels of von Willebrand factor seen in PVD also 
suggest an endothelial element to the abnormal coagulation seen in the 
disease process. Cortellaro et al., reporting on the PLAT study51, Lassila et 
al52, Fowkes et al53, Trifilleti et al54, Woodburn et al55, De Buyzere et al56 
and Lee et al57 all report a statistically significant association between the 
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presence of both symptomatic and asymptomatic peripheral vascular 
disease and raised levels of fibrin degradation products (FDPs). As with 
fibrinogen, Lassila et al17 and Woodburn et al20 demonstrated a significant 
correlation between the severity of the disease, as indicated by both ankle-
brachial pressure indices and the angiographic extent of disease, and 
FDPs. Lee et al49. demonstrated a strong inverse correlation between FDPs 
and ABPIs in both symptomatic and asymptomatic PVD sufferers in the 
Edinburgh Artery Study. The significance of this was reduced after 
adjustment for risk factors including smoking, but remained significant in 
men. This was also the case after adjustment for fibrinogen concentrations. 
Raised FDP levels have also been shown to be related to the progression 
of PVD and to the risk of cardiovascular events. Fowkes et al18 showed a 
significant independent correlation between cross-linked fibrin degradation 
products and progression of PVD (as assessed by serial ABPIs) in 617 
claudicants. There was also a strong relationship between FDPs and 
(combined fatal and non-fatal) cardiac events during a 1 year follow-up 
period. Boneu et al58 showed a relationship between D-dimers and the risk 
of a vascular event at 2 years follow-up in 324 claudicants, but this 
relationship became non-significant on multivariate analysis. Woodburn et 
al59 measured FDP levels before and 16 weeks after resolution of critical 
limb ischaemia but found that, unlike fibrinogen, there was no significant 
change after revascularisation. 
Further evidence of activation of the coagulation system comes from 
studies of TAT complex and Prothrombin F1.2, indicators of thrombin 
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production. De Buyzere et al60 demonstrated that levels of TAT and F1.2 
were significantly elevated in 34 patients with Fontaine61 stage II PVD when 
compared to age and sex-matched controls. These factors were not altered 
by treadmill testing. Similar findings were reported by Herren et al62 in 22 
patients with similar disease when compared to 13 controls. Strano et al63 
were also able to show raised levels of TAT in 103 PVD patients when 
compared to controls. Lassila et al17 demonstrated that TAT levels were 
progressively associated with the angiographic and clinical severity of PVD 
in a similar relationship to that seen with FDPs. Boneu et al23 demonstrated 
that high levels of TAT complexes were independently predictive of vascular 
events in the 324 claudicants studied. These data suggest that there is 
increased activity of the coagulation system in patients with PVD with a 
resultant increase in thrombin formation. However, the subsequent role of 
the thrombin formed is less clear. In the coagulation cascade, thrombin 
cleaves fibrinogen to form fibrin and the protein fibrinopeptide A (FPA). FPA 
is thus a good marker of the action of thrombin on fibrinogen. However, 
there is disagreement in the literature over the relationship between FPA 
levels and vascular disease. Lassila et al17 found elevated levels of FPA in 
60% of their patients with stable claudication and FPA correlated 
significantly with fibrinogen and TAT levels. Fowkes et al19demonstrated a 
significant correlation between urinary FPA levels and the risk of fatal (but 
not non-fatal) coronary events in 617 claudicants. Lee et al14 demonstrated 
a significant independent correlation between urinary FPA levels and the 
risk of intermittent claudication in the same patients. However, neither 
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Herren et al28 nor Lowe et al8 were able to demonstrate a relationship 
between urinary and plasma FPA and the presence of peripheral vascular 
disease, although the former did demonstrate relationships between F1.2, 
TAT and PVD. This may have been related to insensitivity of the assays 
used as the quantities of FPA are very small and it has a half-life of only 
around 4 minutes in plasma. High levels of D-dimer, a product of the 
degradation of fibrin suggests that there is increased fibrin formation in 
patients with PVD. How much of this due to the excess formation of 
thrombin in these patients and to what extent this excess is negated by 
formation of a complex with anti-thrombin remains unclear. 
1.3.4 Fibrinolysis in PVD 
As has been stated above, there is much evidence of activation of the 
coagulation system in the patient with vascular disease. However, there are 
indications that the fibrinolytic system is also deranged. Plasmin catalyses 
the cleavage of fibrin to FDPs in the plasma. It is itself formed from the 
inactive precursor plasminogen by the action of plasminogen activators, t-
PA and u-PA, a process which is weak in the absence of fibrin but is greatly 
enhanced in the presence of excess fibrin. The action of these catalysts is 
opposed by the plasminogen activator inhibitors PAI-1 and PAI-2, though 
the former is much more significant. Studies have demonstrated 
abnormalities in both plasminogen activation and its inhibition in the 
vascular patient. In the PRIME study, Scarabin et al64 conducted a 
prospective study of 10,500 men between 50-59 years old from France and 
Northern Ireland. Patients with coronary arterial disease or peripheral 
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arterial disease showed significantly elevated levels of PAI-1, though this 
association was not seen in men with symptomatic cerebro-vascular 
disease. Elevated PAI-1 was also associated with diabetes mellitus, 
smoking, alcohol intake, higher body mass index, increasing waist: hip ratio 
and plasma triglyceride levels. De Buyzere et al28 and Trifiletti et al65also 
demonstrated significantly elevated levels of PAI-1 in PVD patients. In the 
former, a similar relationship was seen for t-PA antigen levels. They found 
no difference in t-PA antigen levels in patients versus controls. Phillipp et 
al66 reporting on 46 patients in the Arterial Disease Multiple Intervention 
Trial, also found PAI-1 to be significantly elevated in patients but 
multivariate analysis showed this not to be independent of other 
confounding factors. Boneu et al14 showed that high PAI-1 levels correlated 
with subsequent vascular events in claudicants. Roller et al67 demonstrated 
significantly elevated levels of PAI-1 antigen and activity in PVD patients. 
PAI-1 activity at 24 and 48 hours after percutaneous transluminal 
angioplasty also correlated with late re-stenosis at 6 months. An elevated t-
PA antigen level was also seen in PVD patients in this study, but no 
relationship to re-stenosis was seen. Killewich et al68 demonstrated 
significantly elevated PAI-1 levels in patients with both mild and severe 
intermittent claudication, when compared to controls. Low t-PA activity was 
seen in patients in the severe claudication group when compared to the 
mild claudication and control groups, as seen in other studies. Levels of t-
PA antigen also correlated inversely with pain-free walking time. The 
difference between t-PA activity and antigen levels is because the assay of 
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antigen measures both free plasma t-PA and that bound to PAI-1 in active 
complexes. A finding of high antigen levels but low activity would thus be 
consistent with high PAI-1 production, partly neutralised by combination 
with t-PA. Lee et al69 found a correlation between severity of peripheral 
arterial disease, as measured by ABPIs, and t-PA antigen. 
 
1.3.5 Von Willebrand Factor  
A few studies have examined the relationship between Von Willebrand 
factor and vascular disease, as it is a possible marker of endothelial 
disease. Woodburn et al70 found significantly higher vWF levels in patients 
with PVD. The levels were significantly reduced 4 months after 
revascularisation, though still elevated when compared to controls. Lee et 
al49 found a correlation between vWF levels and severity of PVD, but only in 
men. The ADMIT study did not detect any difference in vWF levels between 
patients and controls. Cortellaro et al71 found a significant correlation 
between vascular events and elevated levels of vWF antigen in patients 
with angina pectoris, but not in patients with peripheral vascular disease. 
Relationships between some other elements of the coagulation system and 
vascular disease have also been examined in few studies. Low levels of 
Protein C and Protein S have been demonstrated in PVD patients by Strano 
et al72 reported an increased risk of vascular events in PVD patients 
associated with low Protein C levels. Trifiletti et al73 demonstrated 
significantly elevated plasma thrombomodulin levels in PVD patients which 
may be a marker of endothelial damage and promoter of thrombosis. Boneu 
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et al74 found no association between the level of soluble thrombomodulin 
and the risk of vascular events in claudicants. 
To summarise, a large body of evidence now exists in the literature that, 
patients with peripheral vascular disease exhibit abnormalities in a number 
of elements of the coagulation and fibrinolytic systems. Changes are also 
seen in PVD patients after reconstructive surgery, though not with a 
complete return to normal values. There is also clear evidence of activation 
of the coagulation system, as witnessed by increased thrombin formation 
(raised TAT and F1.2 levels) and fibrinogen turnover (elevated FDPs). 
Conversely, there is also good evidence for defective fibrinolysis in these 
patients. Several studies demonstrate high PAI-1 activity and t-PA antigen 
levels, as well as low t-PA activity suggesting an overall shift in the balance 
of factors affecting fibrinolysis towards decreased fibrinolysis.  
Available evidence point towards a hypercoagulable state in patients with 
peripheral vascular disease, activation of coagulation and impairment of 
fibrinolysis contributes to this. Whether this hypercoagulable state 
contributes to the formation and progression of PVD, or is merely a result or 
reflection of it remains unclear. 
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1.4 THROMBOELASTOGRAPHY (TEG) 
1.4.1 History and Principles of Thromboelastography (TEG) 
Helmut Hartert, a physicist from Germany, first described the 
Thromboelastograph in 1948 and it has been utilised as a research tool since 
then, though it has only been applied to clinical situations in the past two 
decades. 
The end point of blood clotting is the formation of a stable clot that is 
capable of limiting blood loss from a damaged vessel. The production of this 
clot requires the correct functioning of many different components involving 
clotting factors, platelets and other blood cells and the vascular 
endothelium. A similarly complex process governs the dissolution of the 
clot. A defect in one or more of these components, or in the interactions 
between them, will have an adverse effect on the body‘s ability to bring 
about haemostasis effectively. A wide range of tests are available to both 
researchers and clinicians examining blood clotting. However, these are 
usually only able to examine one component of clot formation and it is often 
unclear what impact a specific defect will have on clotting overall. In 
addition, many tests are time-consuming with blood samples needing to be 
separated into cellular and non-cellular components before testing. This is 
of particular concern in the clinical setting. The coagulation profile of a 
critically ill patient often changes very rapidly so that information from 
laboratory-based tests may be obsolete by the time it is received. In 
addition, while current laboratory tests may give information about the rate 
of clot formation, they tell nothing about the quality or stability of the clot. It 
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is clear that there is a place for a global test of blood clotting that may be 
performed rapidly and at the point of care. 
Thromboelastography (TEG)75 measures the visco-elastic properties of a 
blood clot and thereby gives information about the combined function of all 
the factors involved in the process of clot formation and its subsequent 
dissolution. This is in contrast to routinely available coagulation tests, which 
assess only isolated stages of this process. This technique is a global test of 
coagulation that can be performed on a small sample of blood and can be 
performed repeatedly as a point of care testing method to monitor changes in 
coagulation of blood. 
1.4.2 Technique of TEG 
Thromboelastography (TEG) fulfils many of the criteria required of a global 
test of blood clotting. TEG principle is based on the changes in the physical 
properties during and after the process of formation of a blood clot. The 
TEG apparatus consists of a cup or a cuvette heated to 37C containing 
0.36 ml of whole blood. If the blood has been preserved with citrate, then it 
may be recalcified by the addition of 0.15 ml of calcium chloride. The cup 
moves through 40-44 degrees of rotation every ten seconds in an oscillating 
pattern. Into this cup of blood is lowered a pin which is suspended from a 
torsion wire, connected to a transducer (Figure.1.4.1).   
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Figure 1.4.1 Principles of Thromboelastography  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When the blood is in its liquid phase, there is no coupling between the pin 
and the movement of the cup and a flat trace is produced. However, as clot 
begins to form, the pin begins to be dragged along with the cup, a motion 
which increases as the clot progresses. The motion of the pin is converted 
by the transducer into a trace either on paper or, more usually now, onto a 
computer. The TEG is effectively measuring the shear modulus of the clot. 
The TEG, like many conventional tests of clotting, will measure the time it 
takes for clot to first develop. This is known as r (reaction time) and is taken 
as the time from the start of the test to when the TEG tracing reaches 2mm 
in amplitude. The normal range for this is 6-8 minutes. The r value 
represents initial fibrin strand formation.  Whereas this marks the end point 
for most conventional tests, the TEG goes on to measure the rate of clot 
formation. The K value or clot formation time is from the r time until the 
tracing reaches an amplitude of 20mm and indicates the time taken for the 
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clot to attain an arbitrarily chosen (but constant) degree of visco-elasticity. 
This is dependent on the degree of fibrin formation and cross-linking. The 
normal value for this is between 3 and 6 minutes. The Alpha angle is the 
angle of the tracing between the r and K values and denotes the rate of clot 
formation. This is normally between 50 and 60 degrees. The Maximum 
Amplitude (MA) of the trace is indicative of the peak strength that the clot 
attains and is usually between 50 and 60 mm. Once the MA has been 
reached, the clot will begin to weaken as the process of fibrinolysis begins 
to outpace that of coagulation. This is also measured by the TEG. The A60 
is the amplitude of the tracing 60 minutes after MA is attained. It is therefore 
a measure of clot lysis and has a normal range of MA-5mm. The CL30 and 
CL60 are estimates of the proportion of the clot that has been lysed 30 and 
60 minutes respectively after MA has been reached. A typical TEG trace for 
a normal blood sample is shown in Figure.1.4 2. The key measurements of 
the TEG are combined to produce the Coagulation Index (CI). This single 
value gives an overall picture of the coagulation for a given sample and 
allows different samples to be compared easily. It is derived by the following 
formula: 
Coagulation Index = 0.1227r + 0.0092K + 0.1655MA - 0.0241α angle - 
5.0220.76 
1.4.3 Interpretation of a TEG Analysis 
Correlation between TEG and the established tests of coagulation77 is poor 
because of the interactions between different pathways that may affect 
 
 
 
43 
 
overall clotting. However, different TEG variables are disproportionately 
affected by defects in particular components of the coagulation system. The 
initiation and early rate of fibrin strand formation is related to the intrinsic 
pathway and it is therefore defects in this that predominantly affect the r 
time. Deficiencies in coagulation factors, heparinisation or 
hypofibrinogenaemia may all cause the r time to be increased, while it may 
be shortened in conditions that cause hypercoagulability78. The K time 
reflects continued clot formation and its cross-linking and is affected by the 
functioning of intrinsic clotting factors, fibrinogen and platelets. The (Alpha) 
α angle is affected predominantly by fibrinogen and platelet activity and will 
be reduced in the presence of thrombocytopaenia or hypofibrinogenaemia. 
The MA is affected most markedly by any abnormality in the number or 
functional competence of platelets. Some defects of haemostasis do not 
directly affect clot strength or stability and thus do not manifest themselves 
at all in the TEG trace79. The commonest of such defects is the effect of 
low-dose aspirin on platelets. Because aspirin has little effect on thrombin-
induced platelet aggregation it does not affect clot integrity or the TEG 
trace80. Similarly, the reduced adhesion of platelets to the endothelium that 
is characteristic of chronic renal failure does not affect the physical 
properties of the clot that is tested by TEG and thus does not affect the 
trace. 
 
 
 
 
 
 
44 
 
 
Figure 1.4.2 Thromboelastography Trace 
 
 
 
 
 
 
 
 
 
 
 
 
A schematic of a thrombelastograph (TEG(R)) trace showing the r time, K 
time, alpha ([alpha]) angle, maximum amplitude (MA) and A60 (see text). In 
comparison with a normal trace (A), fibrinolysis (B) is associated with a 
prolonged r time, reduced MA and a reduced A60, while hypercoagulability 
(C) is associated with a short r time and an increased MA. 
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Figure 1.4.3 TEG Analyser and a Computer Generated TEG Trace  
 
 
 
 
Thrombelastograph(R) 5000 coagulation analyser (courtesy Medicell Ltd.) 
(Figure 1.4.3) and a normal trace generated by computerized software 
(courtesy of Dr Sue Mallet, Royal Free Hospital). Parameters are given 
together with a normal range in parentheses (Figure 1.4.5). 
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Figure 1.4.4 Heparinase Modified TEG (hepTEG) 
 
 
 
This two-channel, two-colour thrombelastograph trace (Figure 1.4.4 ) was 
generated by simultaneous recordings from a standard cup and a 
heparinase-coated cup at the reperfusion phase of orthoptic liver 
transplantation (courtesy of Dr. Sue Mallet, Royal Free Hospital). The native 
sample (blue trace) initially generates a straight-line trace indicating the 
reperfusion coagulopathy. The improvement that occurs when engraftment 
occurs is indicated by a widening in the amplitude of the trace. Comparison 
with the trace generated from the heparinized cup (red trace) enables the 
contribution of heparin to the coagulopathy to be assessed. The reduced 
maximum amplitude (MA) seen in the red trace from the heparinase cup is 
indicative of a persistent underlying coagulopathy in this patient, unrelated to 
heparin administration. 
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Figure 1.4.5 Normal Citrated Whole Blood TEG Trace 
 
 
 
Key: R, Reaction time (time to initial fibrin formation);K, dynamics of clot 
formation; Angle, acceleration of fibrin buildup and cross-linking (clot 
strengthening); MA, maximum amplitude (ultimate clot strength); CI, 
coagulation index (overall coagulation status); LY30, percent lysis at 30 
minutes after MA;LY60, percent lysis at 60 minutes after MA; G, clot firmness 
as shear elastic modulus; EPL, estimated percent lysis; A, current amplitude 
 
1.4.4 Current Applications of TEG 
Thromboelastography has not become widely accepted as a test of 
coagulation in clinical practice, but its use is well established in some 
specialities, most notably liver transplantation and cardiac surgery that use 
cardiopulmonary bypass81. Patients undergoing orthotopic liver 
transplantation are usually thrombocytopaenic and deficient in clotting 
factors due to their underlying liver disease and are therefore in a 
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hypocoagulable state prior to surgery. During the course of transplantation 
severe fibrinolysis causes this hypocoagulable state to deepen rapidly to 
the extent that no clot is formed in the period shortly after the transplanted 
organ is reperfused. Kang et al 82demonstrated that the patient‘s 
coagulation state could be rapidly monitored in the operating theatre using 
TEG and that this resulted in reduced blood loss in 66 patients undergoing 
liver transplantation. The specific therapy instituted for coagulopathies in 
these patients could be guided by the TEG results. For example, clotting 
factors (in the form of fresh frozen plasma) if the r time was prolonged or 
platelets if the MA was low. This directed therapy ensured that the most 
appropriate blood product was given for the defect present and avoided the 
unnecessary use of others. McNicol et al83 demonstrated reduced blood 
loss and transfusion requirements in 75 patients undergoing liver 
transplantation whose coagulation was monitored using TEG. Harding et 
al84 demonstrated that the use of heparinase-coated cups in TEG allowed 
the presence of heparin-like substances to be allowed for in the monitoring 
of coagulopathies of patients undergoing liver transplantation. Many of the 
defects of haemostasis seen in these patients are also evident in those with 
liver disease such as cirrhosis. Chau et al85 and Papatheodoridis et al86 
successfully applied TEG in the management of these patients. Similar 
problems of hypocoagulability present themselves during cardiac surgery in 
which cardiopulmonary bypass is employed. Patients on bypass are usually 
heparinised and this is commonly reversed with protamine sulphate at the 
end of the procedure. In addition, cardiopulmonary bypass in itself seems to 
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produce abnormalities of haemostasis though it is not known whether this is 
due to bypass, the effects of haemodilution or some other cause. Because 
these changes in coagulation are rapid and unpredictable, the use of TEG 
has been shown to be valuable during and after cardiac surgery87. Spiess et 
al88 showed that TEG was a better indicator of postoperative bleeding and 
the need for re-operation than conventional clotting tests after cardiac 
surgery. They found that transfusion with fresh frozen plasma was not 
indicated by the TEG in any of the 92% of patients who received it after 
cardiac surgery. Of the patients who were given platelet transfusions, 60% 
did so unnecessarily.  
Thromboelastography has also been suggested in a wide range of other 
applications. These include the monitoring of oral anti-coagulation therapy89, 
the management of snake bite90 victims (many of which are powerful natural 
anti-coagulants) and the prediction of bleeding in patients after renal biopsy 
and transplantation91. TEG has been shown to identify functional 
abnormalities of factors involved in coagulation even if their concentration is 
in the normal range and it is a sensitive, specific and rapid way to assess 
coagulation92.  TEG can detect activation of coagulation in patients 
undergoing general surgical93, abdominal aortic94 and neuro- surgical 
procedures95 and TEG guided transfusion protocols have been shown to 
reduce blood and blood product usage in patients undergoing cardiac bypass 
procedures96. TEG in patients undergoing abdominal aortic aneurysm repair 
can identify post- operative hypercoagulability13, monitor the adequacy of 
anticoagulation (heparinisation) during peripheral vascular reconstruction 
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procedures97 and assess platelet function in vascular patients98. TEG has 
been shown to reduce the consumption of blood and blood products in the 
treatment of massive haemorrhage99 complicating open cardiac procedures 
and is now routinely employed as point of care testing method in cardiac 
surgical departments. TEG is now routinely employed to identify 
hypercoagulation following neurosurgery, in major trauma and in liver 
transplantation to guide administration of blood components, coagulation 
factors and platelets. The sensitivity and specificity of this technique has 
been shown to be particularly good when compared to routine tests of 
coagulation, anti-Xa levels, bleeding time, thrombin time and APTT/PT ratio 
estimations100 especially in the management of coagulopathy.  
The application of TEG in the management of patients with peripheral 
vascular disease (occlusive) has not been described. However, many 
abnormalities of coagulation are encountered in these patients. The majority 
will have been on long-term anti-platelet therapy. Many will be anti-
coagulated with heparin during surgery and the surgeon may choose to 
reverse this with protamine sulphate at the end of the procedure. It is known 
that a large proportion of these patients have an underlying 
hypercoagulable state, although the reasons for this have not been fully 
elucidated. Some will undergo procedures of long duration with large 
requirements for intravenous fluid replacement which may also compromise 
coagulation. The combination of these many different factors can make it 
difficult to assess and correct a patient's overall coagulation state 
accurately. Yet it is obviously important to do this to prevent bleeding from 
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vascular anastamoses. TEG may provide the means to do this rapidly in the 
operating theatre or ward setting.          
1.4.5 Citrate Storage of Blood Samples and TEG 
TEG analysis of fresh whole blood sample is performed within 6 minutes of 
collection. This is not always possible as TEG analysers are not readily 
available currently in our hospitals. Hence citration and analysis of samples 
collected are carried out after storage and recalcification to obtain reliable 
TEG parameter values. TEG assay of citrated blood samples exhibit 
variability and are unstable for a period between 0-30 minutes after citration. 
The range provided by the manufacturer is wide, makes no allowance for age 
or sex, and may need to be modified because of local variations in practice. 
Rajwal et al101 found that there was significant difference between TEG 
parameters for fresh native whole blood and citrated whole blood and 
recommended establishment of a specific range for citrated whole blood for 
usage in clinical practice. Dormandy et al102 suggested a formal standard 
operating procedure for citrated whole blood TEG (Figure.1.4.5) that takes in 
to consideration the initial period of instability.  Camenzind et al103looking in 
to the effects of citrate storage on TEG showed that the parameters were 
different in recalcified, citrated blood samples compared with native blood. 
The observed changes were progressive in samples during 0-30 min. of 
storage but were stable thereafter and the authors recommend analysis after 
a citrate storage period between 1- 8 hours for reliable TEG results. 
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1.4.6 The Use of Heparinase in TEG (hepTEG) 
This technique employs modified TEG cups containing heparinase-I, an 
enzyme obtained from Flavobacterium heparinum which selectively breaks 
down the GAGs, heparin and heparan-sulphate11 to identify heparin-like 
activity in a given blood sample. R time represents such anticoagulant 
activity in a given sample of blood. Heparinase has been shown to 
neutralise heparin more effectively than protamine in blood samples 
obtained during cardiopulmonary bypass104. This method has been shown 
to be both sensitive and specific for the detection of changes due to heparin 
activity when compared with conventional tests of anti-Xa activity, activated 
partial thromboplastin time and activated coagulation time105.  The 
technique is used in cardiac surgery to check the extent of heparin reversal 
by protamine in postoperative patients106 and to detect increased 
endogenous heparin activity following orthotopic liver transplantation.9 
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SUMMARY OF INTRODUCTION 
 
Consistent findings of activation of coagulation and impairment of 
fibrinolysis confirm a hypercoagulable state in patients with peripheral 
vascular disease. Whether this hypercoagulable state contributes to the 
formation and progression of PVD, or is merely a result or reflection of it 
remains unclear. 
Atherosclerosis and inflammation along with contributions from activated 
platelets and defective endothelial function lead to formation of 
atherosclerotic plaques. Symptomatic PVD patients incur higher risk of 
cardiovascular morbidity, limb loss and death. 
TEG technique though initially used as a research tool has now been proven 
to be a global test of coagulation that gives comprehensive and reliable 
information regarding the status of coagulation using a small volume of blood 
sample and is now routinely used to assess coagulation in patients 
undergoing cardiac surgery and liver transplantation. 
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AIMS OF THE THESIS AND 
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AIMS OF THE THESIS AND PLAN OF INVESTIGATION 
 
The purpose of the research described in this thesis is: 
 
1. To investigate changes in coagulation using TEG in healthy individuals 
undergoing elective surgical procedures and to obtain reference TEG 
parameter values to act as controls.  
 
2. To identify any effect of peripheral atherosclerosis and ischaemia on 
coagulation in patients with symptomatic PVD. 
 
3.   To identify and document any significant changes in coagulation in 
patients with symptomatic PVD undergoing treatment using TEG. 
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OVERVIEW OF INVESTIGATION 
1. Validation and standardisation of TEG methods 
2. Investigation of the effects of age, gender and anaesthesia on 
coagulation using TEG -   control group study                                       
3. Investigation of the effects of sampling site, peripheral atherosclerosis  
and peripheral ischaemia on TEG                                         
4. Investigation of the thrombogenic potential of non-ionic contrast media 
in PVD using TEG. 
5. Identification of endogenous heparin-like activity in PVD using TEG.                        
Investigation of changes in coagulation changes in aortic aneurysmal 
disease using TEG.                         
6. Investigation of TEG changes in patients with PVD undergoing 
surgery.       
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CHAPTER 2 - MATERIALS AND METHODS 
 
This project was approved by the local ethics committee and registered with 
the Oxford Radcliffe Hospitals Trust. 
All patients and healthy controls were recruited at John Radcliffe Hospitals 
after an informed consent.  
 
2.1 - VALIDATION AND STANDARDISATION OF TEG   
        METHODS 
 
2.1.1 Patients and Participants 
15 patients undergoing abdominal aortic aneurysm repair or peripheral 
vascular surgery consented to participate in the study.  
2.1.2 Blood Sampling 
Manspeizer et al107 in their study involving arterial and venous samples from 
40 cardiac surgical patients, yielding 134 pairs for comparison demonstrated 
that when arterial blood samples were analysed using TEG,  values reflecting 
stronger (larger maximum amplitude) and faster (shorter reaction time and K 
value, wider alpha angle) clot formation were obtained. However twenty-nine 
comparisons (control) were between arterial and arterial samples and were 
not significantly different. Thrombelastograph (TEG) values obtained from 
venous blood samples were different from values obtained from arterial blood 
samples in their study. The results suggested that users of TEG coagulation 
analysers should be consistent with the site of blood sampling given the 
potential differences obtained in cardiac surgery patients. Hence this 
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validation study sought to identify any such differences in the study group 
(patients with PVD) by obtaining peripheral venous blood samples (n=15) 
and radial artery samples (n=15) for analysis using TEG. 
Radial artery samples were obtained by aspiration from an arterial line placed 
prior to commencement of surgery. The samples were obtained before and 
after administration of IV heparin 5000 IU. These samples were used for 
validation of heparinase coated cups and to confirm reversal of heparin effect 
by heparinase108 during TEG analysis. 
Camenzind et al109, in their study involving citrated venous samples for TEG 
analysis showed that TEG parameters were found to be stable and reliable 
when analysed after a period of delay with citrate storage between 1-8 hours.  
Hsu et al110 in their study involving orthopaedic patients and TEG showed 
evidence for activation of coagulation when a tourniquet was used to obtain 
peripheral venous samples for TEG analysis. Hence in this study, peripheral 
venous samples were obtained following venupuncture without application of 
a tourniquet were used for validation of TEG analysis. Blood samples were 
analysed after 1-2 hours of citrate storage using Thromboelastograpy(TEG) 
for this study as it was in the recommended time frame after citration, allowed 
collection of blood samples at closely timed sampling points and for logistical 
reasons including the fact that the TEG analyser was located far from where 
the samples were collected. To assess TEG assay variability, each sample 
analysed was divided in to 3 and each one assayed separately.  
 
 
 
60 
 
2.1.3 TEG Analysis 
The TEG apparatus is ensured that its temperature is at 37C. A plain plastic 
disposable cuvette or a cup is used for analysis of blood samples. 
Heparinase coated cups were used for samples collected after exposure to 
heparin administration. Once the cup or a cuvette is in place, recalcification 
of citrated samples is done by adding 20 microlitres of calcium chloride to the 
pipetted blood (360 microlitres) and a pin connected by a torsion wire which 
in turn is connected to a computer is lowered in to the sample and analysis is 
commenced and TEG trace starts. Five TEG parameters, R time, K time, 
Angle, MA and CI are used in this study. 
2.1.4 Statistics 
To assess TEG assay variability, TEG parameters values obtained (each 
sample which was analysed divided in to 3 and each one assayed 
separately) were tested for intra–assay variability and the reliability 
coefficients were also calculated.  
Validation of the use of heparinase cups by TEG analysis of blood samples 
was done by comparing TEG parameter values obtained before and after 
heparin administration using Mann-Witney test.  
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2.2 - INVESTIGATION OF THE EFFECTS OF AGE, GENDER 
AND ANAESTHESIA ON COAGULATION USING TEG -   
CONTROL GROUP STUDY                                       
 
2.2.1 Subjects 
Subjects undergoing elective general surgical, orthopaedic and 
gynaecological procedures were recruited prospectively for this study. (Table 
2.2.1) 
Exclusion criteria included all patients with any malignancy, a known 
coagulation disorder, chronic liver disease, chronic renal failure, previous 
history of DVT, patients on OC pills, HRT, pregnancy and those with 
symptoms of peripheral vascular disease or an ABPI (Ankle/Brachial 
Pressure Index) of < 0.9.  
The participants did not receive any exogenous heparin prior to surgery (day 
surgery procedures).   
Subjects were recruited based on age, gender and menopausal status 
(n=50). Groups included 1) men aged 35-65 years (n=10), 2) men aged > 65 
years (n=10), 3) pre-menopausal women aged 35-50 years (n=10), 4) 
postmenopausal women aged 50-65 years (n=10) and 5) women aged > 65 
years (n=10). 
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Table 2.2.1 Demographic and Vascular Risk Factor Details of the 
Participants 
 
Group  
(gender / age / yrs) 
 
Men 35-65 
 
Men > 65 
yrs 
 
Women 
35-50yrs 
 
Women 
50-65 yrs 
 
Women > 
65 yrs 
 
Number(n= 50) 
 
 
10 
 
10 
 
10 
 
10 
 
10 
 
Age(median/range) 
 
43.6 +/- 6.3 71.1+/- 4.4 46.7 +/- 
4.6 
62 +/- 1.2 68.2 +/- 1.4 
ABPI(Mean/SD) 1.1+/- 0.10 0.92 +/-
0.12 
1.1+/-
0.24 
1.0 +/-0.28 0.96 +/- 
0.17 
BMI (Kg/m2) 25.06 +/- 2.5 23.1+/- 2.4 23.4 +/- 
3.6 
22.2 +/- 2.2 23.9 +/- 2.7 
DM           -          2          -         1         1 
Hypertension           1          3          -         1         3 
Hyperlipidaemia            2           2          -         1         2 
Prev AMI            -           1          -         -          1 
Prev CVA            -           1          -         -          1 
Prev DVT            -            -          -         -           - 
Abd.Aortic aneurysm            -           1          -         -           - 
Antiplatelet use            2           4          -         1           3 
Statin intake            2           2          -         2           3 
Current smoking            2            1          1         2           - 
Key: ABPI: Ankle/Brachial Pressure Index; BMI: Basal Metabolic Index; DM: diabetes mellitus; AMI: 
acute Myocardial infarction; CVA: cerebro vascular event; DVT: deep vein thrombosis. Hypertension 
defined as any blood pressure measurement above 140/80. 
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2.2.2 Blood Sampling 
Peripheral venous blood samples were obtained at three different time 
points.  
Time points for sampling were 1)10-15 minutes before induction of 
anaesthesia (epidural (n=10), general (n=30) or epidural+ general 
anaesthesia (n=10)), 2) 5-10 minutes after induction of anaesthesia (on table 
/ before skin incision) and 3) at 20-30 minutes after start of surgery.  
Samples were obtained from the ante-cubital vein without tourniquet to 
minimise activation of the coagulation cascade during sample collection.  
Samples were analysed after a delay of 1-2 hours of citrate storage prior 
recalcification. 5 TEG parameters (R, K, Angle (), MA and CI) were used in 
this study. 
2.2.3 Statistical Methods 
TEG values for samples obtained at baseline (pre-induction of anaesthesia), 
post anaesthesia (prior to commencement of surgery) and at 30 minutes of 
surgery were compared. To account for three sampling points, a Bonferroni-
corrected value of P<0.017(obtained by dividing 0.05 by 3) was used to 
identify statistical significance.  TEG data within groups were analysed using 
Wilcoxon Signed Rank Test. Significant differences in TEG parameters 
between groups was sought using Mann-Witney U test. Data are presented 
as mean +/- SD and all p values are two-tailed. 
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2.3 - INVESTIGATION OF THE EFFECTS OF SAMPLING SITE, 
PERIPHERAL ATHEROSCLEROSIS AND PERIPHERAL 
ISCHAEMIA ON TEG     
                                   
2.3.1 Aim of Study 
To measure changes in coagulability of blood as it circulates from the aorta 
through an ischaemic leg to the common femoral vein using 
Thromboelastography® (TEG). 
To identify any relationship between changes in TEG parameters and 
angiographic severity of atherosclerotic disease in the intervening vessels. 
 To identify any relationship between changes in TEG parameters as blood 
flows from common femoral artery to vein and the degree of ischaemia in that 
limb. 
2.3.2 Subjects 
30 sequential patients over the age of 40yr who were undergoing 
transfemoral angiography for lower limb peripheral vascular disease via a 
retrograde femoral puncture and who agreed to participate in the study were 
recruited. 
 Demographic data, the coexistence of other disease and smoking habits 
were all recorded. The ankle/brachial pressure index (ABPI) in both legs was 
measured and that in the symptomatically less affected leg  (see later) used 
as a measure of the severity of ischaemia for the purposes of this study. 
Details are given in Table 2.3.1. 
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All patients underwent duplex study of the lower limb veins bilaterally to rule 
out deep vein thrombosis (DVT) before angiography.   
Exclusion criteria for participants included the presence of DVT, liver 
impairment, a known hypercoagulable state (excluding PAOD) and the 
presence of any malignancy.  Any patients taking Warfarin had this 
medication stopped 3 days before angiography. 
2.3.3 Blood Sampling and Analysis 
Blood samples were obtained from the common femoral vein (Sample V) on 
the same side as the intended arterial puncture, by separate percutaneous 
puncture, after infiltration of the subcutaneous tissue with local anaesthetic 
(lignocaine 1%).  
 The radiology protocol dictated that this puncture was on the side of the less 
symptomatic leg. A sample was then taken from the ipsilateral common 
femoral artery (Sample A) via the angiography sheath and then from the 
abdominal aorta (Sample Ao) via the catheter prior to injection of contrast 
material.   
Samples were analysed after a delay of 1-2 hours of citrate storage prior 
recalcification. 5 TEG parameters (R, K, Angle (), MA and CI) were used in 
this study. 
2.3.4 Assessment of Disease Severity 
Arteriography findings were interpreted by a vascular radiologist blinded to 
the TEG results. Atherosclerotic disease in the aorto-iliac segment on the 
same side as the artery puncture was reported as maximum percentage (%) 
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diameter stenosis and graded as  50% (minimal), 50 – 70%(moderate), and 
70%(severe). Infrainguinal disease was graded in 4 segments (Superficial 
femoral artery /popliteal artery/Trifurcation / Crural vessels) as  50% or  
50% stenosis at any point. A score of 0 for  50% and 1 for  50% was given 
and the total score for infrainguinal disease calculated for the puncture side 
limb of each patient. 
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Table 2.3.1 Demographic and Risk Factor Details of Patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk factors                                                           Number 
 Anti hypertensive therapy                                           26/30 
 Diabetes                                                                      11/30 
Smoking (Current)                                                       16/30 
Hyperlipidaemia                                                           19/30             
Previous AMI (Acute Myocardial Infarction)                  7/30 
Previous CVA (Cerebrovascular accident)                   4/30 
Previous DVT                                                                2/30 
Previous peripheral vascular surgery                          13/30      
Aortic Aneurysmal Disease                                           4/30 
Anti-platelet therapy                                                    12/30 
Anticoagulant therapy                                                   4/30  
(Warfarin stopped 3 days prior to angiography) 
Symptoms 
Short distance claudication                                           7/30 
 
Rest pain                                                                       9/30 
 
Tissue loss                                                                  14/30 
 
Mean ankle/brachial pressure indices (ABPI) 
Puncture side limb                                                        0.74  0.15                                                     
Opposite (more symptomatic) limb                               0.50  0.15 
 Angiographic severity of Iliac disease in the puncture side limb 
(%)  
Stenosis of   70% (severe)                                          8/30                                         
Stenosis of 50-70% (moderate)                                    10/30 
Stenosis of < 50%    (minimal)                                      12/30 
Total angiographic score for                                     2.00  0.81 
Infra-inguinal disease 
(Median  SD)  
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2.3.5 Statistical Methods 
TEG and patient group data were analysed using Wilcoxon Signed Rank 
Test, Spearman`s correlation test and descriptive analyses (SPSS version 
11.00) including mean and standard deviation values for the TEG 
parameters, and frequency of distribution of vascular risk factors. 
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2.4 - INVESTIGATION OF THE THROMBOGENIC POTENTIAL 
OF NON-IONIC CONTRAST MEDIA IN PVD USING TEG 
 
2.4.1 Patients 
 30 sequential patients over the age of 40yr who were undergoing 
transfemoral angiography for lower limb peripheral vascular disease via a 
retrograde femoral puncture and who agreed to participate in the study were 
recruited. Details are given in Table 2.4.1. 
Exclusion criteria for participants included the presence of liver impairment, a 
known hypercoagulable state including DVT (excluding PAOD) and the 
presence of any malignancy. All patients underwent duplex study of the lower 
limb veins bilaterally to rule out deep vein thrombosis (DVT) before 
angiography.  Any patients taking Warfarin had this medication stopped 3 
days before angiography.  
2.4.2 Controls 
30 age matched healthy control subjects who were admitted to undergo 
elective day surgery (details given in Table 2.2.1.) were also recruited to 
obtain peripheral venous samples for comparisons with the study group. 
2.4.3 Blood Sampling  
Blood samples were obtained from the abdominal aorta (Sample Ao) via the 
angiography catheter before heparin flush and contrast injection and within 
two minutes after injection of the last bolus of contrast medium. The contrast 
medium used was Iohexol, a non-ionic contrast medium (NICM) (Omnipaque 
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350,350mg iodine ml-1, Nycomed Amersham, Chesham, UK) and the total 
volume ranged between 80 and120 ml.  
Table 2.4.1 Demographic and Risk Factor Details of Patients 
 
Risk factors 
 Anti hypertensive therapy                                           26/30 
 Diabetes                                                                      11/30 
Smoking (Current)                                                       16/30 
Hyperlipidaemia                                                           19/30             
Previous AMI (Acute Myocardial Infarction)                  7/30 
Previous CVA (Cerebrovascular accident)                   4/30 
Previous DVT                                                                2/30 
Previous peripheral vascular surgery                          13/30      
Aortic Aneurysmal Disease                                           4/30 
Anti-platelet therapy                                                    12/30 
Anticoagulant therapy                                                   4/30  
(Warfarin stopped 3 days prior to angiography) 
Symptoms 
Short distance claudication                                           8/30 
 
Rest pain                                                                       9/30 
 
Tissue loss                                                                  13/30 
 
Ankle/brachial pressure indices (ABPI) 
(MeanSD) 
Puncture side limb                                                        0.74  0.15                                                      
Opposite (more symptomatic) limb                               0.50  0.15 
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2.4.4 Analysis of Blood Samples 
Citrated tubes were used for storage of blood samples prior to analysis. 
Samples were analysed after 1-2 hours of citrate storage using 
Thromboelastograpy (TEG), to identify changes in the coagulability of blood 
samples.  
Samples collected were analysed using heparinase-modified cups to counter 
any residual heparin activity in the blood from previous exogenous 
administration and heparin use during the angiography procedure itself. 
5 TEG parameters (R, K, Angle (), MA and CI) were used in this study. 
2.4.5 Statistical Methods 
TEG and patient group data were analysed using Wilcoxon Signed Rank 
Test, and descriptive analyses (SPSS version 11.00) including mean and 
standard deviation values for the TEG parameters, and frequency of 
distribution of vascular risk factors. 
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2.5 - IDENTIFICATION OF ENDOGENOUS HEPARIN-LIKE 
ACTIVITY IN PVD USING THROMBOELASTOGRAPHY     
                   
2.5.1 Objective 
To measure endogenous heparin like activity in patients with PAOD and to 
identify its relationship to the severity of disease and to determine whether 
replacement of heparin restored coagulability to normal, if so, excluding AT 
deficiency rather than heparin deficiency as a cause of coagulation 
abnormalities. 
2.5.2 Subjects 
Patients 
Sequential patients presenting to the vascular outpatient department with 
claudication or rest pain due to atherosclerotic disease were asked to 
participate. 14 patients with intermittent claudication and 14 patients with 
advanced peripheral vascular disease presenting with rest pain were 
recruited.  
Controls 
15 subjects over 45 years with no symptoms of PAOD and ABPI  0.9 and no 
history of cardiovascular / cerebrovascular disease or malignant disease 
were recruited from amongst general surgical patients.  
Control and patient group demographic and vascular risk factor details are 
given in Table 2.5.1.  
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Part 1: 
Native and heparinase modified Thromboelastography were performed on 
citrated peripheral venous samples to measure heparin-like anticoagulant 
activity. 
Part 2: 
Heparin equivalent to that found in control subjects was added to patient 
samples and baseline (non- heparinase modified) TEG repeated. 
15 patients with symptoms of PAOD including short distance claudication 
(n=4) and rest pain (n=11), admitted for peripheral vascular reconstruction 
procedures, were also recruited.  
No patient in any of the groups received any form of exogenous heparin or 
other anticoagulation agent prior to this study within at least the previous two 
weeks.  
2.5.3 Blood Sampling 
Samples were collected from the ante-cubital vein without tourniquet to avoid 
activation of the coagulation cascade.  Samples were stored in citrated tubes 
for1-2 hours and were analysed after recalcification using both native and 
heparinase modified TEG, a method that gives better reproducibility than 
immediate analysis of fresh sample. 5 TEG parameters (R, K, Angle (), MA 
and CI) were used in this study. 
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2.5.4 Statistical Methods 
TEG data within groups were analysed using Wilcoxon Signed Rank Test 
and significant differences in TEG data in between groups sought using a 
Mann-Witney U test.  Any relationship between TEG variables and subject 
variables were identified using Spearman`s correlation test. A p value of  
0.05 was considered significant (two-tailed). 
Table 2.5.1 Control and Patient Group Demographic and Vascular Risk 
Factor Details 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: IC - Intermittent Claudication; RP – Rest pain; DVT- Deep Vein Thrombosis; SD - 
standard deviation 
Group                                                                        Control               IC                  RP 
   
Number of participants                                                  15                   14                   14 
 
Gender                                                                       2F/13M            4F/10M         2F/12M 
 
Age                                                                     60Yr (49, 74)    66Yr (56,80)   67.5 Yr (54,84) 
(Median/Range) 
Ankle/brachial pressure indices                             1.04  0.11     0.69  0.09     0.45  0.08 
 (MeanSD) 
Anti hypertensive therapy                                              4/15             6/14                 8/14 
 Diabetes                                                                         2/15              3/14              3/14 
Smoking (Current)                                                          3/15              4/14               2/14 
Hyperlipidaemia (on treatment)                                     1/15               3/14               3/14             
Previous MI (Myocardial Infarction)                               0/15              0/14                1/14 
Previous CVA (Cerebrovascular accident)                    0/15               0/14               1/14 
Previous history of DVT                                                 0/15               0/14               0 /14 
Previous peripheral vascular surgery                            0/15               0/14               3/14     
Aortic aneurysmal disease                                             0/15              0/14                1/14 
Anti-platelet therapy                                                       4/15              5/14                9/14 
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Table 2.5.2 Demographic and Vascular Risk Factor Details of Patients 
with PAOD   
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of participants                                                  n= 15                          
 
Gender                                                                           5F/10M  
 
Age (Median/Range)                                                      62Yr (56, 84)     
 
Mean ankle/brachial pressure indices (ABPI)                0.56  0.04      
  
Anti hypertensive therapy                                              9/15              
  
Diabetes                                                                         4/15            
 
Smoking (Current)                                                          2/15          
 
Hyperlipidaemia (on treatment)                                      1/15                     
 
Previous AMI (Acute Myocardial Infarction)                   2/15           
 
Previous CVA (Cerebrovascular accident)                     3/15         
 
Previous history of DVT                                                  0/15         
 
Previous peripheral vascular surgery                             3/15               
 
Aortic aneurysmal disease                                            1/15       
 
Anti-platelet therapy                                                       8/15            
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2.6 - INVESTIGATION OF CHANGES IN COAGULATION 
CHANGES IN AORTIC ANEURYSMAL DISEASE USING TEG                        
 
2.6.1 Objective 
To identify changes in coagulation during elective non-ruptured abdominal 
aortic aneurysm repair and in those undergoing reconstruction procedures for 
occlusive aortic disease using Thromboelastography (TEG) 
2.6.2 Patients 
30 sequential patients undergoing elective infra-renal abdominal aortic 
aneurysm repair (AAA group) and 14 patients who underwent reconstruction 
procedure for occlusive aortic disease (Occ group) and 30 age matched 
subjects (control group) undergoing elective day case surgical procedures 
who agreed to participate in the study were recruited(Tables 2.6.1, 2.6.2 and 
2.6. 3). All patients underwent duplex study of the lower limb veins bilaterally 
to rule out deep vein thrombosis (DVT).   
Exclusion criteria for participants included the presence of DVT, liver 
impairment, a known hypercoagulable state (excluding PAOD) and the 
presence of any malignancy.  Any patients taking Warfarin had this 
medication stopped 3 days before surgery.  
Demographic, clinical data, routine coagulation tests, platelet count, aortic 
cross-clamping time and any thrombotic event recorded. dose of aspirin in 
the 7 days prior to surgery time since last dose of SC Heparin, Anaesthetic 
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technique (GA, Epidural),Fluids given intravenously in the perioperative 
period, Transfusion of blood and blood products, Timing and dose of any 
intravenous heparin, Timing of operative stages (clamp time, duration of 
surgery etc) and Core body temperature. 
Table 2.6.1 Vascular Risk Factors/ Control Group (n=30)  
 
Gender                                                                    12F/18M 
 
Age                                                                          60  8.5 Yr 
 
Mean ankle/brachial pressure indices (ABPI)        1.10  0.11 
  
Anti hypertensive therapy                                             4/30 
  
Diabetes                                                                        2/30 
 
Smoking (Current)                                                         3/30 
 
Hyperlipidaemia                                                             3/30             
 
Previous AMI (Acute Myocardial Infarction)                   0/30 
 
Previous CVA (Cerebrovascular accident)                    0/30 
 
Previous DVT                                                                 0/30 
 
Previous peripheral vascular surgery                            0/30      
 
Aortic Aneurysmal Disease                                           0/30 
 
Anti-platelet therapy                                                      12/30 
 
Anticoagulant therapy                                                   0/30 
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Table 2.6.2 Vascular Risk Factors/ Aortic Occlusive Group (n=14) 
 
 
 
 
  
Gender                                                                      4F/10M 
Age (Median)                                                        66.5  6.9 Yr 
Mean ankle/brachial pressure indices (ABPI)            0.690.9 
  
Anti hypertensive therapy                                             6/14 
  
Diabetes                                                                        3/14 
 
Smoking (Current)                                                         6/14 
 
Hyperlipidaemia                                                             6/14             
 
Previous AMI (Acute Myocardial Infarction)                   2/14 
 
Previous CVA (Cerebrovascular accident)                    1/14 
 
Previous DVT                                                                 0/14 
 
Previous peripheral vascular surgery                            4/14      
 
Aortic Aneurysmal Disease                                            0/14 
 
Anti-platelet therapy                                                       8/14 
 
Anticoagulant therapy                                                   0/14 
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Table 2.6.3 Vascular Risk Factors / Aortic Aneurysm Group (n=30) 
Gender                                                                      5F/25M 
 
Age (Median)                                                        69.5  6.0 Yr 
 
Mean ankle/brachial pressure indices (ABPI)            0.890.2 
  
Anti hypertensive therapy                                             16/30 
  
Diabetes                                                                        6/30 
 
Smoking (Current)                                                         4/30 
 
Hyperlipidaemia                                                             6/30           
 
Previous AMI (Acute Myocardial Infarction)                   2/30 
 
Previous CVA (Cerebrovascular accident)                    1/30 
 
Previous DVT                                                                 0/30 
 
Previous peripheral vascular surgery                             1/30     
 
Anti-platelet therapy                                                       18/30 
 
Anticoagulant therapy                                                    2/30  
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2.6.3 Blood Sampling and Analysis 
Peripheral venous blood samples were collected 1) Before(S1) and after 
anaesthetic induction(S2), 2) Before aortic clamp release(S3) and 5 minutes 
after release of clamp(S4), 3) At the end of surgery(S5), 4) 1 Hour after 
arrival in intensive care unit(S6),5) 6 hours post operatively(S6), 6) 24 
hours(S7), 3 days(S8), and (S9)7days postoperatively. 
Peripheral venous samples collected in citrated tubes were used for storage 
of blood samples prior to analysis. Samples collected were analysed using 
heparinase-modified cups to counter any residual heparin activity in the blood 
from previous exogenous administration and heparin use during surgery.   
Native citrated whole blood TEG and heparinase modified TEG performed 
after storage of between 1-2 hours prior to analysis. 5 TEG parameters (R, K, 
Angle (), MA and CI) were used in this study. 
2.6.4 Statistical Methods 
TEG and patient group data were analysed using Wilcoxon Signed Rank 
Test, and descriptive analyses (SPSS version 15.00) including mean and 
standard deviation values for the TEG parameters, and frequency of 
distribution of vascular risk factors. 
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2.7- INVESTIGATION OF TEG CHANGES IN PATIENTS WITH 
PVD UNDERGOING SURGERY 
 
2.7.1 Objectives 
This study looked at TEG detectable abnormalities of coagulation in patients 
with leg ischaemia presenting for surgery. Identification of any significant 
changes in coagulation during revascularization or amputation and 
investigation of any relationship between baseline TEG profile and any post-
operative thrombotic event (MI, CVA, DVT, graft occlusion) and identification 
of any significant relationship between TEG changes during surgery and any 
post-operative thrombotic event was also carried out. 
2.7.2 Patients 
 86 sequential patients undergoing peripheral vascular reconstruction and 
amputation for symptomatic PVD and 50 age matched subjects (control 
group) undergoing elective day case surgical procedures who agreed to 
participate in the study were recruited. Exclusion criteria for participants 
included the presence of DVT, liver impairment, a known hypercoagulable 
state (excluding PVD) and the presence of any malignancy.  Any patients 
taking Warfarin had this medication stopped 3 days before surgery. Patient 
and control group details are given in Table 2.7.1. and 2.7.2. 
2.7.2.1. Initial assessment  
Clinical data, baseline ECG, ankle/brachial pressure index (severity of 
ischaemia) blood sample for TEG, FBC, haematocrit estimations were 
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obtained. Duplex ultrasound study of deep veins both legs to assess 
preoperative state of deep veins (ie +/-DVT) was completed in all patients.  
2.7.3 Blood Sample Collection and Analysis 
Blood samples (6 ml from arm vein or arterial line (intraoperatively) as it is 
easily accessible, least traumatic and shown in the earlier validation 
experiments to be not significantly different to venous samples) were 
obtained for TEG, platelet count and haematocrit measurements. Samples 
were obtained immediately before and after anaesthetic induction, 
immediately before and at the end of arterial clamping, 5 minutes after 
release of clamps (in the case of vascular reconstruction), at the end of 
surgery, 30 minutes after surgery, at 6 hours after surgery, 24 hours after 
surgery, 3 days after surgery, 7 days after surgery and 6 weeks after surgery. 
Samples were analysed after a delay of 1-2 hours of citrate storage prior 
recalcification. 5 TEG parameters (R, K, Angle (), MA and CI) were used in 
this study. 
2.7.4 Operative Variables  
Dose of aspirin in the 7 days prior to surgery; time since last dose of sc 
Heparin; anaesthetic technique (GA (drugs recorded), Epidural); fluids given 
intravenously in the perioperative period (including blood and blood 
products); timing and dose of any intravenous heparin; timing of operative 
stages (initial dissection, clamping etc); nature of any implant. 
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2.7.5 Detection of Thrombotic Events   
Bilateral leg vein Duplex study 3 and 7days and 6 weeks post operatively to 
detect DVT and 12 lead ECG in theatre recovery with serum troponin 
measurement if any clinical or ECG evidence of new ischaemia, 12 lead ECG 
prior to discharge and clinical assessment, 12 lead ECG at 6 week follow up 
were done to record any evidence of myocardial ischaemia following surgery. 
Occurrence of stroke was recorded after clinical assessment during 
postoperative period and at 6 week follow-up after surgery. Duplex scans 
were done at 7 days and 6 weeks post operatively to pick up graft occlusion 
following surgery.  
 
2.7.6 Statistics 
TEG and patient group data were analysed using Wilcoxon Signed Rank 
Test, and descriptive analyses (SPSS version 11.00) including mean and 
standard deviation values for the TEG parameters, and frequency of 
distribution of vascular risk factors. 
Any relationship between TEG variables and subject variables were identified 
using Spearman`s correlation test. A p value of  0.05 was considered 
significant (two-tailed). 
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Table 2.7.1 Vascular Risk Factor Details of Patient Group (n=86) 
  
 
Gender ( M / F) 62/24 
Age 70.1 +/- 8.4 
Risk Factors 
Anti hypertensive therapy 74/86 
Diabetes 36/86 
Smoking (current) 28/86 
Hyperlipidaemia 55/86 
Previous AMI (Acute Myocardial Infarction) 21/86 
Previous CVA (Cerebrovascular accident) 16/86 
Previous DVT 5/86 
Previous peripheral vascular surgery 10/86 
Aortic Aneurysmal  Disease 12/86 
Anti-platelet therapy 67/86 
Anticoagulant therapy 5/86 
Symptoms 
Short distance claudication 16/86 
Rest pain 31/86 
 
 
 
85 
 
Table 2.7.2 Risk Factor Details of Control Group (n=50) 
   
Gender 22F/28M 
Age 60-85  
Mean ankle/brachial pressure indices (ABPI) 1.10-0.11 
Anti hypertensive therapy 7/50 
Diabetes 2/50 
Smoking (current) 3/50 
Hyperlipidaemia 4/50 
Previous AMI (Acute Myocardial Infarction) 0/50 
Previous CVA (Cerebrovascular accident) 0/50 
Previous DVT 0/50 
Previous peripheral vascular surgery 0/50 
Aortic Aneurysmal  Disease 0/50 
Anti-platelet therapy 14/50 
Anticoagulant therapy 0/50 
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CHAPTER 3 – RESULTS 
 
 
3.1 - VALIDATION AND STANDARDISATION OF TEG  
        METHODS 
 
 
3.1.1 Reliability of Citrate TEG Method 
TEG parameters were found to be stable and reliable when analysed after a 
period of delay with citrate storage between 1-8 hours. To assess TEG assay 
variability, 15 peripheral venous blood samples collected from patients with 
vascular disease undergoing abdominal aortic aneurysm/peripheral vascular 
reconstruction procedures. Citrated tubes were used for storage of blood 
samples prior to analysis. Samples were analysed after a delay of 1-2 hours 
of citrate storage prior recalcification to obtain reliable results. Each sample 
was analysed divided in to 3 and each one assayed separately. The intra–
assay variability was excellent. (p= NS) and the reliability coefficients (Alpha) 
were greater than 0.9 for all parameters studied(R time, K time, Angle, MA 
and CI). Results of this part of the validation study are given in Tables 3.1.1 
to 3.1.10. 
  
3.1.2 Validation of Heparinase Modified TEG 
Validation of the use of heparinase cups for TEG analysis of blood samples 
was again done using the samples obtained from 15 patients undergoing 
aortic aneurysm repair or peripheral vascular reconstruction procedures. The 
samples were taken from a radial artery line before and 2 minutes after 
heparin (5000 I.U) administration via a central vein. No significant differences 
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(Mann-Witney) in TEG parameters between samples analysed before and 
after heparin administration using heparinise coated cups were found thus 
confirming complete reversal of exogenous heparin. Results are given in 
Tables. 3.1.11 to 3.1.17. 
 
 
 
 
89 
 
VALIDATION OF CITRATE TEG AND HEPARINASE MODIFIED TEG 
METHODS 
Table 3.1.1 Intra-assay results -citrated (n=15) - TEG parameter- R time 
R1 R2 R3 
13.00 
11.50 
6.00 
9.10 
9.40 
11.00 
9.00 
9.50 
8.40 
9.80 
7.50 
12.00 
8.40 
8.50 
9.40 
13.40 
11.40 
6.00 
9.10 
9.40 
11.10 
9.00 
9.00 
8.40 
9.80 
7.50 
11.80 
8.40 
8.40 
9.30 
13.00 
11.50 
6.00 
9.10 
9.40 
11.00 
9.10 
9.50 
8.40 
9.80 
7.50 
12.00 
8.40 
8.50 
9.40 
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Table 3.1.2 Intra-assay results –citrated - TEG parameter- K time (K) 
K1 K2 K3 
3.00 
4.90 
2.80 
2.40 
5.50 
3.00 
2.00 
6.00 
3.00 
2.80 
3.80 
5.10 
4.00 
2.00 
2.70 
3.00 
4.80 
2.80 
2.40 
5.50 
2.80 
2.00 
6.00 
3.00 
2.50 
3.80 
5.10 
4.00 
2.00 
2.70 
3.20 
4.90 
2.80 
2.40 
5.50 
2.80 
2.00 
5.80 
3.00 
2.50 
3.80 
5.10 
4.10 
2.00 
2.80 
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Table 3.1.3 Intra-assay results -citrated TEG parameter- Angle (A) 
 
A1 A2 A3 
55.00 
52.50 
64.00 
52.70 
63.00 
44.40 
62.50 
65.60 
55.50 
48.00 
46.00 
43.00 
52.00 
44.00 
56.00 
55.00 
52.50 
63.80 
52.70 
63.40 
44.40 
62.50 
65.60 
55.50 
49.00 
46.00 
44.00 
52.10 
45.00 
56.00 
55.00 
52.50 
64.00 
53.00 
63.40 
44.40 
62.50 
65.60 
55.50 
48.00 
46.00 
43.00 
52.00 
44.00 
56.00 
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Table 3.1.4 Intra-assay results -citrated- TEG parameter- Maximal 
Amplitude (MA) 
MA1 MA2 MA3 
50.80 
57.70 
54.60 
59.00 
49.00 
61.50 
46.60 
55.00 
63.50 
56.00 
54.00 
53.00 
55.00 
54.60 
50.80 
50.80 
57.70 
54.60 
58.00 
48.00 
61.50 
47.40 
55.00 
63.50 
56.20 
54.00 
53.00 
55.00 
54.60 
50.80 
52.00 
57.70 
54.60 
58.00 
49.00 
61.50 
46.60 
55.00 
63.50 
56.00 
54.00 
53.10 
56.00 
54.60 
50.80 
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Table 3.1.5 Intra-assay results -citrated samples- TEG parameter- 
Coagulation Index (CI) 
CI1 CI2 CI3 
-1.07 
.53 
1.05 
1.12 
-.64 
1.44 
-.98 
.28 
2.15 
.73 
1.04 
-.13 
.84 
.91 
-.22 
-1.07 
.53 
1.05 
1.12 
-.64 
1.44 
-.98 
.28 
2.15 
.73 
1.04 
-.13 
.84 
.91 
-.22 
-1.07 
.53 
1.05 
1.12 
-.64 
1.44 
-.98 
.28 
2.15 
.73 
1.04 
-.13 
.84 
.91 
-.22 
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SUMMARY OF RESULTS FOR INTRA- ASSAY TESTS 
Table 3.1.6 Intra- assay TEG parameter values- R time 
 R1 R2 R3 
n =  15 15 15 
Mean 9.5000 9.4667 9.5067 
Std. Deviation 1.79165 1.83874 1.78984 
Variance 3.210 3.381 3.204 
Range 
Reliability(Alpha) 
7.00 
. 
949 
7.40 7.00 
 
Table 3.1.7 Intra- assay TEG parameter values- K time 
 K1 K2 K3 
n =   15 15 15 
Mean 3.5333 3.4933 3.5133 
Std. Deviation 1.28656 1.30026 1.27552 
Variance 1.655 1.691 1.627 
Range 
 
Reliability(Alpha) 
 
4.00 
 
.932 
4.00 3.80 
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Table 3.1.8 Intra- assay TEG parameter values- Angle  
 A1 A2 A3 
n =  15 15 15 
Mean 53.6133 53.8333 53.6600 
Std. Deviation 7.62476 7.40537 7.65831 
Variance 58.137 54.840 58.650 
Range 
Reliability(Alpha) 
22.60 
.944 
21.60 22.60 
 
Table 3.1.9 Intra- assay TEG parameter values Maximal Amplitude (MA) 
 MA1 MA2 MA3 
n =  15 15 15 
Mean 54.7400 54.6733 54.8267 
Std. Deviation 4.51138 4.45605 4.39537 
Variance 20.353 19.856 19.319 
Range 
Reliability (Alpha) 
16.90 
0.902 
16.10 16.90 
 
 
 
Table 3.1.10 Intra- assay TEG parameter values Coagulation Index (CI) 
 CI1 CI2 CI3 
n =   15 15 15 
Mean 0.4706 0.4890 0.4766 
Std. Deviation 0.91986 0.91386 0.92006 
Variance 0.846 0.859 0.846 
Range 
Reliability(Alpha) 
3.22 
0.921 
3.29 3.18 
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Results of Validation of Heparinase Modified TEG Method  
Table 3.1.11 Native TEG (before addition of heparin) and Heparinase 
modified TEG (after addition of heparin) - R time 
 
 
 
 
 
Table 3.1.12 Native TEG (before addition of heparin) and Heparinase 
modified TEG (after addition of heparin) - K time 
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Table 3.1.13 Native TEG (before addition of heparin) and Heparinase 
modified TEG (after addition of heparin) – Angle 
 
 
 
 
 
 
 
Table 3.1.14 Native TEG (before addition of heparin) and Heparinase 
modified TEG (after addition of heparin) – Maximal Amplitude (MA) 
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Table 3.1.15 Native TEG (before addition of heparin) and Heparinase 
modified TEG (after addition of heparin) – coagulation Index 
 
 
Table 3.1.16 TEG Parameter values- Native TEG method 
  R1 K1 A1 MA1 CI1 
n=  15 15 15 15 15 
Mean 9.1600 2.9867 56.8667 56.3467 .5986 
Std. Deviation 1.68387 .87901 5.95107 6.39574 1.19367 
Range 5.60 3.10 20.10 19.30 4.79 
Key: 
R1-    R time before exposure to heparin 
K1-    K time before exposure to heparin 
A1-    Angle before exposure to heparin 
MA1- Maximal Amplitude before exposure to heparin 
CI1- Coagulation Index before exposure to heparin. 
 
 
Table 3.1.17 TEG Parameter values- heparinase modified TEG method 
 R2 K2 A2 MA2 CI2 
n=   15 15 15 15 15 
Mean 8.9000 3.2133 56.9067 56.7933 .8845 
Std. Deviation 1.48276 1.05551 5.30316 6.23097 1.00841 
Range 5.50 2.90 17.60 22.20 3.98 
Key: 
R2- R time after exposure to heparin 
K2- K time after exposure to heparin 
A2- Angle after exposure to heparin 
MA2- Maximal amplitude after exposure to heparin 
CI1- Coagulation Index after exposure to heparin. 
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3.2 -  INVESTIGATION OF THE EFFECTS OF AGE, GENDER 
AND ANAESTHESIA ON COAGULATION USING TEG - 
CONTROL GROUP STUDY                                       
 
Fifty patents were enrolled in the study. Age, gender, BMI and vascular risk 
factor details are given in Table 2.2.1.  No patient was on warfarin or 
received any form of an exogenous heparin in at least 2 weeks prior to 
participation in this study. 
Baseline platelet, haematocrit, coagulation profile and fibrinogen level, renal 
function (creatinine), anaesthesia, type and volume of intravenous fluids 
administered during anaesthesia and surgical procedure details are given in 
Table 3.2.1. 
Baseline (pre-induction of anaesthesia) routine haematological tests 
(Haemoglobin, Platelet count, Haematocrit, PT, aPTT and Fibrinogen levels) 
were within normal range and there were no significant differences between, 
within and in between men and women. There were no significant 
associations between the baseline tests, baseline TEG parameter values and 
BMI identified in this study. 
TEG showed significant reduction in the K time values indicating more rapid 
clot formation in women compared to men (2.76 +/- 1.58 (Mean+/- SD), CI 
2.43, 3.08 Vs 3.44 +/-1.20, CI 2.88, 4.00; p=0.024). This difference was due 
to a significant decrease in K time among pre-menopausal women. Amongst 
women TEG identified that K time was reduced significantly in pre-
menopausal women when compared to post-menopausal women (2.39 +/- 
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0.77, CI 1.83, 2.94 Vs 3.42 +/- 0.28, CI 2.77, 4.06;  p=0.009). No significant 
associations between BMI and baseline haematological tests and TEG 
parameters were identified in this study. 
Induction of anaesthesia led to significant increases in Angle (or Alpha,) 
(acceleration of fibrin build up and cross-linking (clot strengthening) pre-
induction(56.23 +/-0.89, CI  54.42, 58.04  Vs post induction (58.21+/-0.83, CI 
56.54, 59.88;p=0.003) and MA (ultimate clot strength) Pre-induction (56.40 
+/- 0.79 CI 54.80, 58.01) Vs post induction (59.36 +/- 0.89, CI 57.56, 61.15;  
p=0.003) leading to a significant increase in the overall coagulation status CI 
(Coagulation Index)Pre induction (0.71 +/- 0.14, CI 0.42, 1.00) Vs  post 
induction (1.35 +/- 0.17, CI 1.00, 1.69;p=0.003) of blood. These TEG 
parameter values are given Table.3.2.2. Changes in TEG during anaesthesia 
and surgery are presented in Figures.3.2.1 and 3.2.2. 
No significant differences in coagulation were seen between individual 
groups who underwent different modalities of anaesthesia (general, epidural 
and general + epidural anaesthesia). 
There was a significant further increase in Angle, (post induction 58.21+/- 
0.83, CI 56.54, 59.88) Vs at 30 minutes of surgery (60.98 +/- 0.69, CI 59.59, 
62.37; p=0.001) that suggested further activation of fibrin build-up and 
polymerisation observed after induction of anaesthesia during surgery. No 
significant associations between IV fluid type (0.9% Normal saline and 
Hartmann`s) or the volume (145+/-20 ml (mean/SD), CI 70+/-50, 180+/-50 
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ml) and rates (50-120/hr) at which they were administered and TEG 
parameters were found in this study.  
Among demographic vascular risk factors no significant associations were 
found between the use of low dose aspirin (n=9), statin intake (n=6) or any 
anti-hypertensive therapy (n=7) and TEG parameters were found.  
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Table 3.2.1 Baseline Haematological, Anaesthesia and Surgical 
Procedure Details (n=50) 
Group  
 
Men 35-65 
(n=10) 
Men > 65 yr 
(n=10) 
Women 35-50yr 
(n=10) 
Women 50-65yr 
(n=10) 
Women > 65 yr 
(n=10) 
Haematology 
Haematocrit 
 
 
0.42+/-.03 
(0.40,0.45) 
 
0.42+/-.04 
(0.39,0.45) 
 
0.41+/-.02 
(0.39,0.44) 
 
0.41+/-.04 
(0.38,0.42) 
 
0.43+/-.03 
(0.41,0.45) 
 
Platelet count 
 
229+/-59 
(187,272) 
 
 
271+/-47 
(236, 305) 
 
239+/- 54 
(200,278) 
 
238+/-70 
(188, 288) 
 
267+/-67 
(219, 315) 
 
PT 
 
 
10.94+/-0.12 
(10.88,11.02) 
 
10.46+/-0.47 
(10.14,10.82) 
 
10.71+/-0.42 
(10.71,11.01) 
 
10.72+/-0.34 
(10.48,10.97) 
 
10.70+/-0.29 
(10.49,10.91) 
 
aPTT 
 
 
30.10+/-3.44 
(27.63,32.56) 
 
29.50+/-4.11 
(26.55,32.44) 
 
30.30+/-3.56 
(27.75,32.84) 
 
30.00+/-3.94 
(27.17,32.82) 
 
28.00+/-2.99 
(26.75,31.04) 
 
Fibrinogen 
 
 
241.60+/-29.30 
(228.11,284.69) 
 
251.10+/-41.10 
(228.11,284.69) 
 
239.50+/-24.65 
(281.33,357.67) 
 
247.50+/-23.60 
(248.99,318.41) 
 
257.80+/-24.65 
(239.98,321.02) 
 
Creatinine 
 
 
94.04+/-28.03 
(68.06,86.06) 
 
96.04+/-35.03 
(66.02,73.05) 
 
99.04+/-29.02 
(72.00,88.02) 
 
92.04+/-28.03 
(63.06,80.04) 
 
94.14+/-32.08 
(66.02,83.06) 
Laparoscopic 
.Cholecystectomy 
(n=9) 
 
 
 
2 
 
 
 
2 
 
 
 
3 
 
 
 
2 
 
 
 
- 
 
Open hernia 
repair(n=11) 
 
4 
 
3 
 
 
 
- 
 
2 
 
2 
 
Lump excision 
(n=6) 
2 1 - 2 1 
Urological 
procedures 
(n=8 
2 3 - 1 2 
Gynaecological 
procedures 
(n=5) 
- - 2 1 2 
Thyroid surgery 
(n=2) 
  1 1 - 
Colorectal surgery 
(n=3) 
2  - 1  
ENT surgery 
(n=2) 
1  - 1  
Orthopaedic 
surgery 
(n=4) 
 2  1 1 
Anaesthesia 
Epidural 
(n=10) 
 
2 
 
1 
 
3 
 
2 
 
2 
General (n=30) 6 7 5 6 6 
Epidural+ General 
(n=10) 
 
2 
 
4 
 
- 
 
1 
 
3 
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Table 3.2.2 TEG (Citrated, Native) Values at Baseline, Post Induction of 
Anaesthesia and at 30 Minutes after Commencement of Surgery  
TEG parameter Baseline  Post 
induction of 
anaesthesia 
At 30 minutes 
after start of 
surgery 
Baseline Vs 
Post 
induction of 
anaesthesia
(p value) 
Post 
induction of 
anaesthesia 
Vs 30 
minutes 
after start 
of surgery 
(p value) 
R  time(minutes) 
 
9.38+/-1.70 8.58+/-1.82 8.19+/-1.92 0.046 0.102 
K time (minutes) 
 
3.27+/-1.11 2.96+/-1.05 2.57+/-0.94 0.078 0.142 
Angle(α) (degrees) 
 
56.23+/-6.35 58.21+/-5.87 60.98+/-4.88 0.003 0.001 
MA (mm) 
 
56.40+/-5.64 59.36+/-6.32 62.99+/-8.48 0.003 0.022 
CI 
 
0.71+/-1.02 1.35+/-1.21 1.97+/-1.55 0.003 0.018 
(Key: p values <0.017 considered significant (after Bonferroni correction) as multiple 
comparisons were made between groups and sampling points in this study.) 
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Figure 3.2.1 Citrated Whole Blood TEG Showing Changes in 
Coagulation during Surgery 
 
Key: R, Reaction time (time to initial fibrin formation); K, dynamics of clot 
formation; Angle, acceleration of fibrin build up and cross-linking (clot 
strengthening); MA, maximum amplitude (ultimate clot strength); CI, 
coagulation index (overall coagulation status); LY30, percent lysis at 30 
minutes after MA; LY60, percent lysis at 60 minutes after MA; G, clot 
firmness as shear elastic modulus; EPL, estimated percent lysis; A, current 
amplitude 
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Figure 3.2.2 TEG Changes during Anaesthesia and Surgery 
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3.3 - INVESTIGATION OF THE EFFECTS OF SAMPLING SITE, 
PERIPHERAL ATHEROSCLEROSIS AND PERIPHERAL 
ISCHAEMIA ON TEG 
 
The 30 patients (median age 72 Years  9.6, 21male/9 female) in this study 
underwent transfemoral angiography for a range of ischaemic symptoms 
including intermittent claudication (8), rest pain (9) and ischaemic tissue loss 
(13). Further details are given in Table. 2.2.1. 
55% of common femoral arterial punctures were on the left side.  
Angiographic scoring for disease severity is given in Table. 2.2.1. An 
overview of sampling and TEG results were given in Figure.3.3.1. 
When comparing common femoral artery samples with aortic samples (Table 
3.3.1) there was a decrease in R (time to onset of clotting -reflecting platelet 
activity) (p0.05) (Figure. 3.3.2), an increase in MA (clot strength) (p0.05) 
(Figure.3.3.3) and an increase in CI (coagulation 
index)(p0.002)(Figure.3.3.4) consistent with an increase in coagulability due 
to both platelet activation and increased thrombin generation as blood flowed 
down the iliac arteries. These changes in TEG parameters also correlated 
with the severity of atherosclerotic disease in the ipsilateral aorto- iliac 
segment (R, r=0.442,p0.05 / MA, r=0.379, p0.05 / CI r=0.429, p0.05). 
TEG parameters showed significant differences in R p0.05), Angle 
(measure of clot development) (p0.05), (MA) (p0.005) and CI (p0.001) 
between common femoral arterial and venous samples confirming that 
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venous samples were more coagulable in this group of patients, again due to 
increased platelet activation and thrombin production (Table 3.3.2.). This 
difference in coagulation between the arterial and venous ends of the 
circulation in the puncture side limb correlated inversely with degree of 
ischaemia (ABPI) on that side (CI v ABPI r = -0.427 p0.05, MA v ABPI r 
=-0.370 p0.05) (Figure 3.3.5. and Figure.3.3.6.).  The change in MA across 
the limb circulation also correlated with the angiographic score for infra-
inguinal disease (MA r=0.459,p0.05) (Figure.3.3.7.) but none of the other 
TEG parameters did so. 
 
Table 3.3.1 TEG Changes and Aorto-Iliac Disease 
 
 
 
 
 
 
 
 
 
 
 
      Mean difference between                        Correlation with      
      Aortic & Femoral samples                        Iliac disease(r, p) 
      (Mean/CI) 
 
R         -0.44 ± 3.1(-1.6,.72)                                    r = .443   p = 0.014                                  
 
K      0.08 ± 1.67(-0.54,.7)                                       r = .151   p = 0.151                 
 
Angle   2.08 ± 12.3(-2.5,6.6)                                   r = .218   p = 0.248 
 
MA       3.1  ±   9.97(-0.62,6.8)                                r = .379   p = 0.039 
 
CI         0.75 ± 1.42(0.22,1.2)                                  r = .429   p = 0.018 
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Figure 3.3.1 Overview of Sampling Sites and TEG Results 
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Figure 3.3.2 Severity of Iliac Disease and Change in Time to Fibrin 
Formation 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3 Severity of iliac Disease and Change in Ultimate Clot 
Strength 
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Figure 3.3.4 Severity of Iliac Disease and Change in Overall Coagulation 
Status 
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Table 3.3.2 Correlation between Changes in TEG Parameters between 
CFA and Vein and ABPI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Mean difference across                         Correlation with              
       (A-V segment (Mean/CI)                                   ABPI (r, p)                                    
 
R          -0.91 ± 0.43 (-1.7, -.02)                        r = -0.370  p=0.074            
 
K          -0.30 ± 0.15 (-.62,.01)                          r = 0.129   p=0.496 
 
Angle    3.53 ± 1.49 (0.47,6.5)                         r = -0.209  p=0.268                    
 
MA       3.81 ± 1.04 (1.6,5.9)                            r = -0.370   p=0.044            
 
CI         0.76 ± 0.19 (.36,1.16)                          r = -0.427   p= 0.018 
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Figure 3.3.5 Relationship between Peripheral Ischaemia and Overall 
Coagulation Status 
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Figure 3.3.6 Relationship between Severity of Peripheral Ischaemia and 
Ultimate Clot Strength 
 
  
 
 
 
114 
 
Figure 3.3.7 Angiographic Severity and its Relation to Change in 
Ultimate Clot Strength across Arterio-Venous Segment of an Ischaemic 
Limb 
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3.4 - INVESTIGATION OF THE THROMBOGENIC POTENTIAL 
OF NON-IONIC CONTRAST MEDIUM IN PVD USING TEG 
 
The 30 patients (median age 72 years (range 54-92) 21male/9 female) in this 
study underwent transfemoral angiography for a range of ischaemic 
symptoms including intermittent claudication (n=8), rest pain (n=9) and 
ischaemic tissue loss (n=13). More details of the patients are given in Table 
2.4.1.  55% of common femoral arterial punctures were on the left side. 
Median age of control subjects was 62 years (range 50-82).  
TEG tracings of samples taken from the aorta after injection of Iohexol 
showed a significant increase in R time (time to fibrin formation) (CI 7.8,10.18 
minutes)  (p=0.036), in K time (dynamics of clot formation) (CI 2.2,2.8 
minutes) (p=0.028), and a reduction in Angle (decreased acceleration of 
fibrin build up) (CI 53.10,62.7 degrees) (p=0.013), Maximal amplitude 
(MA)(reduced ultimate clot strength) (CI 54.5,62.7 mm) (p=0.013) and 
Coagulation Index (CI) (decreased overall coagulation status) (0.31,1.95) 
(p=0.032), (Figure 3.4.2-6) demonstrating a significant reduction in the 
coagulability of aortic blood samples taken after the last bolus of contrast 
medium (NICM) but prior to any intervention procedure. This reduction in the 
coagulation status suggests that there is at least a temporary reduction in the 
coagulability of blood during angiography in patients with PAOD when a 
NICM (Iohexol) is used. Despite this reduction in the coagulability of aortic 
samples after exposure to NICM, patients with PAOD remain 
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hypercoagulable when compared to age matched controls whose results are 
also shown in Fig 2-6. 
These changes in TEG parameters suggest that the local effect of NICM is a 
reduction of coagulation activity rather than the activation suggested by some 
previous studies and in patients with peripheral vascular disease iohexol, a 
NICM leads to no further increase in their blood coagulability during 
peripheral diagnostic angiography. 
 
Figure 3.4.1 R time and NICM 
 
 
P values: Pre Vs Post NICM (p= 0.018); Post NICM Vs Controls (p=0.029) 
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Figure 3.4.2 K time and NICM 
 
 
P values: Pre Vs Post NICM in patients (p= 0.028); Post NICM Vs Controls (p=0.001) 
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Figure 3.4.3 Angle and NICM 
 
 
P values: Angle: Pre Vs Post NICM in patients (p= 0.013); Post NICM Vs Controls (p=0.003) 
 
 Figure 3.4.4 MA and NICM 
 
P values: MA: Pre Vs Post NICM in patients (p= 0.018) Post NICM Vs Controls (p=0.020) 
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Figure 3.4.5 CI and NICM 
 
 
P values: CI: Pre Vs Post NICM in patients (p= 0.032); Post NICM Vs Controls (p=0.014) 
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Figure 3.4.6 Effect of Non-Ionic Contrast Medium (NICM) on 
Coagulability of Aortic Blood Samples Shown by TEG 
 
 
 
Key: R, Reaction time (time to initial fibrin formation);K, dynamics of clot 
formation; Angle, acceleration of fibrin buildup and cross-linking (clot 
strengthening); MA, maximum amplitude (ultimate clot strength); CI, 
coagulation index (overall coagulation status); LY30, percent lysis at 30 
minutes after MA;LY60, percent lysis at 60 minutes after MA; G, clot firmness 
as shear elastic modulus; EPL, estimated percent lysis; A, current amplitude 
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3.5 - IDENTIFICATION OF ENDOGENOUS HEPARIN-LIKE 
ACTIVITY IN PVD USING TEG 
 
Part 1 
ABPI measurements of patients and controls are shown in Tables 2.5.1 and 
2.5.2. 
The baseline TEG parameters showed a significant increase in the 
coagulability of blood samples from patients with symptoms of PAOD 
compared to the control group (Figure3.5.1) (shortened R time (6.53  0.40 
min / CI 5.69,7.36 Vs 9.40  0.44 min / CI 8.40,10.36 / p=0.004), K time 
(1.92 0.15 min / CI 1.69,2.36 Vs 2.88  0.16 min / CI 2.52,3.23  / p=0.011), 
increased Angle (64.88 1.71 degrees / CI 61.37,68.39 Vs 56.23 1.26 
degrees / CI 53.51, 58.95 p=0.008), increased MA (66.80 1.57 / CI 
63.57,70.02  Vs 58.07 1.28 / CI 55.30, 60. 83 / p=0.033)  and increased CI 
(2.26  0.24 / CI 1.76,2.77 Vs 1.06  0.23 / CI 0.56,1.57   p=0.009).  
In the control group heparinase modified TEG showed a significant decrease 
in the R time (9.40  0.44 min / CI 8.40,10.36 Vs 8.62  0.37 min / CI 7.82, 
9.42 / p=0.002), K time ( 2.88  0.16 min / CI 2.52,3.23 Vs 2.59  0.11 min / 
CI 2.33,2.84  / p=0.021), Angle (56.23 1.26 degrees / CI 53.51, 58.95 Vs  
57.72 1.25 degrees / CI 55.03, 60.41/ p=0.038) and CI (1.06  0.23 / CI 
0.56,1.57 Vs 1.20  0.26 / CI 0.63, 1.78 p=0.011) (Table 3.5.3) when 
compared to the native TEG confirming heparinase-1 sensitive endogenous 
heparin-like activity (Figure 3.5.2).   
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The same method revealed a significant reduction in R time (7.50  0.44 min 
/ CI 6.54,8.46 Vs 7.17  0.40 min / CI 6.30, 8.05 / p=0.041) suggesting the 
presence of a detectable heparinase-1 sensitive endogenous heparin-like 
activity, in patients with intermittent claudication but not in those with rest 
pain and tissue loss (Figure3.5.3). Tables 3.5.4, 3.5.5 and 3.5.6.  
A significant negative relationship between change in the R time and the 
severity of disease (ABPI) (correlation coefficient: abpi: 1.000 / change in R 
time 0.350 / p=0.021) was identified in patients with PAOD suggesting 
reduced endogenous heparin-like activity with advanced peripheral vascular 
disease. (Figure 3.5.4)  
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Figure 3.5.1 TEG Comparison between Baseline Venous Sample from 
Control Subjects and Patients with PAOD  
 
Key: R, Reaction time (time to initial fibrin formation);K, dynamics of clot 
formation; Angle, acceleration of fibrin buildup and cross-linking (clot 
strengthening); MA, maximum amplitude (ultimate clot strength); CI, 
coagulation index (overall coagulation status); LY30, percent lysis at 30 
minutes after MA;LY60, percent lysis at 60 minutes after MA; G, clot firmness 
as shear elastic modulus; EPL, estimated percent lysis; A, current amplitude 
 
 
 
124 
 
 
Figure 3.5.2 Heparin-like Activity in Controls 
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 Figure 3.5.3 Endogenous Heparin-like Activity in Patients with PVD 
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Figure 3.5.4 Relationship between Heparin-like Activity (R time) and 
Degree of Peripheral Ischaemia (ABPI) 
 
Part 2 
When unfractionated heparin (0.1 I.U/ml) equivalent to the level of 
endogenous heparin found in normal human plasma5, was added to the 
blood samples from patients with symptoms of PAOD, TEG showed 
significant increases in the R time (5.84  0.39 min / CI 4.98,6.69 Vs 8.33  
0.72 min / CI 6.77, 9.89 / p=0.002) and K time (1.84  0.17 min / CI 1.45,2.22 
Vs 2.96  0.36 min / CI 2.16, 3.75  p=0.001) and reductions in Angle (66.41 
2.00 degrees / CI 62.10, 70.72 Vs  58.12 2.22 degrees / CI 53.35, 62.90/ 
p=0.001), MA (65.94 2.42 degrees / CI 60.75, 71.14 Vs  61.112.45 / CI 
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55.83, 66.38/ p=0.001) and CI (2.89  0.32 / CI 2.19,3.59 Vs 1.72  0.32 / CI 
0.97, 2.47 p=0.001) (Table 7) restoring coagulability to that of control 
subjects (Figure 3.5.5).  
 
Figure 3.5.5 TEG changes following addition of exogenous heparin (0.1 
I.U/ml) to venous blood samples from patients with PAOD 
 
 
Key: R, Reaction time (time to initial fibrin formation);K, dynamics of clot 
formation; Angle, acceleration of fibrin buildup and cross-linking (clot 
strengthening); MA, maximum amplitude (ultimate clot strength); CI, 
coagulation index (overall coagulation status); LY30, percent lysis at 30 
minutes after MA;LY60, percent lysis at 60 minutes after MA; G, clot firmness 
as shear elastic modulus; EPL, estimated percent lysis; A, current amplitude 
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Figure 3.5.6 Heparin Effect in PVD 
 
No significant effects of antiplatelet agents on the TEG parameters in any 
group and no significant difference in endogenous heparin-like activity on 
TEG in between those with evidence of coexistent systemic atherosclerotic 
disease (previous AMI/CVA) (n=7) compared to those without (n= 25). (Table 
3.5.1 and 3.5.2) was identified amongst the study groups.  
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Table 3.5.1 Differences in TEG parameters between native and 
heparinase modified methods in the control group. (Mean  SD/ CI) 
 
TEG 
parameters 
 
Native TEG 
 
Heparinase 
modified TEG 
Change in TEG 
from native to 
heparinase 
modified method 
 
p value 
R  
 
K   
 
Angle(alpha) 
 
MA 
 
CI 
9.40  0.43 
(8.48,10.33) 
 
 
2.88  0.16 
(2.52,3.23) 
 
 
56.23  1.26 
(53.51,58.95) 
 
 
58.07  1.28 
(55.30,60.83) 
 
1.06  0.23 
(0.56,1.57) 
8.62  0.37 
(7.82,9.42) 
 
 
2.59  0.11 
(2.33,2.84) 
 
 
57.72  1.25 
(55.03,60.41) 
 
 
58.33  1.35 
(55.42,61.23) 
 
1.20  0.26 
(0.63,1.78) 
0.78  0.18 
(0.39,1.16 min) 
 
 
0.28  0.11 
(0.04, 0.52 min) 
 
 
 -1.49  0.65 
(-2.90,-0.08 deg) 
 
 
-0.26  0.43 
(-1.18, 0.66 mm) 
 
-0.14  0.06 
(-0.274, -0.007) 
0.002 
 
 
 
0.021 
 
 
 
0.038 
 
 
 
0.277 
 
 
 
0.011 
(Key: R- Reaction time/ K- coagulation time/ Angle-acceleration of clot formation/ MA- 
Maximal Amplitude/ CI- Coagulation Index. SD-Standard deviation/ CI- 95%Confidence 
Interval) 
Table 3.5.2 Heparin-like activity (R time) in study groups 
R time 
(heparin like 
activity) 
Control  Intermittent 
Claudication 
Rest pain 
Native TEG 9.40  0.43 
(8.48,10.33 min) 
7.50  0.44 
(6.52,8.42 min) 
5.55  0.58 
(4.29,6.81) 
Heparinase 
modified TEG 
8.62  0.37 
(7.82,9.42 min) 
7.17  0.40  
(6.30,8.05 min) 
5.30  0.51 
(4.18, 6.42) 
Change in R time 0.78  0.18 
(0.39,1.16 min) 
0.32  0.156 
(0.0041,0.653min) 
0.250  0.126 
(-0.022,0.522) 
p value 0.002 0.034 0.070 
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Table 3.5.3 Heparinase Sensitive Anticoagulant Activity in Study 
Groups 
 
a) Intermittent claudication group 
 
TEG 
parameters 
 
Native TEG 
 
Heparinase 
modified TEG 
 
Change in TEG 
parameter.  
 
p value 
R  
 
K   
 
Angle(alpha) 
 
MA 
 
CI 
7.50  0.44 
(6.54,8.46) 
 
 
2.14  0.24 
(1.61,2.66) 
 
 
66.52  2.71 
(60.64,72.39) 
 
 
64.17  2.37 
(59.04,69.30) 
 
2.21  0.42 
(1.29,3.12) 
7.17  0.40 
(6.30,8.05) 
 
 
1.87  0.24 
(1.34,2.41) 
 
 
65.47  2.74 
(59.54,71.40) 
 
 
64.81  2.45 
(59.51,70.11) 
 
2.40  0.42 
(1.49,3.31) 
0.32  0.15 
(0.004,0.65) 
 
 
-0.14  0.69 
(0.16,0.13) 
 
 
 1.05  0.81 
(-0.70,2.80) 
 
 
-0.64  0.78  
(-2.33, 1.04) 
 
-0.19  0.14 
(-0.49, 0.11) 
0.034 
 
 
 
0.255 
 
 
 
0.148 
 
 
 
0.379 
 
 
 
0.198 
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Table 3.5.4 Heparinase-1 Sensitive Anticoagulant Activity in Study 
Groups 
 
b) Rest Pain Group 
 
TEG 
parameters 
 
Native TEG 
 
Heparinase 
modified TEG 
 
Change in TEG 
parameter.  
 
p value 
R  
 
 
K   
 
 
Angle(alpha) 
 
 
MA 
 
CI 
5.55  0.58 
(4.29,6.81) 
 
 
1.71 0.19 
(1.29,2.13) 
 
 
63.25  2.08 
(58.74,67.75) 
 
 
69.42  1.88 
(65.34,73.50) 
 
 
2.32  0.27 
(1.73,2.91) 
5.30  0.51 
(4.18,6.42) 
 
 
1.70  0.20 
(1.26,2.13) 
 
67.64  1.83 
(63.68,71.59) 
 
 
75.57  2.09 
(71.04,80.09) 
 
 
2.89  0.28 
(2.27,3.51) 
0.25  0.12 
(-0.02,0.12) 
 
 
0.014 0.069 
(-0.13, 0.16) 
 
 
 -4.39  1.60 
(-7.87, -0.91) 
 
 
-6.14  2.14  
(-10.78, -1.50) 
 
 
0.25  0.12 
(-0.22, 0.52) 
0.070 
 
 
 
 
 
0.878 
 
 
 
 
0.022 
 
 
 
 
0.008 
 
 
 
 
0.109 
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Table 3.5.5 Differences in TEG Parameters between Native and 
Heparinase Modified Methods in Study Groups 
 
 
R time (minutes) 
Group native Heparinase 
modified 
Change in R 
time 
p value 
Controls 9.40  0.43 
(8.48,10.33) 
8.62  0.37 
(7.82,9.42) 
0.78  0.18 
(0.39,1.16) 
0.002 
Claudication 7.50  0.44 
(6.54,8.46) 
7.17  0.40  
(6.30,8.05) 
0.32  0.156 
(0.004,0.65) 
0.034 
Rest pain 5.55  0.58 
(4.29,6.81) 
5.30  0.51 
(4.18, 6.42) 
0.25  0.12 
(-0.02,0.52) 
0.070 
 
 
 
K time (minutes) 
Group native Heparinase 
modified 
Change K  
time 
p value 
Controls 2.88  0.16 
(2.52,3.23) 
 
2.59  0.11 
(2.33,2.84) 
 
0.28  0.11 
(0.04, 0.52) 
0.021 
Claudication 2.14  0.24 
(1.61,2.66) 
1.87  0.24 
(1.34,2.41) 
-0.14  0.69 
(0.16,0.13) 
0.255 
Rest pain 1.71 0.19 
(1.29,2.13) 
1.70  0.20 
(1.26,2.13) 
0.014 0.069 
(-0.13, 0.16) 
0.878 
 
 
Angle (degrees) 
Group native Heparinase 
modified 
Change in 
Angle 
p value 
Controls 56.23  1.26 
(53.51,58.95) 
57.72  1.25 
(55.03,60.41) 
 
-1.49  0.65 
(-2.90,-0.08) 
0.038 
 
Claudication 66.52  2.71 
(60.64,72.39) 
64.81  2.45 
(59.51,70.11) 
1.05  0.81 
(-0.70,2.80) 
0.148 
Rest pain 63.25  2.08 
(58.74,67.75) 
67.64  1.83 
(63.68,71.59) 
-4.39  1.60 
(-7.87, -0.91) 
0.022 
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MA (millimeters) 
Group native Heparinase 
modified 
Change in 
MA 
p value 
Controls 58.07  1.28 
(55.30,60.83) 
58.33  1.35 
(55.42,61.23) 
 
-0.26  0.43 
(-1.18, 0.66) 
0.277 
 
Claudication 64.17  2.37 
(59.04,69.30) 
64.81  2.45 
(59.51,70.11) 
-0.64  0.78  
(-2.33, 1.04) 
0.379 
Rest pain 69.42  1.88 
(65.34,73.50) 
75.57  2.09 
(71.04,80.09) 
-6.14  2.14  
(-10.78,-1.50) 
0.008 
 
 
 
CI 
Group native Heparinase 
modified 
Change in  CI p value 
Controls 1.06  0.23 
(0.56,1.57) 
1.20  0.26 
(0.63,1.78) 
-0.14  0.06 
(-0.27, 0.00) 
0.011 
Claudication 2.21  0.42 
(1.29,3.12) 
2.40  0.42 
(1.49,3.31) 
-0.19  0.14 
(-0.49, 0.11) 
0.198 
Rest pain 2.32  0.27 
(1.73,2.91) 
2.89  0.28 
(2.27,3.51) 
0.25  0.12 
(-0.22, 0.52) 
0.109 
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Table 3.5.6 Differences in Native TEG Parameters before and after 
Addition of 0.1 I.U/Ml of Unfractionated Heparin in Patient Group (Mean 
 SD/ CI) 
 
 
TEG 
parameters 
 
Native TEG 
 
Native + 
Heparin  TEG 
Change in TEG 
after heparin  
 
p value 
R  
 
K   
 
Angle(alpha) 
 
MA 
 
CI 
5.84  1.54 
(4.98,6.69) 
 
 
1.84  0.69 
(1.45,2.22) 
 
 
66.41  7.78 
(62.10,70.72) 
 
 
65.94  9.39 
(60.74,71.14) 
 
1.72  1.26 
(2.19,2.59) 
8.33  3.81 
(6.77,9.89) 
 
 
2.96  1.43 
(2.16,3.75) 
 
 
58.12  8.62 
(53.35,62.90) 
 
 
61.11  9.52 
(55.83,66.38) 
 
1.72  1.35 
(0.97,2.47) 
2.49  2.78 
(0.95, 4.03 min) 
 
 
1.12  1.38 
(0.04, 0.52 min) 
 
 
 -8.28  6.32 
(-11.78,-4.78 deg) 
 
 
-4.83  4.70 
(-7.44, -2.22 mm) 
 
-1.17  0.94 
(-1.69, -0.065) 
0.002 
 
 
 
0.001 
 
 
 
0.001 
 
 
 
0.001 
 
 
 
0.001 
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3.6 - INVESTIGATION OF CHANGES IN COAGULATION 
CHANGES IN AORTIC ANEURYSMAL DISEASE USING TEG  
 
                        
Demographic, vascular risk factor details of the patients and the control are 
given in Tables 2.6.1 - 3.  
Baseline TEG analyses showed significant reduction in AAA group when 
compared to the control group in R time (p=0.001); K time (p=0.008) and a 
significant increase in the overall coagulation status, coagulation Index (CI) 
(p=0.047)(Figures 3.6.1, 3.6.2, 3.6.4 and 3.6.5). No significant differences in 
base line TEG parameters were found in between the AAA group and aortic 
occlusive group.  
TEG identified significant increase in R time (p=0.042), K time (p=0.037) and 
reductions in MA (p=0.044) and CI (p=0.007) in the AAA group in aortic pre -
clamp release samples when compared to the samples obtained from control 
subjects during surgery(S3). No such significant differences found in between 
the AAA group and the aortic occlusive group at the same sampling point 
(Figure 3.6.6). 
Abdominal aortic cross clamp release led to a further significant decrease in 
the R time (p=0.042); K time (p=0.043) and significant increases in the MA 
(p= 0.034) and CI (p=0.026) suggesting further activation of coagulation 
following release of aortic cross clamp in the AAA group. No significant 
relationship between clamp time and TEG parameters were identified in both 
AAA and occlusive groups. 
Significant increases in MA (p=0.042); Angle (p=0.0026) and CI (p=0.044) in 
the post op samples obtained on Day 3 was found in the aortic aneurysm 
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group but not in the occlusive group. No significant differences in coagulation 
patterns between the AAA group and the aortic occlusive disease group were 
found in the post op samples obtained at days 3 and 7. 3 episodes of 
myocardial ischaemia (troponin positive), one acute myocardial infarction and 
I below knee DVT were diagnosed in the AAA group and 2 MI and 1CVA 
(TIA) episode and 2 DVTs were diagnosed in the aortic occlusive group. No 
significant relationships between these ischaemic, thrombotic events and 
TEG (baseline/post op) variables were found in this study. 
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Figure 3.6.1 R time - groups  
 
 
 
 
 
 
138 
 
Figure 3.6.2 K time - groups 
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Figure 3.6.3 Angle - groups 
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Figure 3.6.4 MA - groups 
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Figure 3.6.5 CI - groups 
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Figure 3.6.6 TEG Patterns during Aortic Cross Clamp 
 
 
 
Key: R, Reaction time (time to initial fibrin formation);K, dynamics of clot 
formation; Angle, acceleration of fibrin buildup and cross-linking (clot 
strengthening); MA, maximum amplitude (ultimate clot strength); CI, 
coagulation index (overall coagulation status); LY30, percent lysis at 30 
minutes after MA;LY60, percent lysis at 60 minutes after MA; G, clot firmness 
as shear elastic modulus; EPL, estimated percent lysis; A, current amplitude 
 
 
 
 
 
143 
 
3.7- TEG CHANGES DURING PERIPHERAL VASCULAR 
SURGERY 
 
TEG analysis of citrated blood samples from symptomatic PVD patients 
undergoing surgery (Table.2.7.1) was carried out as per study plan outlined 
in section 2.7. 
Baseline TEG analyses showed significant increase in R time (p=0.003) 
(Figure 3.7.1), Angle (p=0.016) (Figure.3.7.2.) MA (p=0.002) (Figure.3.7.3) 
and CI (p=0.002) (Figure.3.7.4.) when compared with control group 
confirming activation of coagulation in the PVD group at the outset. 
 
Figure 3.7.1 PVD Vs Control group. R time 
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            Figure 3.7.2 PVD Vs Control group (Angle) 
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Figure 3.7.3 PVD vs Control group. MA (Maximal Amplitude) 
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Table 3.7.4  PVD Vs Control group. Coagulation Index (CI)  
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Details of anaesthetic and surgical procedures involving patients with 
symptomatic PVD are given in Table.3.7.1.and Table.3.7.2. 
 
Table 3.7.1 Vascular Surgical procedures 
 
 Surgery 
Frequency Percent Valid Percent 
Cumulative 
Percent 
 Above knee vein 
graft 
8 9.3 9.3 9.3 
Above knee PTFE 
graft 
9 10.5 10.5 19.8 
Below knee vein 
graft 
7 8.1 8.1 27.9 
Femoro-distal graft 9 10.5 10.5 38.4 
Above knee 
Amputation 
14 16.3 16.3 54.7 
Below knee 
amputation 
20 23.3 23.3 77.9 
Femoro-Femoral 
crss over graft 
6 7.0 7.0 84.9 
Femoral 
endarterectomy 
7 8.1 8.1 93.0 
Aorto-bifemoral graft 4 4.7 4.7 97.7 
Axillo-bifemoral graft 2 2.3 2.3 100.0 
Total 86 100.0 100.0  
Key: PTFE: Poly Tetra Fluoro Ethylene. 
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Table 3.7.2 Anaesthetic details of PVD group 
 
 Anaesthesia 
Frequency Percent Valid Percent 
Cumulative 
Percent 
 GA 53 61.6 61.6 61.6 
Epidural 29 33.7 33.7 95.3 
EpiduraI+ 
Sedation 
4 4.7 4.7 100.0 
Total 86 100.0 100.0  
Key: GA: General anaesthesia 
 
TEG parameter values obtained at sampling points outlined earlier are given 
in the Tables. 3.7.3 to Table.3.7.9. 
 
TEG parameter Values 
Table 3.7.3 Control group Baseline TEG parameter values 
 
 Baseline R time Baseline K time Baseline Angle Baseline MA Baseline CI 
n =   50 50 50 50 50 
Mean 7.6400 3.0360 57.8480 57.3440 .5019 
Std. Deviation 2.80866 1.05883 5.75160 6.71535 1.11371 
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Table 3.7.4 PVD group Baseline TEG parameter values 
 
 
 
PVD Baseline 
 R time 
PVD Baseline  
K time 
PVD Baseline 
Angle  
PVD Baseline 
MA 
PVD Baseline 
CI 
n =   86 86 86 86 86 
Mean 6.3233 2.5209 61.9733 62.1360 1.5569 
Std. Deviation 1.89400 1.10081 9.36726 8.99669 2.19672 
 
 
Table 3.7.5 PVD group TEG- R time values 
 
 n Mean Std. Deviation 
 
r1 
 
86 
 
6.2849 
 
1.99184 
 rr2 86 6.5163 2.12646 
r3 86 6.9209 2.41379 
r4 86 6.5721 2.13930 
r5 86 7.0547 2.12258 
r6 86 7.0128 2.58970 
r7 86 7.5151 2.90276 
r8 86 7.3512 2.11986 
r9 86 7.0279 2.33675 
r10 86 6.9430 2.62430 
r11 86 7.1663 2.30200 
r12 86 7.1186 2.15491 
    
    
     
 
Key: r1:R time immediately before anaesthetic induction; r2: R time after 
anaesthetic induction; r3: R time immediately before arterial clamping;r4:R 
time at the end of arterial clamping; r5:R time 5 minutes after release of 
 
 
 
150 
 
clamps (in the case of vascular reconstruction); r6: R time at the end of 
surgery; r7:R time 30 minutes after surgery; r8:R time at 6 hours after 
surgery; r9:R time 24 hours after surgery; r10:R time 3 days after surgery; 
r11:R time 7 days after surgery; r12:R time 6 weeks after surgery. 
 
Table 3.7.6 PVD group TEG- K time values 
 
 n Mean Std. Deviation 
 
k1 
 
86 
 
2.1849 
 
.88922 
k2 86 2.1326 .73283 
k3 86 2.1721 .61331 
k4 86 2.2302 .57334 
k5 86 2.2570 .82769 
k6 86 2.2930 .74420 
k7 86 2.2198 .47819 
k8 86 2.2302 .57334 
k9 86 2.2302 .57334 
k10 86 2.2267 .50746 
k11 86 2.2674 .51505 
k12 86 2.4523 .79004 
    
    
 
Key: k1:K time immediately before anaesthetic induction; k2: K time after 
anaesthetic induction; k3: K time immediately before arterial clamping; k4:K 
time at the end of arterial clamping; k5:K time 5 minutes after release of 
clamps (in the case of vascular reconstruction); k6: K time at the end of 
surgery; k7:K time 30 minutes after surgery; k8:K time at 6 hours after 
surgery; k9:K time 24 hours after surgery; k10:K time 3 days after surgery; 
k11:K time 7 days after surgery; k12:K time 6 weeks after surgery. 
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Table 3.7.7 PVD group TEG - Angle values 
 
 n Mean Std. Deviation 
 
a1 
 
86 
 
66.3477 
 
6.95890 
a2 86 66.4953 6.72890 
a3 86 66.4198 6.20396 
a4 86 66.2337 7.36637 
a5 86 65.6814 7.41470 
a6 86 66.6733 7.58933 
a7 86 66.2849 7.68878 
a8 86 66.4953 6.72890 
a9 86 66.4198 6.20396 
a10 86 65.9349 6.18322 
a11 86 66.2442 5.38378 
a12 86 65.3395 6.16146 
    
    
 
Key: a1:Angle immediately before anaesthetic induction; a2: Angle after 
anaesthetic induction; a3: Angle immediately before arterial clamping; a4: 
Angle at the end of arterial clamping; a5:Angle 5 minutes after release of 
clamps (in the case of vascular reconstruction); a6: Angle at the end of 
surgery; a7:Angle 30 minutes after surgery; a8:Angle at 6 hours after 
surgery; a9:Angle 24 hours after surgery; a10:Angle 3 days after surgery; 
a11:Angle 7 days after surgery; a12:Angle 6 weeks after surgery. 
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Table 3.7.8 PVD group TEG – Maximum Amplitude (MA) values 
 
 n Mean Std. Deviation 
 
ma1 
 
86 
 
67.7453 
 
7.42466 
ma2 86 74.1465 8.37798 
ma3 86 72.6942 8.06342 
ma4 86 74.2872 8.10543 
ma5 86 72.5860 7.17832 
ma6 86 71.9791 9.06683 
ma7 86 74.0895 9.38093 
ma8 86 72.3663 9.18146 
ma9 86 73.6419 8.51956 
ma10 86 71.1907 14.01948 
ma11 86 71.7826 8.52378 
ma12 86 74.0163 8.37556 
    
    
 
 
Key: ma1:MA immediately before anaesthetic induction; ma2: MA after 
anaesthetic induction; ma3: MA immediately before arterial clamping; ma4: 
MA at the end of arterial clamping; ma5: MA 5 minutes after release of 
clamps (in the case of vascular reconstruction); ma6: MA at the end of 
surgery; ma7: MA 30 minutes after surgery; ma8: MA at 6 hours after 
surgery; ma9: MA 24 hours after surgery; ma10: MA 3 days after surgery; 
ma11: MA 7 days after surgery; ma12: MA 6 weeks after surgery. 
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Table 3.7.9 PVD group TEG – Coagulation Index (CI) values 
 
 n Mean Std. Deviation 
 
ci1 
 
86 
 
3.0823 
 
1.24632 
ci2 86 4.0818 1.41629 
ci3 86 3.9452 1.55836 
ci4 86 4.0580 1.40521 
ci5 86 3.8304 1.29179 
ci6 86 3.7604 1.32876 
ci7 86 3.8485 1.82485 
ci8 86 3.5841 1.57309 
ci9 86 3.7992 1.41972 
ci10 86 3.5237 2.47205 
ci11 86 3.5393 1.44658 
ci12 86 3.9452 1.55836 
    
    
 
Key: ci1: CI immediately before anaesthetic induction; ci2: CI after 
anaesthetic induction; ci3: CI immediately before arterial clamping; ci4: CI at 
the end of arterial clamping; ci5: CI 5 minutes after release of clamps (in the 
case of vascular reconstruction); ci6: CI at the end of surgery; ci7: CI 30 
minutes after surgery; ci8: CI at 6 hours after surgery; ci9: CI 24 hours after 
surgery; ci10: CI 3 days after surgery; ci11: CI 7 days after surgery; ci12: CI 6 
weeks after surgery. 
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TEG parameters obtained at induction of anaesthesia, after the induction of 
anaesthesia and at 30 minutes after commencement of surgery obtained 
from control group were compared with the TEG parameters obtained from 
the PVD  group undergoing surgery at corresponding sampling points. 
Significant reductions in R time (p=0.018), Maximal amplitude (p=.024) and 
CI (p=0.004) were noted in the PVD group after the induction of anaesthesia. 
No significant relationships between type of anaesthesia and TEG 
parameters were identified in this study. Amongst PVD subjects significant 
elevations in Angle (p=0.023) and MA (p=0.034) were found in patients with 
diabetes when compared to non-diabetics with PVD.  
No significant relationships between time duration of starvation prior to 
surgery haematocrit, time from last dose of LMW heparin and type and 
volume of IV fluids administered and the TEG parameters were found. 
Routine haematological tests including baseline coagulation tests were within 
normal range for the PVD group at this sampling point. When TEG 
parameters of samples obtained at 30 minutes after commencement of 
surgery were compared, there were significant reductions in the R time 
(p=0.016) and significant increase in Angle (p=0.002) and MA (p=0.018) 
values were identified. No significant TEG changes due to the type of graft 
used were found in this study. 
When pre and post revascularisation samples were analysed TEG identified 
significant increases in R time (p=0.026), Maximal amplitude (p=0.004) and 
Coagulation Index values (p=0.002) confirming activation of coagulation 
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following revascularisation of an ischaemic limb. This sharp rise in TEG 
values at corresponding sampling point  was not in seen in the samples 
obtained from those who underwent major limb amputation for irreversible, 
non reconstructable peripheral  ischaemia (p=0.146) 
Further postoperative TEG analysis of samples obtained from PVD patients 
who underwent surgery showed consistent increase in Maximal Amplitude 
(p=0.013) and Coagulation Index (p=0.032) values when compared to the 
baseline values. No significant TEG parameter changes were identified 
between those who had amputation or revascularisation surgery up to 6 
weeks following surgery. 
 
DETECTION OF THROMBOTIC EVENTS 
Table 3.7.10 Detection of Thrombotic Events 
 
Post-operative thrombotic events 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 AMI 10 11.6 11.6 11.6 
DVT 8 9.3 9.3 20.9 
PE 2 2.3 2.3 23.3 
TIA 6 7.0 7.0 30.2 
Stroke 2 2.3 2.3 32.6 
Grocc 4 4.7 4.7 37.2 
Death 2 2.3 2.3 39.5 
None 52 60.5 60.5 100.0 
Total 86 100.0 100.0  
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Key: AMI: acute myocardial ischaemia; DVT: Deep vein Thrombosis; PE: Pulmonary 
Embolism; TIA: Transient Ischaemic Attack; Grocc: Graft Occlusion. 
 
Post-operative clinical and laboratory methods of detection of thrombotic 
events (details given in section 2.7) detailed above (Table 3.7.10) occurred in 
those with PVD who underwent revascularisation or amputation procedures. 
TEG profiles of PVD patients obtained at the baseline and during the course 
of surgery and in the post period were analysed. Among the TEG parameters 
an MA value of more than 60 at 72 hours after surgery is found to be related 
to occurrence of any thrombotic event. The ROC curve estimation value is 
0.647 suggesting a significant association between raised MA value obtained 
after surgery (Day3) and any postoperative thrombotic event.  
Figure 3.7.11 MA at Day 3 after Surgery and Post-Op Thrombotic Event 
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Further analysis of TEG parameter profiles obtained from PVD subjects 
during the postoperative period, identified no such associations to the 
occurrence of a thrombotic event. No significant relationship between these 
events and the routine haematological tests including platelet count and 
coagulation screening tests (aPTT and PT) were identified in this study.  
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3.8 - SUMMARY OF RESULTS 
 
The summary of the results of the investigations detailed in this thesis is as 
follows: 
This study confirmed that TEG analysis following citrate storage of 1-2 hours 
produce reliable and reproducible TEG parameter values. Heparinase 
modified TEG method can unmask underlying coagulation defect 
(hypercoagulation) when samples are analysed after administration of 
heparin.  
This study found that blood increases in platelet and coagulation factor 
activity as it flows down the iliac vessel in proportion to the extent of iliac 
atherosclerotic disease. This study has also shown that blood circulating 
through an ischaemic limb increases in coagulability.  
TEG analysis in this study has shown that the local effect of NICM is a 
reduction of coagulation activity rather than the activation suggested by some 
previous studies and in patients with peripheral vascular disease iohexol, a 
NICM leads to no further increase in their blood coagulability during 
peripheral diagnostic angiography. 
Using heparinase modified method, this study has conclusively proven that 
patients with advanced PAOD exhibit reduced endogenous heparin activity 
and this reduced activity is related to the severity of peripheral ischaemia. 
TEG analysis of blood samples from those with abdominal aortic aneurysm 
show activation of coagulation. Reperfusion after aortic aneurysm repair lead 
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to a hypercoagulable state that was consistent and sustained in the post-
operative period. 
TEG analysis of PVD subjects undergoing surgery confirmed the presence of 
a hypercoagulable state at the outset which further accelerates following 
revascularisation or amputation. This study has shown that raised values of 
one of the TEG parameters, MA (maximal amplitude) is significantly 
associated with the occurrence of any post-operative thrombotic event. 
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CHAPTER 4 - DISCUSSION AND FUTURE 
PLANS 
 
 
4.1 - OVERVIEW 
 
 TEG method was used as a research tool when the concept was first 
promoted for use in identifying coagulation abnormalities in the late 70s. This 
technique has now been incorporated as an important bedside test in 
majority of intensive care units, in liver and pancreas transplant units and in 
the management of coagulation abnormalities that complicate major cardiac 
surgical procedures. This study used TEG technique to identify coagulation 
changes in patients with peripheral vascular disease. TEG method needs 
standardisation and needs modified methods to uncover underlying 
coagulation abnormality when there is evidence of exposure to exogenous 
anticoagulant administration i.e., heparin. Using heparinase modified TEG 
method this study looked in to natural endogenous heparin- like activity in 
patients with symptomatic PVD. Using TEG, this study also looked in to the 
coagulation changes in abdominal aortic aneurysmal disease focussing on 
the changes during the perioperative period.  This study is based on the 
central premise that peripheral atherosclerosis and ischaemia has a role to 
play in coagulation. Local (ischaemic limb) and systemic blood sampling 
methods were used to identify significant changes due to severity of PVD 
following surgery and document any significant relationship between 
observed TEG changes and postoperative thrombotic events that occurred 
during the study period. 
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4.2 - VALIDATION AND STANDARDISATION OF TEG   
        METHODS 
 
 
This study has shown that reliable baseline TEG parameter for studies 
employing citrated whole blood TEG method can be obtained by 
recalcification and analysis after a minimum period of 1-2 hours of citrate 
storage following collection of a sample. This study has also confirmed that 
heparinase coated cups negate any heparin effect in a given blood sample 
and it can be used to carry out TEG analysis of blood samples obtained after 
exposure to any form of exogenous heparin to reveal underlying coagulation 
patterns.  
Thromboelastography is a valuable tool in the management of coagulation 
defects in an acute care setting. TEG is capable of measuring global 
coagulation activity in a small sample of whole blood but is subject to 
variability due to many factors. Sample collection, its storage, time to 
analysis, and local variations in the availability of the analyser and personnel 
are some of the important factors. Citrate TEG method needs to be 
standardised for reliable, reproducible results. The range provide by the 
manufacturer is wide, makes no allowance for age or sex, and may need to 
be modified because of the above mentioned factors. TEG assay of citrated 
blood samples exhibit variability and has been shown to be unreliable when 
samples are analysed between 0 and 30 minutes after citration. Rajwal et 
al111 found that there was significant difference between TEG parameters for 
fresh native whole blood and citrated whole blood and recommended 
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establishment of a specific range for citrated whole blood for usage in clinical 
practice. Dormandy et al112 suggested a formal standard operating procedure 
for citrated whole blood TEG that takes in to consideration, the initial period 
of instability.  Camenzind et al113looking in to the effects of citrate storage on 
TEG confirmed that the parameters were different in recalcified, citrated 
samples in comparison to native blood samples. The observed changes were 
progressive during 0-30 min. of storage but were stable thereafter and 
recommended analysis after a citrate storage period between 1- 8 hours for 
reliable TEG results. This study followed the above method and carried out 
TEG after a citrate storage period of 1-2 hours for all samples in an effort to 
obtain reliable results. 
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4.3 - INVESTIGATION OF THE EFFECTS OF AGE, GENDER  
        AND ANAESTHESIA ON COAGULATION USING TEG –  
        CONTROL GROUP STUDY         
                         
The main objective of this study is to obtain baseline values for citrate TEG 
method using blood samples obtained from a group of participants acting as 
controls for our study looking in to coagulation changes in patients 
undergoing during peripheral vascular surgical procedures and their 
relationship to postoperative thrombotic events. This study also looked at any 
significant changes in coagulation due to host factors (i.e., age, gender and 
BMI) and perioperative variables (induction of anaesthesia, IV fluid 
administration and surgery) towards coagulation during surgery.  
This study found no significant relationships between baseline routine 
coagulation tests and TEG parameters from control subjects, which is not 
surprising as routine coagulation tests to do not take in to consideration the 
extrinsic component of coagulation cascade and the contribution from 
platelets, an important aspect of coagulation. Findings of this study are 
consistent with previous studies employing citrated TEG.  
 
Various factors including, preoperative starvation, hydration, temperature, 
anxiety and stress related to undergoing a surgical procedure can influence 
coagulation. There is now convincing evidence that patients undergoing 
major surgical procedures exhibit hypercoagulability114,115 albeit transient, 
during the perioperative phase. Several investigators have attempted to 
identify the factors that may be responsible for this hypercoagulable state 
observed during the perioperative period using Thromboelastography. 
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Among other factors stress, anxiety prior to surgery, starvation, 
dehydration116, preparation for anaesthesia117, iv fluid administration118, 
anaesthesia119 and surgical stimulus120 are identified as possible reasons for 
the changes in coagulation observed during surgery. 
This study did not identify any significant relationship between duration of 
starvation or body temperature and baseline TEG parameters. However, 
Gorton et al121 in their study involving 20 women undergoing caesarean 
section found significant changes towards hypercoagulation on TEG. They 
attributed these changes in TEG parameters to events during the pre-
induction phase of anaesthesia i.e., placing of venous cannula, period of 
waiting in an area next to the operative theatre and possibly due to increase 
in circulating catecholamines.  
 
Bauer et al122 (Normative Ageing Study) found significant positive 
correlations between increasing age and F1+2 levels, fibrinopeptide A and 
protein C activation peptide levels.  Ofosu et al123  reported significant 
increases in coagulation system proteins including markers of activation of 
coagulation resulting in high thrombotic risk with ageing.  Boldt et al124 using 
TEG, found significant activation of coagulation in elderly (>80 years) cardiac 
surgery patients compared to younger patients (< 60 years) prior to surgery. 
Boldt et al125 again reported that elderly patients showed more prothrombin 
activation/thrombin generation and increased fibrinolytic activity prior to 
surgery (baseline) than younger patients among those undergoing major 
general surgical procedures. Yamamoto et al126 in their review state that 
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increased levels of PAI-1, a principal inhibitor of fibrinolysis, found to increase 
significantly with age in several studies, could play a key role in the 
progression of cardiovascular disease in the elderly by promoting thrombosis 
and atherosclerosis. Age is also associated with abnormal platelet function 
and procoagulant activity127 as its consequence and can lead to development 
of athero-thrombotic events.  
No significant associations between age and TEG parameters were found in 
this study in contrast to studies involving ageing and coagulation and 
thrombotic risk where investigators have found altered platelet function, 
abnormal tissue factor pathway inhibition (TFPI),128 with increasing age. 
These findings could well be due to the fact that very few (n=3) of the 
participants were over 80 years in this study.  
 
Gorton et al129 showed gender differences in coagulation using 
Thromboelastography with significant trend towards increasing whole blood 
coagulability from men through non-pregnant to pregnant women. Pre-
menopausal women were found to be significantly more hypercoagulable 
following trauma when compared to men and TEG was sensitive in 
identifying this coagulation abnormality in the first 24 hours after trauma130. In 
post-menopausal women, the combination of ageing and oestrogen 
deficiency has been found to be significantly associated with a significant 
increase in the incidence of myocardial infarction, claudication and stroke 
compared to pre- menopausal women131.  Koch et al132 in a study involving 
outcomes after cardiac bypass surgery found that female gender is 
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associated with more complications predominantly due to activation of 
coagulation and fibrinolytic impairment especially after menopause leading to 
a significant increase in athero-thrombotic events.   
The incidence of thrombotic events like myocardial infarction, stroke and 
deep vein thrombosis increases with age and it increases exponentially in 
women after menopause133. There is convincing evidence of activation of 
coagulation shown by significant increases in coagulation factors including 
thrombin, in elderly women compared to pre-menopausal women due to 
ageing and associated changes in vascular and haemostatic mechanisms 
related to oestrogen deficiency.134 There are no useful markers or definitive 
tests of thrombotic tendency due to oestrogen related changes in coagulation 
and fibrinolytic mechanisms to identify individuals at risk. However, TEG has 
been shown to reflect changes associated with hormonal status of an 
individual especially in those on oestrogen containing oral contraceptive pills 
by identifying rapidity in fibrin formation and acceleration of increase in clot 
firmness among its users. The literature suggests that post- menopausal 
women exhibit increased coagulability compared to pre-menopausal women 
and men. Women in general, respond to trauma with significantly increased 
activation of coagulation than men. 
Various studies have noted that obesity is associated with significant arterial 
and venous thrombotic events. Body mass index (BMI) is associated with 
increase in activation of coagulation factors, impaired fibrinolysis, defective 
endothelial function and increased levels of circulating tissue factor (TF)135 
leading to a prothrombotic state in patients with high BMI. Abnormal lipid 
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metabolism and hyperglycaemia are other significant abnormalities 
associated with this condition. Hyperlipoproteinaemia, which behaves like 
LDL (low-density lipoprotein) due its composition leads peroxidation resulting 
promotic inflammation that in turn leads to activation of coagulation and 
progression of atherosclerotic lesions.  Abnormal glucose metabolism i.e., 
hyperglycaemia hyperinsulinaemia and insulin resistance have all been 
shown to promote activation of coagulation leading to a prothrombotic state 
in diabetes mellitus.  Hyperglycaemia associated with increasing plasma 
level of fibrinogen, levels of activated factors VII, VIII, von Willebrand and X. 
This is also associated with significant increases in TAT complexes 
(thrombin-antithrombin) and soluble tissue factor levels irrespective of insulin 
levels. Hyperinsulinaemia on the other hand has been shown to inhibit 
fibrinolysis by decreasing plasminogen activator activity by increasing the 
PAI-1 levels irrespective of glucose levels. Insulin resistance is associated 
again with elevated PAI-1 inhibitor levels, increased levels of coagulation 
factors, endothelial dysfunction leading to suppression of synthesis of nitric 
oxide and prostacyclin and platelet activation resulting in high incidence of 
atherothrombotic events in these patients.136   
The effect of intravenous fluids on coagulation has been a much-debated 
topic. Ruttmann et al137 in their initial study found that when patients‘ whole 
blood samples were haemodiluted with 0.9% saline in vitro there was a 
significant increase in coagulability than when a colloidal solution (Haemacel) 
was used on TEG especially, the clot strength. Ruttmann et al138 later in an 
in vivo study of haemodilution of normal blood reported a procoagulant effect; 
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possibly, by enhancement of thrombin formation due to low levels of AT-III 
was noted following haemodilution. They also reported that in vitro 
haemodilution-induced coagulation enhancement is attenuated, but not 
prevented, if AT III levels were maintained in the normal range in keeping 
with the concept of an antithrombin threshold preventing positive coagulation 
feedback into the intrinsic pathway. The same group also found that this 
hypercoagulable response following haemodilution was unaffected by Aspirin 
administration.139  Boldt et al140reported a small but significant shift towards 
hypercoagulability immediately after surgery and five hours after the end of 
surgery in those undergoing major abdominal surgical procedures receiving 
intravascular volume replacement with crystalloids (Ringer‘s lactate (n=21) 
and 0.9% saline solution (n=21)) and found no significant differences in 
coagulation patterns in between those who received Ringer‘s lactate 
(18750+/-1890ml) and 0.9% saline solution (17990+/-1790ml). Gorton et al18 
also found no significant changes in coagulation on TEG after fluid 
administration (500ml of Gelofusine IV over 15 minutes) during the pre-
induction phase. 
Ng et al141 after a randomised control study involving patients undergoing 
major hepato-biliary surgery found that replacement of 30% of blood volume 
with saline over 30 minutes(n=10) can induce a hypercoagulable state when 
compared to those who did not receive (n=10) any such replacement of 
blood volume. However Butwick et al142 found no significant effects on 
coagulation following preloading with 1500 mL Ringer`s lactate using TEG 
and Ekseth et al143 (n=12 patients) suggested that with crystalloids and 
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albumin, dilution had to exceed 50% before coagulation was impaired. 
Available evidence suggests that there is an increase in the coagulation 
activity when significant haemodilution takes place and that the effect may be 
more marked with saline solution than other IV fluids. TEG is a sensitive test 
for identifying subtle and early changes due to fluid administration especially 
haemodilution with various colloid and crystalloid solutions that are used 
during the induction phase of anaesthesia.  
Significant changes in TEG parameters have been reported with 
administration various colloid, crystalloid infusions, blood and blood products 
during induction of anaesthesia and surgery. The predominant change 
observed so far in TEG patterns due to crystalloid administration was that of 
a temporary hypercoagulable pattern after haemodilution by rapid infusion of 
isotonic (0.9%) saline ranging between 30-50% of total blood volume. This 
study group did not receive such volumes and no significant relationships 
between the type of fluids (0.9% Normal saline and Hartmann`s) or the 
volume (145+/-20 ml (mean/SD), CI 70+/-50, 180+/-50 ml) and rates (50-
120/hr) at which they were administered and TEG parameters were found in 
this study.  
Anaesthetic techniques/agents (general/spinal/epidural/regional/local) have 
been shown to affect blood coagulability.  Several investigators have used 
TEG to identify such changes in coagulation due to anaesthetic agents 
(inhalational, intravenous and local anaesthetic). Sharma et al144 found 
significant reductions in r and k times in patients who received a general 
anaesthetic (n=15) when compared to those who had a spinal anaesthetic 
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(n=15) prior to caesarean section. General anaesthesia in combination with 
epidural analgesia has been shown to lead to fewer post op thrombotic 
events than general anaesthesia alone. Possible mechanism involved in this 
finding include a reduced response to stress during surgery and is associated 
with reduced cortisol and epinephrine levels in those who had combined 
general anaesthetic and epidural analgesia resulting in reduced athero-
thrombotic cardiac events145. In addition, there was less platelet aggregation 
during surgery, in the GA+EPI group compared to GA alone146.  Bupivacaine, 
a routinely used long acting (local / epidural) anaesthetic on TEG®  lead to 
significant reductions in MA (Maximal Amplitude) values when used at 
2.5µg/ml dosage in vitro.147.  Kohrs et al148 in another in vitro study reported 
that Bupivacaine inhibits thromboxane A2 (TX) signalling and suggested that 
it might partly explain the beneficial effects of epidural anaesthesia on 
postoperative thrombotic events. However, no consistent results were shown 
by other studies looking at the effects of local anaesthetic agents at varying 
dosages for epidural anaesthesia.149 Benzon et al150 in a randomised, double 
blind study found no significant differences in TEG® variables due to 
Bupivacaine on epidural Fentanyl epidural analgesia. Gibbs et al151 found in 
12 patients no significant effects on TEG variables due to Bupivacaine in 
clinically relevant doses (2.7µg ml). Niemi et al152 found that I.V. regional 
anaesthesia (IVRA) with high i.v. lignocaine concentrations (median 144.4 
micrograms ml-1 in cubital veins at the end of the tourniquet time) potentiated 
ischaemia-induced fibrinolysis activation during IVRA. Kohro et al153  in an in 
vitro study (14 patients) again using TEG® reported that Propofol promoted 
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fibrinolysis. Law et al154 in a prospective randomised study found no such 
coagulation abnormalities on TEG® due to propofol use and in between 
those who received propofol (n=19) or isoflurane (n=20).  
This study has shown that significant activation of coagulation occurs 
following induction of anaesthesia.  However, no significant relationship 
between the type anaesthesia (Epidural, Epidural +General or General) or 
the agents used and the TEG parameters considered in this study. Contrary 
to previous studies showing reduction in overall coagulability with 
Bupivacaine, a long acting local anaesthetic agent using TEG no such 
alterations in TEG were found when the agent is used for epidural 
anaesthesia (2.7µml-1ml) in this study.  Sharma et al155 in their study 
concluded that general anaesthetic is associated with accelerated 
coagulability when compared with spinal anaesthesia. No such significant 
difference in TEG parameters due to a specific anaesthetic method was 
identified in our study. Findings could well be due to the fact that these 
studies involved pregnant women who are about to undergo caesarean 
section and their overall coagulability is significantly increased at the outset 
and probably not an ideal group for comparison. The significant shift towards 
hypercoagulation after induction of anaesthesia seen in this study is more 
likely due to the cumulative effects of various factors including IV fluid usage, 
anaesthetic method and agents administered than any one of these factors 
on its own.   
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Various studies have shown activation of coagulation and fibrinolysis by 
measuring significant increases in markers of the same including Thrombin-
antithrombin III complexes (TAT), soluble fibrin monomer complexes 
(SFMC), fibrin degradation products (FDP), D-dimers (D-D), fibrinogen 
(FIB)156 in blood samples obtained immediately at the end of a surgical 
procedure and in another study involving patients undergoing total hip 
arthroplasty procedures, Prothrombin fragments 1+2 157 on post op day 1. 
Platelet activation resulting in increased aggregation that extends up to 20 
hours after completion of surgery completes a picture of an acquired 
hypercoagulable state following surgery158 resulting in increased thrombotic 
risk during the same period. Stress response to surgery (both endocrine and 
metabolic), activation of tissue factor, endothelial dysfunction, associated 
stasis and alteration of constituents (viscosity) of blood (Virchow`s triad) due 
to preoperative factors (starvation, dehydration, IV fluid administration etc.,) 
are some of the possible causes for these alterations in coagulation observed 
during the peri-operative phase. Significant activation of coagulation and 
fibrinolysis occurs within the first 24 hours (18.1+/-6.4 hours) after trauma 
and as mentioned previously, more commonly seen in women159. Studies 
have shown that this increase in coagulability is decreased in laparoscopic 
procedures in comparison with open procedures,160 increased activation of 
coagulation in older patients undergoing surgery than in younger patients42, 
increased thrombo-embolic events in those undergoing surgery for 
malignancy161 and a prolonged period of hypercoagulability ( post op day 7) 
after major abdominal162 and aortic163 surgical procedures. 
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Various investigators have identified a period of hypercoagulability albeit 
transient in those undergoing major abdominal, vascular and cardiac surgical 
procedures.  The significance of this finding lies in the fact that these patients 
were found to have normal coagulation pattern following baseline 
haematologic and routine coagulation tests carried out prior to 
commencement of a surgical procedure as in our study.  Several studies 
have reported significant activation of coagulation in the postoperative period 
following major surgery identified by TEG but there were no specific 
information with regard to the contribution of individual events or factors 
involved during surgery.  
This study has demonstrated that the hypercoagulable response that starts 
after the induction of anaesthesia continues at a higher level during surgery 
identified by a significant increase in Angle, representing acceleration of fibrin 
build up and cross-linking (clot strengthening). This phenomenon also 
appears to be independent of the level of complexity of surgical procedure 
involved with no significant differences in TEG parameters among patients 
who underwent various surgical procedures detailed in this study. 
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4.4 - INVESTIGATION OF THE EFFECTS OF SAMPLING SITE, 
PERIPHERAL ATHEROSCLEROSIS AND PERIPHERAL 
ISCHAEMIA ON TEG        
 
                                  
For this study Thromboelastography (TEG)164 was used to measure changes 
in platelet function and the coagulation cascade across the ischaemic limb 
and then sought to determine whether the changes in coagulability were 
caused by flow through an atherosclerotic vessel or through ischaemic 
tissue.  
Peripheral venous blood samples demonstrate a systemic increase in 
coagulability in patients with peripheral arterial occlusive  disease (PAOD) 
affecting the legs165166167168. Fibrinogen169 and products of the coagulation 
cascade including thrombin-antithrombin complexes and prothrombin 
F1+F2170 as well as D- dimers171, indicating increased thrombin synthesis 
and fibrinolysis, are found consistently raised in patients with PAOD. 
Ischaemic heart disease is associated with similar changes172173174. The 
mechanism responsible for these changes is not clear. Potential causes of 
activation of the coagulation cascade include contact between circulating 
blood and atherosclerosis in the vessel wall or passage of blood through 
ischaemic tissue. Circulating fibrinogen levels in PAOD correlate inversely 
with the mean ABPI 175 and with angiographic scoring176. The degree of 
coagulation activation, indicated by systemic levels of thrombin-antithrombin 
complex, increases with the severity of disease on angiography or duplex 
scanning.11 Fibrinolytic activity, reflected in D-dimer levels, also correlates 
inversely with mean ABPI12 and angiographic scoring11. It is therefore clearly 
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established that an ischaemic limb is associated with increased clotting 
activity but although Lassila et al11 and Woodburn et al12 showed a 
correlation between the level of activation and the extent of atherosclerosis, 
the latter also correlates with the degree of ischaemia and so it is still not 
clear which drives the increase in clotting activity. 
This study has clearly shown that blood coagulability increases as it flows 
down an atherosclerotic artery and that the magnitude of that change relates 
to the severity of stenosis. It is likely that the changes in blood coagulability 
are caused either by exposure to atherosclerotic disease itself or possibly by 
the turbulence produced by a stenosis. It is unlikely that ischaemia plays a 
part in this situation. The changes recorded as blood flows through the 
ischaemic limb are more complex.  Presumably the same mechanisms which 
induced a change in coagulability in the iliac segment also play a part in the 
changes within the limb. Sobel et al177 demonstrated increased thrombin 
generation within the ischaemic limb by measuring fibrinopeptide A (FPA) 
levels that were consistently higher in venous samples than in the arterial 
inflow to an ischaemic limb. The same authors found no increase in  
thromboglobulin and concluded that there was no activation of platelets 
across the ischaemic leg although other studies have found systemic 
evidence of platelet activation in such subjects178.   
This attempt to measure the extent of atherosclerotic disease in the 
infrainguinal vessels using angiographic scoring may seem like a simplistic 
approach but arteries which are very heavily diseased are likely to cause 
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diversion of flow into disease free collateral vessels; indeed blood will never 
be exposed to the most heavily diseased (occluded) arteries. This study did 
show a correlation between the increase in coagulability across a limb and 
the extent of ischaemia, measured by ABPI on that side. Thus flow through 
ischaemic tissue may promote coagulation but this cannot exclude the 
possibility that this relationship arises through the close association between 
the severity of ischaemia and the extent of atherosclerotic disease past which 
the blood must flow to the distal limb. The changes in coagulability could all 
be due to exposure to atherosclerotic disease.  
ABPI was used as a measure of ischaemia in this study rather than as a 
measure of atherosclerotic disease in the limb because it reflects the 
perfusion pressure at ankle level and thus relates to the level of ischaemia. It 
depends on flow through collateral vessels as well as through stenosed 
arteries and is therefore not a measure simply of atherosclerotic disease. 
Presenting symptoms could have been used as a measure of ischaemia (ie 
asymptomatic v claudication v rest pain) in this study but in the less 
symptomatic leg (the limb in this study) any symptoms of claudication could 
have been masked by more severe disability in the other leg. 
TEG was used to assess coagulation because its sensitivity and specificity 
compares well with routine coagulation tests179180 and it provides a measure 
of the overall coagulation status of a given blood sample rather than of 
individual clotting factors in isolation181.  TEG analysis of citrated samples is 
more sensitive in the detection of procoagulant alterations than other 
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coagulation tests and is therefore ideal for the assessment of coagulation in 
patients with PVD. 
This study has confirmed that blood becomes more coagulable as it 
traverses the ischaemic limb and has shown that platelet activation, as well 
as increased thrombin production, takes place within the limb. This study has 
clearly shown that blood coagulability increases as it flows down an 
atherosclerotic iliac artery and that the magnitude of that change relates to 
the severity of stenosis.  Ischaemia is unlikely to play a part here and it is 
probable that the changes in blood coagulability are caused by the presence 
of atherosclerotic disease. This may be due to interaction with the 
atherosclerotic plaque but in the carotid and coronary arteries, where this has 
been extensively studied, enhanced coagulation is usually associated with 
‗unstable plaque‘ and ulceration.  Another possible cause of coagulation 
activation in the iliac arteries might be the increased shear 
stress182associated with localised stenosis. This has been shown to induce 
platelet aggregation in both acute coronary syndromes183and chronic 
coronary artery disease184. It is possible that other steps in coagulation are 
also activated under such circumstances. The third possibility is that 
turbulence in blood flow over irregular plaque promotes coagulation although 
there is no direct evidence for this in the literature. 
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4.5 - INVESTIGATION OF THE THROMBOGENIC POTENTIAL 
OF NICM IN PVD USING TEG 
 
Patients with PAOD are known to be systemically hypercoagulable and many 
of these patients undergo angiography or angioplasty and any changes in 
coagulability caused by injection of contrast medium may have major 
implications for the patient. This would be particularly important if contrast 
injection led to an increase in coagulability because it could promote 
thrombosis at the site of angioplasty and in the poorly perfused distal vessels 
of an ischaemic leg. This study looked at the changes in coagulation adjacent 
to the site of contrast injection/potential angioplasty to determine the 
magnitude of change locally.  
There have been conflicting data from both in vitro and in vivo studies 
regarding the effect of non-ionic media (NICM). NICM have been shown to 
interact with haemostatic factors via platelet185, endothelial186, coagulation187 
and fibrinolytic188 mechanisms to increase coagulability when mixed with 
blood in vitro. Comparisons with ionic contrast media (ICM) in these studies 
suggest that the NICM have a greater procoagulant effect. At least one 
prospective in vivo study189, however, in which peripheral venous samples 
were taken for analysis before and after injection of contrast media in 
patients undergoing angiography for peripheral arterial occlusive disease 
(PAOD) and randomised to NICM or ICM, has shown no difference between 
the effects of the different contrast media.  
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Modern techniques have led to a reduction in thrombo-embolic episodes in 
patients undergoing diagnostic and therapeutic angiographic procedures and, 
in those undergoing angioplasty procedures, much improved patency 
rates.190 Despite this positive trend there is anxiety among radiologists and in 
the cardio-vascular fraternity about the role of contrast medium in thrombo-
embolic complications. Patients with coronary and peripheral vascular 
disease have an activated state of coagulation manifest by consistently 
elevated of markers of activation of platelet, endothelium and coagulation 
factor mechanisms. When these patients undergo angiographic procedures 
there is a potential risk of further activation of these coagulant mechanisms 
due to interactions with the contrast medium used and the endothelial injury 
following angioplasty.  
Contrast agents and their effect on coagulation in patients undergoing 
diagnostic and therapeutic angiographic procedures has been a much 
debated topic.  Various investigators have reported the pro and anti-
coagulant effects of both ICM and NICM using in vitro and in vivo methods. 
Grines et al191 found ICM caused less in-vivo thrombosis than NICM in a 
canine model of arterial injury. Hwang et al192 suggested that the use of 
NICM increased the potential risk of thrombosis in patients undergoing 
coronary angioplasty procedures. Kopko et al193 reported thrombin 
generation in peripheral venous blood after mixing with NICM in glass 
syringes and Robertson et al194 reported clot formation in angiographic 
syringes containing NICM. Grollman et al195 reported three cases in which 
clots formed during angiography with NICM and Fareed et al196 in their 
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review also suggested that the potential for thrombotic complications is 
higher with non-ionic contrast agents based on generation of thrombin when 
blood is mixed with NICM in glass syringes and reported a procoagulant 
response on TEG profile197 when NICM (Iopamidol) was mixed at a ratio of 
1:80 (contrast media: blood). Gasperetti et al198 reported an incidence of 
thrombosis up to 18% in patients undergoing coronary angioplasty when 
NICM was used compared to 4% in those where an ionic contrast agent was 
used. Davidson et al199 however reported an incidence of thrombosis in 
0.18% in 7230 consecutive patients who underwent cardiac catheterisations 
and found no difference in thrombotic events between ICM and NICM usage. 
This study included patients who were on heparin prior to catheterisation and 
the results were attributed to the effect of heparin. Recently Mukherjee et 
al200 reported an increase in thrombin-antithrombin (TAT) and F1 and F2 in 
peripheral venous samples 30 minutes after Iohexol (NICM) use in 10 
patients undergoing coronary angiography but no such increase in patients 
who underwent coronary angioplasty who also received heparin during the 
procedure suggesting that the thrombogenic potential of iohexol was 
neutralised by heparin. Contrast agents are also reported to affect the 
platelet aggregation and adhesion in various in vitro studies. Wiesel et al201 
found increased platelet adhesion in vitro on the luminal surface of a vascular 
graft and Grabowski et al202 reported platelet adhesion on the endothelial 
surface in another in vitro model after exposure to NICM. Heptinsall et al203 
reported potentiation of platelet aggregation and degranulation with the use 
of NICM using flow cytometry and P-selectin measurements after mixing 
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contrast agents with peripheral venous samples. Brosstad et al204 in their 
review stated that the observed discrepancies in contrast induced changes 
are due to the various in vitro tests being at best, comparable to stagnant 
flow conditions and suggested that satisfactory comparisons can only be 
made in vivo studies under dynamic flow conditions as in this study.  
This study identified a global reduction in the coagulability of blood adjacent 
to the site of injection of NICM during routine diagnostic peripheral 
angiography. This should reflect the situation at the site of proposed 
angioplasty prior to starting the procedure, with mixing of contrast agent and 
circulating blood rather than the static situation studied in the in vitro studies 
discussed above. TEG also identifies overall changes in coagulation rather 
than changes in individual factors and so has more relevance to the clinical 
situation.  
Results from this study shows that contrary to several published reports 
Iohexol, a NICM does not lead to activation of coagulation in patients 
undergoing diagnostic angiography but in fact reduces overall coagulability. 
The effect of contrast injection in the aorta, in a volume used for angiography, 
is to partly counteract that hypercoagulability associated with PAOD. Despite 
this reduction the overall coagulation status of patients with PAOD remains 
significantly elevated when compared to the baseline peripheral venous 
samples obtained from age matched control subjects (p=0.014). Peripheral 
venous samples from controls were used for comparisons as it is difficult 
ethically to justify invasive aortic sampling and the coagulation should be 
similar in healthy subjects irrespective of site of blood sampling. 
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The significant changes found in TEG parameters suggest that the local 
effect of NICM is a reduction of coagulation activity rather than the activation 
suggested by some previous studies and in patients with peripheral vascular 
disease iohexol (a NICM) leads to no further increase in their blood 
coagulability during peripheral diagnostic angiography. 
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4.6 - IDENTIFICATION OF ENDOGENOUS HEPARIN-LIKE 
ACTIVITY IN PVD USING TEG                         
 
This study for the first time showed that PVD is associated with reduced 
heparin- like activity in the blood and the magnitude of reduction relates to 
the severity of atherosclerotic disease measured by ABPI. This study 
demonstrated that heparinase modified TEG can identify endogenous 
heparin activity in both controls and patients with PAOD.  
 
Patients with peripheral vascular disease are known to have systemic 
hypercoagulability. This study was based on a hypothesis that part of the 
heightened coagulant activity is related to reduced production of endogenous 
heparin-like substance in these patients. Long-term intermittent heparin 
therapy in non-anticoagulant doses has been shown to significantly reduce 
the cardiovascular deaths when compared to control groups in patients with 
angina205 and intermittent exogenous heparin in non-anticoagulant doses has 
also been shown to reduce fibrinogen levels206, an independent marker for 
cardiac event in patients with PVD.  
 
Studies involving patients with PVD have shown improvement in pain free 
walking distances and maximum walking distances in those receiving heparin 
compared to platelet agents207,208. Tuman et al, 24 using the heparinase 
modified TEG method in 42 healthy volunteers, found no significant 
endogenous heparin-like activity in most of samples obtained from healthy 
volunteers analysed 3 minutes after collection and citration although they did 
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find some activity in a small group which they ascribed to contamination. 
Ideally blood samples should be analysed within 6 minutes after collection209. 
This is often not practicable and samples are usually citrated and analysed 
after a delay.  
 
A recent study210looking in to the effects of citrate storage on TEG confirmed 
that TEG parameters were different in recalcified, citrated blood samples 
compared with native blood. The observed changes were progressive in 
samples during 0-30 min. storage but were stable thereafter and the authors 
recommend analysis after a citrate storage period between 1- 8 hours for 
reliable TEG results. We followed the above method and carried out native 
and heparinase modified TEG after a citrate storage period of 1-2 hours for 
all samples in an effort to obtain reliable results. This may explain the 
difference between our results and those of Tuman et al211.  
The reduction in heparin like activity is probably related to both reduced 
production in the arterial wall and increased heparin consumption. Studies of 
atherosclerotic human coronary arteries have shown a reduction in HSPG in 
the arterial wall with a proportional increase in chondroitin-6-sulphate and 
dermatan sulphate proportional to the increasing severity of 
atherosclerosis212. Heparan sulphate content in the intima of human arteries 
especially in atherosclerosis-prone regions such as coronary arteries, renal 
arteries, internal carotid artery at the level of the carotid sinus, abdominal 
aorta and stenotic iliac arterial segments have been shown to decrease with 
an increase in the severity of atherosclerotic lesions.213 There may well be 
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increased consumption of heparin in PAOD in view of increased activity of 
coagulation cascade with a positive feedback from increased thrombin levels 
and reduced anti-thrombin levels shown to exist in patients with progressive 
peripheral vascular disease21.  
Heparin exerts its effects through two mechanisms, both of which requires 
binding of antithrombin, firstly to the pentasaccharide polymer within the AT 
structure that leads to a change in the protein that mediates its inhibition of 
factor Xa and secondly binding of thrombin (factor IIa) to heparin close to the 
pentasaccharide AT binding site.  Formation of this complex between AT, 
thrombin and heparin results in inactivation of thrombin214. Thus the effects of 
heparin on coagulation are mediated through AT. We know that serum from 
patients with PAOD has reduced levels of AT.  Lack of antithrombin activity 
may account for reduced measured heparin activity. Reduced ―heparin-like‖ 
activity has obvious implications. Endogenous heparin and HSPGs found on 
the negatively charged215 luminal surfaces of the endothelial cells are 
essential for inhibition of coagulation at the endothelial surface216 and 
lipoprotein lipase function217 both of which are defective in atherosclerotic 
vascular endothelium218. Circulating endogenous heparin and heparan 
sulphates in the proteoglycan layer of the intima subjacent to the lumen bind 
with and activate anti-thrombin to form an effective anticoagulant complex on 
the endothelial surface11. Endogenous heparin has also been shown to 
decrease micro thrombi formation at sites of endothelial injury219. Heparin 
has been shown to inhibit platelet activation following flow through vessels 
with a high and moderate shear stress by its action that is not mediated by its 
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antithrombin activity220. Heparin also prevents endothelial cell dysfunction 
following ischaemia by augmenting vasodilation mediated by endothelial 
derived relaxing factor by a mechanism independent of its anticoagulant 
effect.221 These non-anticoagulant actions of heparin are of particular 
importance as both high shear and endothelial dysfunction following 
ischaemia are shown to exist in patients with PVD. 
Patients with PVD manifest changes in haemostatic factors222, and platelet 
function.223,224 Studies of haemostatic factors and products of coagulation 
show a similar trend in both cardiac and PAOD patients suggesting activation 
of coagulation. Once patients get to a stage where endogenous heparin 
activity is significantly reduced then the obstructive effects of atherosclerosis 
on blood flow may be compounded by an increasing tendency to thrombosis 
within the downstream vessels. These changes in coagulation are particularly 
exaggerated during the perioperative period and can predispose PAOD 
patients to thrombotic events following revascularisation225,226.  
A variety of heparin related products have also been shown to inhibit 
vascular smooth muscle cell proliferation227 and they play a regulatory role 
that alters the endothelial response after vascular injury.  Indeed, exogenous 
heparin preparations have been shown to effectively suppress smooth 
muscle cell proliferation following injury to vascular endothelium228. Low 
molecular weight heparin (LMWH) has been shown to reduce neointimal 
hyperplasia in cultured human saphenous vein and the use of heparin in non-
anticoagulant doses to achieve similar benefit in practical clinical situations 
has been suggested by the authors of the study229. Low levels of 
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endogenous heparin may allow excessive intimal hyperplasia at parts of 
trauma within the vascular system –either due to clinical intervention or in 
areas of turbulence within the circulation.230 
  Studies undertaken to check the clinical and haemostatic effects of small 
doses of LMWH (15,000 anti Xa units/day/SC) in patients with PAOD has 
shown an improvement in absolute claudication time and distance along with 
a significant increase in activated partial thromboplastin time (APTT) that 
remained within normal limits. A three month course of unfractionated 
heparin (12,500 I.U once daily) has also been shown to improve pain free 
walking distances to a greater extent than an anti-platelet agent, ticlopidine 
alone231,232,233 in patients with PAOD. 
This study provides supporting evidence for the use of low dose heparin in 
patients with PVD. This may be particularly important around the time of 
prolonged immobility and surgical intervention. 
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4.7 - INVESTIGATION OF CHANGES IN COAGULATION 
CHANGES IN AORTIC ANEURYSMAL DISEASE USING TEG  
 
This study looked at coagulation changes in patients with non-ruptured 
abdominal aortic aneurysm (AAA) undergoing elective aneurysm repair.  
Bradbury et al234 reported that preoperative haematological parameters were 
frequently found to be normal in this group of patients who later developed 
thrombocytopenia, significantly related to the duration of aortic cross-clamp, 
thrombocytosis and hyperfibrinogenaemia in the postoperative period. Similar 
changes were also seen in patients undergoing aortic surgery for occlusive 
disease. Gibbs et al235 reported that when coagulation factors were 
measured preoperatively, and on days two, four, and six postoperatively it 
was found that there were no significant changes outside the normal range in 
prothrombin time, partial thromboplastin time, or thrombin clotting time. 
However, there were large increases in the procoagulants, fibrinogen, factor 
VIII coagulant, factor VIIIRag/von Willebrand factor, and in alpha 1-
antitrypsin. Over the same time there were marked decreases in the naturally 
occurring anticoagulants, protein C and antithrombin III, and in alpha 2-
macroglobulin. These changes implied that the patients were 
"hypercoagulable" in the postoperative period. The maximum changes in the 
procoagulants occurred on either postoperative day two or day four. The 
maximum changes in the natural anticoagulants occurred on postoperative 
day two. There were no significant changes in factor V, factor X, alpha 2-
antiplasmin, or platelet aggregability. The timing of the changes coincided 
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with a period of high risk of perioperative myocardial infarction and other 
thrombotic events.  
Holmberg et al236 found that prothrombin fragment 1+2 (F1+2), thrombin-
antithrombin complex (TAT) and soluble fibrin (SF) were elevated 
preoperatively in AAA patients. During aortic clamping all parameters 
increased significantly in cubital blood as well as in femoral blood and after 
aortic declamping F1+2 and TAT increased further. F1+2, TAT and SF were 
significantly higher in femoral than cubital blood. Postoperatively F1+2 and 
TAT returned to preoperative values, while SF still had a significantly higher 
level than preoperatively. The findings indicated that the coagulation system 
was strongly activated in the presence of an AAA with a further activation 
seen after surgery. The activity was still high, but on decline, one week 
postoperatively. Ischaemia and reperfusion of the lower part of the body were 
considered as major stimuli for thrombin generation and activity. 
 Holmberg et al237 also found that F1+2, TAT, and D-dimer values in preop 
AAA  patients were significantly higher compared to age matched controls 
and in the post-op period these parameters were significantly lower 
compared to preoperative period. The activity of the coagulation and 
fibrinolytic systems were shown to decrease after AAA surgery however, the 
activity was still found to be higher than in healthy age matched controls and 
the explanation may be that the thrombogenicity is lower in a vascular graft 
than in an aneurysmal sac but still higher than in a nonaneurysmal aorta.  
Adam et al238 in their study involving ruptured and non-ruptured AAA 
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demonstrated that ruptured AAA repair is associated with inhibition of 
systemic fibrinolysis and intense thrombin generation. Similar changes were 
also seen in non-ruptured AAA but are of a lesser magnitude. They also 
concluded that the observed procoagulant state contributes to the 
microvascular and macrovascular thrombosis that leads to myocardial 
infarction, multiple organ failure, and thromboembolism. Skagius et al239 
indicated a state of activated coagulation in patients with a non-ruptured AAA 
that was intensified by rupture. They also reported normal fibrinolytic 
activities in patients with a non-ruptured AAA, but increased systemic 
fibrinolysis, as demonstrated by elevated tissue plasminogen antigen (tPAag) 
level, in patients with a ruptured AAA. The hyperfibrinolytic state was 
reinforced by shock in that study. However, they also found a relatively high 
incidence of thrombosis-related deaths, indicating a prothrombotic state 
instead of a hyperfibrinolytic state in patients presenting with shock following 
a ruptured AAA. 
Patients with aortic aneurysm are in a chronic inflammatory state and a 
chronic hypercoagulable state. Preoperative thrombin-antithrombin complex 
(TAT), d-dimer, and cytokines are increased when compared with healthy 
subjects, indicating a hypercoagulable state. The hypercoagulable state and 
inflammatory process activate macrophages and leukocytes to release 
cytokines. These cytokines further induce hypercoagulability and an 
inflammatory reaction Thus, excessive activation of coagulation or severe 
inflammation can occur after aortic aneurysm surgery that leads to organ 
failure.  Bown et al240  in their study involving  those undergoing elective 
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asymptomatic AAA repair, those with symptomatic but nonruptured AAA, and 
those with ruptured AAA reported 89% of the elective group, 92% of the 
emergency nonruptured (urgent) group, and 100% of the ruptured group 
developed systemic inflammatory response syndrome (SIRS). Multiorgan 
failure occurred in 3.8% of the elective group, 38% of the urgent group, and 
64% of the ruptured AAA group.  
 Recent study by Wallinder et al241 investigating haemostatic markers, 
Thrombin-antithrombin (TAT), prothrombin fragment 1+2 (F 1+2)--markers of 
thrombin generation, and von Willebrand factor antigen (vWFag) considered 
as a reliable marker of endothelial dysfunction, in patients with nonruptured 
abdominal aortic aneurysm with special regard to the influence of aneurysm 
size found high higher levels of TAT and D-dimer in patients with abdominal 
aortic aneurysm. The highest level of TAT and D-dimer were detected in 
patients with large compared to small AAA indicating a state of activated 
coagulation in patients with abdominal aortic aneurysm which is dependent 
on aneurysm size. 
In a study conducted to determine activation of coagulation in patients 
undergoing open and endovascular infrarenal abdominal aortic aneurysm 
repair (EVAR), elevated markers of coagulation were measured in both 
groups. Fibrinopeptide A and D-dimer levels did not differ significantly 
between the groups but the levels of fibrin monomer and thrombin-
antithrombin complex were significantly higher in patients undergoing EVAR 
reflecting increased thrombin activity and thrombin formation compared with 
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open surgery suggesting increased procoagulant activity in EVAR when 
compared with open surgery.  
Gibbs et al242 compared postoperative changes in procoagulant, 
anticoagulant, and antifibrinolytic factors in patients undergoing abdominal 
aortic surgery, carotid endarterectomy, and femoro-popliteal bypass. 
Significant increases in plasma fibrinogen and factor VIII coagulant levels 
were found following all three procedures. There were significant decreases 
in antithrombin III and protein C, and increases in thrombin-antithrombin 
complex levels were found in the abdominal aortic group only and no 
significant changes in type 1 plasminogen activator inhibitor levels following 
any of the groups. The results indicated that all three procedures are 
associated with an increased potential for thrombosis. However, patients 
undergoing abdominal aortic surgery are particularly at risk due to concurrent 
decreases in natural anticoagulant factors.  Many studies have reported 
similar haemostatic abnormalities and observed thrombotic events and 
especially an increased incidence of myocardial infarction in those with AAA 
undergoing surgery. A prospective multi-centre study conducted by Joint 
Vascular Research Group243 involving patients undergoing elective 
abdominal aortic aneurysm (AAA) surgery investigated the relationship 
between intraoperative intravenous heparinisation, blood loss during surgery 
and thrombotic complications reported that 5.7% of the non-heparin group 
but only 1.4% of the heparinised patients suffered a fatal perioperative 
myocardial infarction (MI); p < 0.05. All MI, including non-fatal events, 
affected 8.5% and 2% respectively (p = 0.02).  Suggested intravenous 
 
 
 
194 
 
heparin, given before aortic cross clamping, can play an important 
prophylactic role against perioperative MI in relation to AAA surgery. The 
current practice of intravenous heparin prior to aortic cross clamping and 
subsequent administration of low molecular weight heparin in the 
postoperative period reflect the need to counteract the hypercoagulability and 
its consequences observed after AAA surgery.  
Routine coagulation tests in patients undergoing uncomplicated abdominal 
aortic aneurysm repair do not reflect the sustained hypercoagulability 
observed and reported by various studies. These tests do not reflect well-
documented abnormalities of platelet function and deranged fibrinolytic 
mechanisms especially in the postoperative phase where hypercoagulability 
can lead to thrombotic events involving critical vessels leading to increased 
morbidity and mortality. This hypercoagulability is not reflected by standard 
coagulation monitoring244 and seems to be predominantly caused by 
increased platelet reactivity. 
TEG technique involves coagulation and dissolution and provides the 
information lacking in standard tests of coagulation, i.e, the functional aspect 
of platelets, coagulation factors and the speed and extent of fibrinolysis in 
given blood sample within a reasonable short period of time that can be 
repeated to assess the effectiveness of the treatment. This is important as 
coagulopathy and massive bleeding complicating ruptured abdominal 
aneurysm surgery are the major causes of death in patients who present with 
shock following rupture of AAA.  
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TEG has been shown to reduce the consumption of blood and blood 
products in the treatment of massive haemorrhage245 complicating open 
cardiac procedures and is now routinely employed as point of care testing 
method in cardiac surgical departments. TEG is now routinely employed to 
identify hypercoagulation following neurosurgery, in major trauma and liver 
transplantation to guide administration of blood components, coagulation 
factors and platelets. The sensitivity and specificity of this technique has 
been shown to be particularly good when compared to routine tests of 
coagulation, anti-Xa levels, bleeding time, thrombin time and APTT/PT ratio 
estimations especially in the management of coagulopathy.  
Thrombelastography can identify hypercoagulability following abdominal 
aortic bypass surgery using a small volume whole blood sample. Modified 
TEG techniques, incorporating specific blockers to negate the effects of 
specific anticoagulant(heparin), platelet blocking agent(Aspirin, Absciximab) 
or a component of the coagulation cascade(Tissue factor) that can give 
accurate and sensitive assessment of the underlying coagulation pattern.   
Gibbs et al246 employing native whole blood thrombelastography  performed 
preoperatively and on days 1, 2, and 3 postoperatively observed  a significant 
decrease in r on day one (P < 0.0001), with concurrent increases in alpha (P 
< 0.0001) and MA (P < 0.001). On days 2 and 3 there were further increases 
in MA (P < 0.0001). These changes indicated enhanced procoagulant activity 
and progressive increases in maximum clot strength. Butler et al identified 
similar hypercoaculable pattern in recalcified whole blood in the samples 
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obtained during surgery and in the immediate postoperative period. 
Increased fibrinogen concentration was identified as the dominant factor in 
determining the post-operative changes shown by TEG. Mahla et al247 tested 
the hypothesis that the parallel use of standard and abciximab-cytochalasin 
D-modified TEG can assess 7 days' postoperative hypercoagulability and 
can estimate the independent contribution of procoagulatory proteins and 
platelets and concluded that serial standard and modified 
thromboelastography can reveal prolonged postoperative hypercoagulability 
and the independent contribution of platelets and procoagulatory proteins to 
clot strength.  
Gibbs et al248 used TEG native whole blood TEG and Heparinase modified 
TEG to identify the effect of low-dose heparin on postoperative 
hypercoagulability in patients undergoing elective abdominal aortic surgery 
who received unfractionated heparin 5000IU bd SC commencing on the first 
postoperative day found significant decreases in r and K, and increases in 
alpha in the heparinase-modified TEGs postoperatively (P < 0.01). There 
were significant differences between the postoperative native whole blood 
and heparinase-modified TEGs for all TEG variables (P < 0.01). The results 
indicated that low-dose heparin reduces postoperative hypercoagulability 
following abdominal aortic surgery as assessed by TEG. 
This study has shown that non-ruptured AAA and aortic occlusive disease 
are associated with activation of coagulation. TEG identified baseline 
hypercoagulation in these groups in the absence of any significant 
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abnormality in routine coagulation tests performed at the baseline. This study 
also showed a significant reduction in hypercoagulation during aortic cross 
clamping in AAA group but not in the occlusive group. This is an interesting 
finding as platelet sequestration and consumption of coagulation factors are 
shown to be responsible for this change in the coagulation observed in AAA 
patients without rupture and is reported to be more pronounced in those 
presenting with rupture and shock. Continued hypercoagulability after cross 
clamping in occlusive group is consistent with further activation of 
coagulation resulting from additional peripheral ischaemia over and above 
pre-existing critical limb ischaemia with or without tissue loss.  
Significant increase in TEG parameters in the post-operative period observed 
in patients with non-ruptured AAA and in those with aortic occlusive disease 
undergoing reconstruction procedures is consistent with findings in many 
studies employing markers of activation of haemostasis and tests of 
fibrinolysis. TEG has shown significant and sustained activation of 
coagulation during surgery which is sustained for up to six weeks in the 
postoperative period. However, absence of any significant relationship 
between baseline TEG, haemostatic variables and observed thrombotic 
events in this study identified the reduced predictive value of TEG 
parameters used in this study.  
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4.8 - INVESTIGATION OF TEG CHANGES IN PATIENTS WITH 
PVD UNDERGOING SURGERY       
 
Patients with peripheral arterial occlusive disease (PAOD) are at significantly 
increased risk of morbidity and mortality from cardiovascular and 
cerebrovascular events.249 This is particularly the case in the early post-
operative period. Myocardial infarction is the commonest life-threatening 
complication of major vascular surgery. Overt myocardial infarction occurs in 
12% of patients following lower limb surgery250, and in a recent study a 
significant rise in troponin occurred in 37%.251 Abnormal platelet function has 
been implicated in the development and progression of atherosclerosis, as 
well as in the pathogenesis of acute cardiac ischaemic events.252. Brittenden 
et al253 and others have shown that platelet activation is increased in patients 
with lower limb ischaemia suggesting an underlying pro-thrombotic state.254 
In addition to platelet activation, coagulation activation has been implicated in 
the increased incidence of ischaemic events in patients with PAOD.255 
Raised levels of various markers of coagulation have been shown to occur in 
patients with intermittent claudication such as D-dimer and thrombin-
antithrombin complex (TAT)256. In addition, a number of studies have 
demonstrated the presence of a hypercoagulable state following lower limb 
revascularisation.257,258 Peripheral venous blood samples demonstrate a 
systemic increase in coagulability in patients with peripheral arterial occlusive   
(PAOD) affecting the legs259260261. Fibrinogen262 and products of the 
coagulation cascade including thrombin-antithrombin complexes and 
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prothrombin F1+F2263 as well as D- dimers264, indicating increased thrombin 
synthesis and fibrinolysis are consistently raised in patients with PAOD. 
Ischaemic heart disease is associated with similar changes265266267. It is also 
clearly established that an ischaemic limb is associated with increased 
clotting activity.  
The primary aim of this study is to assess the effects of major arterial 
revascularization surgery on coagulation activation in patients with 
symptomatic peripheral vascular disease and to document any significant 
relationship to TEG changes observed during and after surgery 
This study has shown that PVD subjects exhibit an heightened state of 
coagulation at the outset shown by significantly raised TEG parameter values 
consistent with activation of coagulation when compared to control subjects.  
Serial TEG analysis of subjects undergoing surgery has shown significant 
activation of coagulation during surgery but before revascularisation when 
compared to the control subjects. This study has shown further activation of 
coagulation following revascularisation of an ischaemic limb. After 
revascularisation, an on-going prothrombotic state lasting more than a week 
has been demonstrated in this study. This study also demonstrated 
significant activation of coagulation before, during and after revascularisation 
procedures for critical limb ischaemia. This has been observed despite the 
use of heparin and aspirin. These findings add support to the concept that 
arterial revascularisation surgery in patients with PAOD is associated with 
increased coagulation and platelet activation. It is unclear whether this is 
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related to an ischaemia-reperfusion injury or indeed if surgery in non-vascular 
patients may also induce these effects. This study did not show any 
significant changes in TEG values that can be attributed to the effect of 
confounding factors such as clamp time and type of surgical procedure. 
Patients with PVD are at risk of developing a significant postoperative 
thrombotic event. This study has identified a significant association between 
MA, a measure of ultimate clot strength (a reflection of activation of platelets 
and coagulation factor; thrombin) in a given blood sample and occurrence of 
any postoperative thrombotic event.  
Significant changes in TEG parameter values that were sustained during the 
postoperative phase up to 6 weeks is consistent with activation of platelet 
activity and coagulation factors in this group of patients. Interestingly there 
were no abnormalities in the routine coagulation tests during the same period 
in this study. This suggests that TEG is helpful in identifying such changes 
and that appropriate therapeutic interventions i.e., prolonged use of heparin 
outside immediate perioperative period can be helpful in reducing the 
incidence of thrombotic events in this group of patients. 
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4.9 - FINAL COMMENTS 
To summarise, this prospective clinical study has confirmed that TEG can be 
used to monitor coagulation changes in patients with symptomatic peripheral 
vascular disease. For the first time this study has shown that the presence of 
a hypercoagulable state in PVD may have its origins in an ischaemic limb 
itself. While severe systemic atherosclerotic load and presence of ischaemic 
tissue can be the reasons for the activation of coagulation in patients with 
symptomatic PAOD, the same need not be the case with those with 
abdominal aortic aneurysmal disease. Routine coagulation tests often do not 
identify any haemostatic abnormality at the outset in patients with abdominal 
aortic aneurysm while tests for thrombophilia and fibrinolysis have 
consistently shown activation of coagulation and reduced inhibition of 
fibrinolysis. This pattern continues after surgery for a significant length of time 
and again routine coagulation tests again do not identify this sustained 
hypercoagulabiltiy. Period of ischaemia of lower limbs following aortic cross 
clamping during aortic surgery and presence of  significant systemic 
atherosclerosis are logical explanations for the observed coagulation 
changes in these patients. However activation due to other factors such as 
stress related to surgery, administration of fluids, blood products, 
anaesthesia and surgery itself  as in any non-vascular surgery cannot be 
discounted.  This study also confirmed reduced endogenous heparin-like 
activity in PVD, a finding that provides evidence for use of low dose heparin 
in subjects with symptomatic ischaemia following surgery or prolonged 
periods of immobility. 
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Finally, this study has shown significant procoagulant changes during 
peripheral vascular surgery using Thromboelastography. These changes are 
significantly related to the occurrence of an ischaemic event in the 
postoperative period.   
  
 
 
 
203 
 
4.10 - FUTURE PLANS 
This prospective clinical study using TEG has shown activation of 
coagulation during peripheral vascular surgery and has identified a significant 
positive relationship between postoperative coagulation status and 
occurrence of an ischaemic event.  
 
Possible future research avenues include: 
o Further studies using modified TEG methods, incorporating tissue 
factor blockade and aspirin blockade to identify specific defects in 
coagulation and platelet function in PVD. 
o Further TEG studies involving postoperative PVD patients to assess if 
there is any significant reduction in postoperative ischaemic events as 
a result of current treatment guidelines that includes routine use of low 
molecular weight heparin in postoperative PVD patients following 
surgical revascularisation or amputation for critical limb ischaemia. 
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